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Abstract 
Introduction 
Patients surviving a severe stroke are at risk of developing contractures.    
Evidence suggests that spasticity may be a cause of contractures, particularly in 
patients who have not recovered functional movement. The relationship and the 
time course of spasticity and contractures remain unclear. 
This thesis aims to identify when spasticity can be identified and investigate 
whether treating spasticity at onset using botulinum-toxin, might slow 
contracture development. 
Methods 
A double blind randomised placebo-controlled trial with an initial six-week 
screening phase was conducted in an acute NHS hospital. 
Patients with no arm function (Action Research Arm Test grasp-score<2) within 
six-weeks of stroke were eligible for screening.  Screening for spasticity was 
carried out using a neurophysiological method. Patients who developed 
spasticity were randomly assigned to receive intra-muscular injections of 
0.9%sodium chloride solution or onabotulinumtoxinA. 
Measures of spasticity and contracture development (reduced passive range of 
motion (PROM) and increased stiffness) were taken at the wrist and elbow at 
baseline, weeks-two, four, six and twelve post injection and six-months post 
stroke. 
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Results 
Over a 23-month period, 1143 patients were admitted with stroke and 120 
consented to study participation. Of these, 100 developed spasticity without 
functional recovery 84%(95% confidence interval(95%CI):76%-89%). Mean 
time of spasticity onset was 13.5-days(SD:8.5).   
Of the 100 eligible for randomisation 93 were included in intention to treat 
analysis. At six-weeks, treatment results in a reduction in wrist spasticity (mean 
difference(MD):4.8µV;95%CI:1.2to8.4;p=0.009), stiffness 
(MD=4.2mN/deg;95%CI:0.7to7.7;p=0.02) and PROM 
(MD=13.8o;95%CI:6.1to21.6;p=0.01).  At the elbow; four-weeks spasticity 
(MD=9.8µV;95%CI:4.3to15.4;p=0.001), four-week stiffness 
(MD=4.8mN/deg;95%CI:-0.1to9.6;p=0.056) and twelve-weeks PROM–
(MD=6.5o;95%CI:0.6to12.3;p=0.03).  These changes were not maintained at the 
six-month follow-up assessment. 
Conclusion 
Spasticity occurs earlier and is more common than previously reported.  
Treating spasticity early with onabotulinumtoxinA can reduce the rate of 
contracture formation.  Further work is required to elucidate who is at greatest 
risk of contractures and to explore if these treatment effects can be sustained 
with adjunct therapies. 
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Activities and personnel involved in the study 
This study could not have been achieved without support and assistance being 
provided to the candidate.  This section clarifies what contribution the candidate 
made to the study.  Activities have been divided in to intellectual and practical 
tasks as suggested by Wade (2010).  
Intellectual tasks 
Specifying the question 
This PhD is slightly unusual in that the candidate came with a specific clinical 
question that they wanted to answer.  In order to investigate that question three 
unsuccessful grant applications to various funders were submitted by the 
candidate with gradually reducing advice from Anand Pandyan (ADP).  This led 
to an iterative process whereby feedback from unsuccessful grant applications 
led to a refining of the study question.  The candidate also entirely 
independently organised a patient and public involvement event.  Information 
from this event informed the grant application and was important in identifying 
some of the objective measures that needed to be included. 
The successful National Institute for Health Research (Research for Patient 
Benefit) grant application which awarded £245,000 for the study was written 
and submitted by the candidate on behalf of Sandwell and West Birmingham 
NHS Trust.  ADP advised on the application form and helped to write section ten 
(Background) and eleven (Research plan and methodology). 
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The candidate was advised to submit the initial literature review protocol to the 
Cochrane Library.  This protocol was accepted by the Cochrane library and the 
subsequent Cochrane systematic review has been published. 
Designing the Study 
Although the grant application specified a general research plan and 
methodology, this was not sufficient to produce a protocol.  
The candidate was initially advised that this study did not require Medical and 
Healthcare Regulatory Authority (MHRA) approval.  Having independently 
established that this was incorrect the candidate wrote the study protocol and 
applications for research ethics committee and MHRA approval.  This included 
writing patient, legal representative and GP information sheets, legal 
representative and family consent forms, sample diary forms and providing the 
summary of product characteristic for onabotulinumtoxinA.  Steve Sturman 
(consultant neurologist and Principal Investigator) advised on the protocol and 
ethics and MHRA application forms.  ADP was asked to assist with specific 
questions relating to the scientific methodology to ensure quality of the study. 
During the writing of the protocol, the candidate persuaded Steve Sturman (SS) 
the Principal Investigator, that it was essential to use a localisation technique 
while injecting to be able to categorically state that the appropriate muscles 
were injected, and this was included in the protocol. 
Following advice from Professor Christine Roffe the candidate wrote and 
submitted the protocol for publication in a peer reviewed journal and ensured 
that the protocol was registered with clinicaltrials.gov.   
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A further issue occurred after the first five patients had been randomised.  SS 
became worried that the agreed doses were too large.  Although there is no 
evidence that the small doses used could cause dysphagia, SS was still worried 
and the candidate wrote a substantial amendment to the protocol. 
Once the PhD began the candidate wrote the pharmacy standard operating 
procedures (SOPs) which included: dispensing and preparation SOPs, 
emergency unblinding SOP, and forms for safe injection of the blinded 
preparation.  Julie Simpson (JS) provided very useful advice and helped in 
completing these SOPs.   
Identifying essential data  
ADP identified the tools to collect the contracture and spasticity data based on 
his having developed and used these methods previously. 
ADP advised that only EMG measurements should be taken as a measure of 
spasticity.  The candidate strongly felt that a clinical measure had to be used as 
the long term aim was to change clinical practice.  The Tardieu scale was 
therefore taken for every measurement. 
Both ADP and SS were unsure whether the candidate would be overly 
burdened by attempting to take outcome measures at five time points following 
randomisation – they both suggested 6, 12 and 24 weeks.  The candidate 
however, felt that measurements at two and four weeks would be useful in 
identifying the contracture development and this was agreed. 
As documented already, the candidate independently organised a patient and 
public involvement event.  This event identified that pain should be included as 
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an outcome measure and that a way of identifying how difficult caring for the 
patient was, should be measured.   
Analysing Data 
Following the end of recruitment, data that had been collected was reviewed.  
ADP wrote a bespoke programme of functions within Mathcad 15 to allow 
analysis of the data files.  The candidate was required to have a good 
understanding of this programme as each of the files required manual input of 
data to ensure the correct time-points could be analysed.  During this process 
the candidate identified issues in the initial formulae which meant data points 
were not being appropriately identified.  In order to ameliorate this problem ADP 
showed the candidate how to identify the middle 70% of a movement.  Having 
further analysed the data the candidate changed the formulae so that the 
middle 80% of the movement was analysed. 
Over 8000 data files had to be converted from a text file to a Mathcad file before 
being analysed.  Once the candidate had ensured data had been appropriately 
converted and then analysed, it was then transferred to an excel spreadsheet.   
The candidate cleaned the data on the Excel spreadsheet before transferring it 
to SPSS.  ADP provided teaching and training on statistical analysis and the 
use of SPSS and advised on how best to analyse the data statistically.  The 
data was then all analysed by the candidate. 
At one conference the candidate was approached by a team from Australia who 
introduced him to different ways of analysing serial measurements.  This has 
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led him to further review how the data may be analysed in future papers; the 
results are not presented in this thesis. 
Interpreting data analysis 
The candidate was pro-active in presenting data to audiences and identified 
potential conferences that may be appropriate.  The candidate wrote, submitted 
and presented nine abstracts to national or international conferences.  ADP 
reviewed all the abstracts and provided feedback on drafts.   
Presenting these abstracts subjected the candidate to criticism and forced him 
to defend both the methodology and interpretation in both one to one and group 
settings.  One example occurred at the International Society of Physical and 
Rehabilitation Medicine Conference in 2015 where the presentation of this 
study’s results directly contradicted the previous speaker’s results (data from 
the Sunnerhagen group which investigated spasticity development using the 
Ashworth Scale as an outcome measure). 
Practical Tasks 
Patient Selection and Monitoring 
Once the trial began patients were generally identified by the physiotherapy 
team. Once patients were identified the candidate approached and provided 
information to all patients who fulfilled the entry criteria for screening.  Having 
ensured that the patient had capacity to make a decision the candidate attained 
consent from the patient or assent from the relative. 
All screening and blinded assessments were carried out by the candidate.  
During screening, if the patient fulfilled criteria for randomisation the candidate 
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re-assessed capacity, formally co-ordinated a medical consultant, research 
pharmacy technician, trained clinician to reconstitute and injector to complete 
the injection. 
Julie Simpson (JS) was also the named pharmacist who held the randomised 
list at the hospital.  Peter Jones (Keele University) produced the randomisation 
list and provided this to JS.   
The day after injection the candidate checked for bruising and provided the 
patient and or carer with training on use of the electrical stimulation.  The 
candidate ordered, set up, maintained and kept a register of the electrical 
stimulation machines. The ward physiotherapist continued to provide this to all 
in-patients on the programme. 
Once discharged the candidate made all appointments and carried out all 
follow-up assessments.  Due to patients’ personal circumstances some of these 
appointments were carried out in unexpected environments such as a 
Gurdwara and homeless shelter. 
As the candidate was the blinded assessor he was able to identify and 
document all adverse events and these were fed back to the Principal 
Investigator as per the protocol.  SS was succeeded by Sissi Ispoglou as the 
Principal Investigator for the study in August 2012. 
Management of the Grant 
The candidate wrote three substantial amendments to the protocol following 
discussion at the steering committee which all required ethical approval. 
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The candidate ordered all the necessary equipment for the trial and ensured the 
grant funding was used appropriately.  He assisted the R&D accountant to 
provide the annual statements to the NIHR and also wrote an unpaid extension 
request application to the NIHR. 
The candidate also wrote the annual report to the NIHR with SS.  
The candidate was encouraged to establish two other clinical trial sites 
(University Hospitals Birmingham (UHB) and at Royal Wolverhampton).  This 
required a great amount of time to alter documents and establish contacts with 
the R&D departments at both sites and establish clinical links to ensure the 
logistics of additional electrical stimulation and injections would be possible.  
Unfortunately no patients were recruited from these sites. 
Jocelyn Bell as head of the Sandwell and West Birmingham Research and 
Development Office and her team ensured good clinical practice was 
maintained and protocols were adhered to.  This was the first occasion that the 
NHS Trust had acted as a sponsor of a clinical trial involving a medical product.  
The candidate maintained the Trial Master Folders and these were presented 
for internal audit inspection on two separate occasions. 
Keele University was subject to an MHRA inspection subsequent to the initial 
PhD submission for which all the trial information from this trial was inspected.  
Since the candidate had been in control of all the tasks involved in ensuring 
good clinical practice and documenting data it was gratifying to hear that no 
major concerns were raised by the MHRA inspection.  
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1. Introduction 
More people are living longer following a stroke and also surviving much more 
severe strokes (Feigin et al 2014, Crichton et al 2016, Minnerup et al 2015).  
While these facts are positive, the residual impairments following a total anterior 
circulatory stroke can make the survivor almost entirely dependent on others.  
With the aim of optimising participation in society, and minimising distress and 
discomfort, the process of rehabilitation is important in improving survivors’ 
outcomes following stroke (Wade 2015).   
Spasticity and contracture are two impairments that cause distress and 
discomfort to patients following stroke (Esquenazi 2011).  In order to optimise the 
process of stroke rehabilitation it is important to identify when spasticity 
develops. Although this remains unclear, there is a theoretical argument that by 
treating spasticity earlier in the rehabilitation process than is currently the case, 
contracture development may be slowed (Cousins et al 2010). 
This thesis will aim to investigate these issues within the specific context of the 
arm following a stroke.  This introductory chapter will review the definition of 
spasticity, briefly introduce its pathophysiology and identify how spasticity can be 
measured.  It will then review the development of contractures in animal models 
and in humans following a stroke before discussing the evidence for the role of 
spasticity in contracture development.  Current treatments in the management of 
spasticity will then be reviewed before presenting the research questions. 
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1.1 Definition of spasticity 
Spasticity is poorly defined in the published literature.  In a review of 250 papers 
where reduction of spasticity was used as a stated outcome the definition of 
spasticity was examined (Malhotra et al 2009).  Malhotra (et al 2009) concluded 
that the papers could be split into three, with one third providing no definition, 
one third considering it increased muscle tone, and one third using the Lance 
(1980) definition (Malhotra et al 2009).  The following section will introduce 
current terminology and definitions.  
1.1.1 Tone 
Defining spasticity as increased tone or hypertonia is problematic as the term 
tone has been used variably.  The term tone/tonus was first used by Galen (131 
– 201 A.D.) to describe the shoulder being held at 90 degrees (cited in Fulton 
1926).  In this context tonus clearly meant isometric contraction.  Johannes 
Müller in 1838 has been identified by Fulton (1926) and Rushworth (1960) as the 
scientist who altered the word’s usage to describe the ‘slight contractile tension’ 
of normal skeletal muscle at rest. 
Tone continues to have two divergent definitions within the scientific literature.  
One definition taken to its basic level refers to whether the muscle is innervated - 
a muscle’s “readiness to move” Bernstein (1967).  Tone in this context, is not 
related to spasticity at all but refers to paresis (i.e weakness) of a muscle.  In 
cases where a muscle is entirely paretic the term hypotonia has been used. 
Tone in the context of spasticity has been variably defined.    Two definitions of 
(spasticity-related) tone are ‘the sensation of resistance that is encountered as a 
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joint is passively moved through a range of motion’ (Morris 2002, p54) or ‘the 
resistance of resting muscle to passive movements’ (Kheder and Nair 2012, 
p289).  Both of these definitions are similar to “the slight steady enduring tension 
so characteristic of muscles…” described by Sherrington (1915, p192).  It is 
worth noting that Sherrington (1915) was describing some patients with what 
would now be diagnosed as dystonia.  All three of these definitions of tone 
describe stiffness which can be assessed quantitatively as Cobb and Wolff 
highlighted as early as 1932.   
In summary, the term tone has become intertwined with spasticity over many 
decades to the extent that a continuum from hypotonia through normal tone to 
hypertonia has developed.  The hypotonia relates to the Bernstein (1967) 
definition, hypertonia relates to the Morris (2002) definition.  These two 
definitions describe entirely different pathophysiological processes and should 
not be confused as two opposing ends of a scale.    Such confusion makes it 
understandable why Cobb and Wolff (1932, p673) made a plea that the term 
tone be “discarded or returned to its former home in smooth muscle”.  
1.1.2 Lance definition 
The Lance definition of spasticity is a 'motor disorder characterized by a velocity-
dependent increase in the tonic stretch reflexes (muscle tone) with exaggerated 
tendon jerks, resulting from hyper excitability of the stretch reflex, as one 
component of the upper motor neurone syndrome' (Lance 1980, p485).   Lance’s 
definition has some problems.   Firstly, it includes ‘muscle tone’ which has 
already been discussed and concluded to be an inappropriate term.  The 
definition is also very specific, and it excludes some well accepted clinical 
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presentations of spasticity (Pandyan et al 2005).  It also classifies spasticity as a 
purely motor disorder, but spasticity is also dependent on changes to the 
processing of sensory input as will be described later in this thesis.   
1.1.3 Recent definitions of spasticity 
In an effort to improve on the Lance (1980) definition, two more recent definitions 
have been developed through consensus.  Sanger et al (2003) were a group of 
North American paediatricians who used the Lance definition as a basis for 
development.  They defined spasticity “as hypertonia in which one or both of the 
following signs are present: 1) resistance to externally imposed movement 
increases with increasing speed of stretch and varies with the direction of joint 
movement, and/or 2) resistance to externally imposed movement rises rapidly 
above a threshold speed or joint angle” (p91 Sanger et al 2003). 
This definition is immediately confused by the assertion that “spasticity is 
hypertonia”.  This means that a prior definition of hypertonia is required.  Sanger 
et al (2003) provide a definition of hypertonia as “abnormally increased 
resistance to externally imposed movement about a joint.”  This once again 
describes stiffness. 
Another concern regarding the Sanger et al (2003) definition highlighted by 
Malhotra et al (2009) was the addition that “resistance… rises rapidly above a 
threshold speed”.  This rapid rise in resistance is later described as a “spastic 
catch” by Sanger et al (2003) in their explanation.  This issue, and the arbitrary 
velocity threshold that is described, make this definition no improvement on the 
initial Lance (1980) definition, a conclusion that was also made by Malhotra et al 
(2009).   Arguably, the main flaw, which does not appear to have been 
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highlighted before, is that the authors have attempted to define a physiological 
symptom based on the “features of the clinical examination”.  If the clinical 
examination involved in assessing spasticity relied on a clear objective (interval 
data or ratio data level) outcome measure then this might well be acceptable, but 
spasticity measurement is not that straightforward.   
Another definition which does not appear to be limited by previous definitions, 
terminology or clinical measurements has also been reported.  A European 
consensus group of clinicians and researchers proposed that spasticity could be 
defined as “disordered sensory-motor control, resulting from an upper motor-
neuron lesion, presenting as intermittent or sustained involuntary activation of 
muscles” SPASM group (Pandyan et al 2005 p5).   
This SPASM definition is potentially too general and, on initial reading (and to 
clinicians in particular), makes measurement difficult to perform. It can also be 
argued that such a definition would include clinical presentations that are not 
traditionally considered as spasticity, such as clonus, spasms and perhaps 
dystonic posturing.  These presentations are certainly consistent with the 
definition and, in clinical practice are very often called spasticity.  This is perhaps 
because the main treatments are similar for all of them.  Such an argument does 
not therefore harm the definition, but taken to its very limits such a general 
definition could become problematic.  This definition could potentially include 
seizure activity (intermittent involuntary activation of muscles) during an epileptic 
seizure (upper motor neuron lesion) and at this point the definition does appear 
to become too general.  The phrase disordered sensory-motor control could 
feasibly prevent seizure activity from being included since an epileptic seizure is 
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“abnormal excessive or synchronous neuronal activity in the brain” (Fischer et al 
2005 p470).  
By accepting the SPASM (Pandyan et al 2005) definition, understanding of the 
clinical problem is clarified.  Fundamentally, the result of a lesion in the central 
nervous system causes abnormally increased involuntary muscle activity.   
The phrase ‘abnormally increased muscle activity’ explains that the muscle is 
active when it should not be, in much the same way as Gracies (2005) defines 
muscle over-activity as ‘increased involuntary motor unit recruitment’.  The 
Gracies (2005) phrase ‘muscle over activity’ however, does not make clear the 
important abnormal element to the muscle activity.  Another key benefit of using 
the SPASM definition is that the term tone is then removed entirely from the 
vocabulary. 
Although it still has weaknesses, this thesis will use the SPASM group definition 
(Pandyan et al 2005) as it is currently the only definition that is not confounded 
by describing stiffness of muscle.  The pathophysiology of spasticity, which will 
be reviewed presently, is purely a nervous system disorder so the definition 
should clearly indicate this. 
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1.1.4 Pathophysiology of spasticity 
Having defined spasticity, it is important to provide some background to the 
current understanding of its pathophysiology.  Spasticity is the result of 
disinhibited cortical and spinal networks that produce an overall increase in the 
activity of spinal reflexes. 
In order to describe spasticity, it is first necessary to understand the normal 
spinal reflex system.  Essentially, there are two systems (an excitatory system 
and an inhibitory system) which normally act together to balance the control of 
the spinal reflexes (Sheean 2002). 
The medial reticulospinal tract and vestibulospinal tract make up the excitatory 
system.  These tracts arise in the brainstem (tegmentum of the midbrain and 
pontine, and reticular formation and in the vestibular nucleus respectively) and 
generally cause an increase in spinal reflexes (Sheean 2008).   
The inhibitory system is under much greater cortical control (Dietz and Sinkjaer 
2007). Cortico-reticular tracts from the pre-motor and supplementary motor areas 
descend through the internal capsule to the venteromedial reticular formation 
(Sheean 2008).  The resulting dorsal reticulospinal tract provides the main 
inhibition to the spinal reflex activity (Sheean 2002). 
Following a stroke, it is this inhibitory system that can become reduced (or 
disinhibited), leading to exaggerated spinal reflex activity which results in 
increased activity at the affected muscle.   
The reduced inhibition on the spinal reflexes (stretch, proprioceptive or 
cutaneous reflexes) manifests in an increased propensity of activation to a 
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stimulus (Dietz and Sinkjaer 2007).  The Pandyan et al (2005) definition of 
spasticity encompasses abnormal muscle activity as a result of either a 
disinhibited stretch reflex or cutaneous reflex.  This means that the presentations 
of clonus, spasm and stretch reflex can all be included under this definition of 
spasticity.   
1.1.4.1 Specific mechanisms underlying spasticity 
The current study does not intend to investigate the underlying mechanisms of 
spasticity but, for completeness, it is worthwhile to briefly review the current 
understanding.  There is uniform agreement that the specific mechanisms 
underlying spasticity are not fully understood (Nielsen et al 2007, Dietz and 
Sinkjaer 2007, Sheean 2008, Burke et al 2013 and Mottram et al 2014).  One 
inherent difficulty with understanding the mechanisms involved is that there are 
clear differences in pathophysiology of spasticity between spinal and cerebral 
lesions (Nielsen et al 2007).  Other problems that are yet to be resolved include 
normal circuitry in humans varies during rest and activity making the assessment 
of how spasticity interferes with functional movement difficult (Nielsen et al 2007, 
Dietz and Sinkjaer 2007), and, difficulty in measuring two mechanisms at the 
same time.  Additionally, some studies have been confounded by including 
patients that may have developed contractures rather than muscle over activity 
(Burke et al 2013). Burke et al (2013) identify three major mechanisms involved 
in spasticity.     Some of these mechanisms may be the natural neural re-
organisation that occurs following injury with the intention of increasing excitation 
through the system. 
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1. Changes in the properties of the spinal motor neuron – primarily through 
persistent inward currents (sustained excitatory drive following minimal 
excitation) (Gorassini et al 2004) 
2. Changes in the afferent input to the spinal motor neuron – three 
mechanisms suggested by Burke et al (2013); enhanced fusimotor drive 
via γ motor neuron activation, decreased pre-synaptic inhibition and 
homosynaptic depression (also termed post-activation depression). 
3. Changes in reflex circuits that affect the motor neuron – at least eight 
reflex circuits have been identified. 
(For further detail on the proposed mechanisms and evidence regarding whether 
these mechanisms are involved in post stroke spasticity please see Appendix 1) 
The one mechanism whose presence appears uniformly accepted in the stroke 
population (although there is not consensus on the name) is homosynaptic / 
post-activation depression.  This mechanism fits into Burke et al’s (2003) 2nd 
mechanism (above) whereby afferent inputs to the spinal motor-neuron are 
altered.   
Post-activation depression was initially described in the cat by Curtis and Eccles 
(1960) who identified that the size of Ia excitatory postsynaptic potentials 
(EPSPs) varied with frequency of stimulation.  The depression of the Ia EPSPs 
with longer intervals occurred as a result of previous transmitter release (Grey et 
al 2008).  However, once again the aetiology of this mechanism is not 
understood (Grey et al 2008).  In humans, Aymard et al (2000) found that post 
activation depression correlated with the amount of spasticity in a population 
post stroke measured using the H-reflex. 
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1.1.5 Measurement of spasticity 
Spasticity occurs as a result of damage to a part of the brain which disinhibits the 
spinal reflexes.  Spasticity may be characterised as abnormal muscle over-
activity which presents as a spasm, clonus or increased stretch reflex.  With 
these essential points in mind, the measurement of spasticity can be clinically or 
physiologically based.    
There are clinical scales that measure spasm (Penn Spasm Frequency scale) 
(Penn et al 1989), and scales that measure changes in clonus (Tardieu Scale) 
(Held & Pierrot-Deseilligny 1969).  These scales are valid, reliable, provide 
ordinal level data and are appropriate for recording in both the clinical and 
research context.  Measurement of the increased stretch reflex appears to have 
been less well developed in the clinical context.  
Current clinical methods to assess spasticity include the Ashworth scale 
(Ashworth 1964) and Tardieu scale (Held & Pierrot-Deseilligny 1969).  Both 
these scales are, to a greater or lesser extent, dependent on the development of 
stiffness and make the assumption that any change in stiffness is directly 
attributable to a change in neural activity. While these scales are recognised as 
being reliable, their reliance on stiffness means that their validity has repeatedly 
been brought into question (Nielsen and Sinkjaer 1996, Pandyan et al 1999, 
Patrick and Ada 2006, Fleuren et al 2010 and Naghdi 2014). 
Since spasticity is characterised by abnormal muscle activity it seems necessary, 
and almost fundamental, to measure the activity of the muscle.  The method of 
electromyography (EMG) provides a measure of muscle activity.  It records the 
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electrical activity at the motor end plate where the nerve stimulates the muscle, 
thereby providing information as to how active the muscle is at any given time. 
By providing an input to the sensory system it is possible to identify whether an 
abnormal output from a muscle occurs.  This purely neurophysiological method 
involves electrical stimulation of the Ia afferent fibres (Burke 2016).  This is 
termed the H-reflex and has been used to investigate various mechanisms 
including the presence or absence of post-activation depression (Grey et al 
2008), the one uniformly recognised mechanism of spasticity in stroke 
population. 
An alternative method involves passively stretching a “relaxed” joint and 
measuring any resulting muscle activity.  The muscle of a person with no upper 
motor neuron lesion will remain inactive when a muscle is passively stretched 
through range (Thilmann et al 1991).  In patients with severe stroke the muscle 
becomes overactive when passively stretched, and this increased output can be 
measured by using surface electrode EMG. 
In conclusion, it is established that, with regard to spasticity measurement, there 
are validity issues identified with current clinical measurements and that carrying 
out H-reflex measurements are time-consuming and invasive. Accordingly, the 
method most likely to provide clinically relevant and useful data is to use surface 
EMG to measure the reflex activation of a relaxed muscle during an imposed 
passive stretch. This method has been used previously by Burke et al (1970), 
Ashby and Burke (1971), Powers et al (1989) and Pandyan et al (2001).  A 
similar method has been used by Sorinola et al (2009) and identified that 
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measuring spasticity using EMG correlated well with muscle weakness and lack 
of active flexion but not with the Modified Ashworth Scale.   
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1.2 Contractures 
Contractures can be characterised as a combination of increasing stiffness and 
loss of range of movement at a joint (O’Dwyer et al 1996, Pandyan et al 1997 
and Harburn and Potter 1993).  The incidence of contractures occurring at any of 
six joints at six months following a stroke was identified as 52% (Kwah et al 
2012).  When those of the 200 consecutively sampled patients who had had a 
very mild stroke (NIHSS<6) were removed from the data the incidence increased 
to 66% of stroke survivors (Kwah et al 2012) with arms affected much more than 
legs.   
The research indicates that contractures are caused by a combination of two 
factors acting together following stroke: one factor is the relatively shortened 
positions that a joint naturally rests in; the other factor is spasticity (Pandyan 
2003, Lannin 2007).  Studies using animals have greatly enhanced the 
understanding of the causative nature of these two factors (joint held in a 
shortened position, and spasticity).  The following section will review how 
contracture development and spasticity might interact and then discuss the 
evidence for the development in stroke survivors.   
 
1.2.1 Contracture development – joint held in shortened 
position 
In animal models, immobilising a muscle in a shortened position will lead to loss 
of range at the joint (Williams and Goldspink 1984, and Prado et al 2005).  The 
loss of range is the result of a decrease in both the number of sarcomeres in 
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series and the length of the sarcomeres (Goldspink et al 1974) which directly 
results in decreased passive extensibility (Williams and Goldspink 1978).  This 
was clearly shown by Tabary et al (1972) who identified a 40% loss of 
sarcomeres when a cat soleus muscle was examined after four weeks of 
immobilisation in a shortened position. 
This research group went through an iterative protocol to establish whether other 
processes played a part in the loss of range in the animal model.  Goldspink et al 
(1974) identified that there was no significant difference in loss of sarcomeres 
between a muscle that was denervated or innervated.  This is an important 
finding because it suggests that loss of sarcomere is dependent primarily on the 
position that a muscle is immobilised in rather than the presence or not of 
paresis.  This finding led to the hypothesis that connective tissue was involved in 
the development of contractures. 
The perimysium which surrounds each muscle fascicule (Lieber 2009) is one of 
the three levels of connective tissue surrounding muscle but most important in 
contributing to passive stiffness (Williams and Goldspink 1984).  The collagen 
forming the perimysium provides a structural support network for the neuro-
vascular anatomy. Perimysium is present in greater quantities in postural 
muscles such as the soleus compared to the gastrocnemius (Purslow 2002).  
Purlslow (2002) suggests that the variation in quantities might correspond with 
the increased vasculature required for postural slow twitch muscles compared to 
fast twitch muscles.  The perimysium is made up of loose weaved “crimped” 
collagen fibres which have been shown to be able to alter and un-crimp as a 
muscle is lengthened (Purslow 1989).  The body replaces collagen constantly 
and normal loading of muscles causes immature collagen to become aligned 
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along the direction of the muscle force.  If the muscle does not move then this 
loading does not occur meaning that collagen becomes shortened (i.e. further 
crimped) and more collagen is laid down (Williams and Goldspink 1984).  The 
end result is that the ability for the collagen to uncrimp may be lost and the 
capacity for the muscle to comply with a stretch may be limited (Williams and 
Goldspink 1984).  Williams and Goldspink (1984) discovered that an increase in 
perimysial collagen deposition occurred within 48 hours of a muscle being 
maintained in a shortened position. 
1.2.2  Contracture development – abnormal muscle over 
activity 
The most important experiment in the context of this review was the protocol of 
De La Tour et al (1979).  This study investigated the impact of increased muscle 
activity on the rate of sarcomere loss.  This was achieved through a localised 
injection of tetanus toxin to the crural muscles (in the Guinea Pig).  This study 
identified that there was a much greater and faster loss of sarcomeres when the 
joint was immobilised in a shortened position and the muscle was abnormally 
active than when the joint was immobilised in a shortened position without 
increased activity.  A 45% loss of sarcomeres was seen in six days compared to 
the immobilised-only group (De La Tour et al 1979).  Using a different method to 
achieve outcome of increased muscle activity Tabary et al (1981) identified that 
electrically stimulating the sciatic nerve caused a 25% loss in sarcomere 
numbers in just twelve hours (in the Guinea Pig).  No changes in sarcomere 
length were identified in the shortened and immobilised group within this short 
timeframe (Tabary et al 1981).  Using the same methodology as Tabary et al 
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(1981), Williams (1988) identified that there was a 47% loss of sarcomeres in 
seven days (in the rabbit).   
Due to the need for invasive experimentation, all these studies have been in 
animal models.  However, when placed in the clinical context, these findings 
explain why patients who have severe cerebral irritation can lose range in less 
than 24 hours.   
1.2.3 Contracture development in the stroke population 
Pandyan et al (2003) identified that loss of range developed within six to eight 
weeks following stroke in the wrist when there was no arm function immediately 
after the stroke. The important finding was that those who had some function, 
and who are therefore able to use the arm in functional tasks, were less likely to 
lose range of movement at a joint.  Due to the study design the cause of 
contracture was not able to be identified, but, when combined with the work of 
Ada et al (2006), the evidence becomes stronger and clearer.  Ada et al (2006) 
carried out a longitudinal study with eight assessment points over a year in 27 
stroke patients beginning two weeks after stroke.  The study objective was to 
investigate the evolution and interaction of spasticity, strength and contracture at 
the elbow flexors and their effects on function following stroke.  They identified 
that the main factor causing contracture development over the first four months 
following stroke was spasticity and lack of strength became more significant 
between six and nine months (Ada et al 2006). 
These two studies clarify that if function is lost, and no functional recovery 
occurs, then contracture development is highly likely and that spasticity is an 
important factor in early contracture development.  Further studies have 
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reinforced these conclusions and provide evidence on the rate of contracture 
development in stroke survivors which will be reviewed in more detail now 
(Lannin et al 2007, Malhotra 2013).   
1.2.4 Rate of contracture development in the stroke population 
Lannin et al (2007) investigated splinting the wrist in 62 patients after a stroke 
and used 21 of these as a control.  While the unaffected wrist had a mean 
maximum extension of 64.5o standard deviation (SD)=10.1 at the point of 
randomisation (mean 30 days post stroke SD=13.3) the affected wrist had 
already lost range with mean maximum extension of 56.2o (SD=15.0).  At four-
week follow up, mean extension was 47.3o (SD=16.9) and two weeks later was 
39.4o (17.8).    If we make two assumptions: 1, the affected wrist and unaffected 
wrist both had the same range of movement to begin with and 2, in the 30 days 
following the stroke there had been no loss of range to the unaffected wrist, then 
a simple calculation indicates that 25o of range were lost in the first ten weeks 
post stroke. 
Using secondary data from the control group of a randomised controlled trial 
Malhotra et al (2011) divided the group in to those who did not recover function 
(measured as ability to pick up a two centimetre cube) and those who did 
recover function.  The 25 patients without function lost a mean 25o in the first 
twelve weeks whereas those who recovered did not lose any range of 
movement.  The Lannin et al (2007) and Malhotra et al (2011) studies both 
showed that those without recovery of function in the arm lost range at the wrist, 
confirming the earlier findings of Pandyan et al (2003) described in section 1.2.3.  
The Malhotra protocol also measured spasticity and they were able to identify 
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this in all 25 patients. Importantly, spasticity was also identified in the group of 
patients who recovered function (n=5) suggesting that spasticity was not the only 
contributing factor to the development of contracture. 
1.2.5    Stiffness 
Section 1.2 began by stating that contractures can be characterised as a 
combination of increasing stiffness and loss of range of movement at a joint.  
The majority of investigations presented so far have focussed on loss of range 
rather than the development of stiffness (with the exception of Williams and 
Goldspink (1984)).  Studies investigating stiffness have varied in methodology 
within the stroke population. 
In order to specifically quantify stiffness, some studies have measured the 
impedance to movement over a small mid-range of available movement (Given 
et al 1995, Kamper et al 2006).  These protocols do not measure the increase in 
stiffness that can be identified towards the end of range of movement (i.e. torque 
versus angle displacement curve).  In order to identify this end of range stiffness 
some studies have used a specified torque to measure the range of movement.  
Most studies that have used this method have employed a within subject 
standardisation technique (e.g. Moseley et al 1991, Moseley et al 2008 and 
Kwah et al 2012). This method does not quantify the stiffness but measures the 
loss of range at a joint as a result of increasing stiffness. 
The method described by Pandyan et al (2001) allows for the resistance to 
passive movement to be measured throughout the passive range.  Such a 
method allows stiffness to be quantitatively measured as the force required to 
move a joint through range (i.e. force over angle).  
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From the evidence, it can be concluded that if a person does not recover function 
in the arm following a stroke then it is likely that they will develop a contracture 
(Pandyan 2003, Lannin 2007 and Malhotra 2011).  Spasticity following stroke 
appears to be a major factor causing contracture development over the first four 
months (Ada et al 2006).  This evidence in the stroke population is consistent 
with that identified in animal studies investigating contracture development. 
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1.3 Current rehabilitation strategies in the management of spasticity 
and contractures 
Following a stroke that results in loss of arm function, the general position that is 
taken up by the arm is one of flexion.  In some cases, the patient may pick the 
paretic arm up and place it in front of them so that they can visualise where it is 
due to decreased sensation.  In other cases, patients may be placed in a chair 
and the arm left in a flexed position.  Because of paresis, the arm does not move 
and so the joint is maintained in prolonged immobilisation with the flexor muscles 
at a shortened length.  
While this prolonged immobilisation in the general population might not be 
enough to cause contracture, the acceleratory effect of spasticity on the 
development of contractures (evidenced by Tabary et al 1981) places surviving 
stroke patients at a much higher risk of contracture development, as indicated by 
the work of Ada et al (2006) and Malhotra et al (2012).  The following section will 
critically review current strategies for treating spasticity. This will include the 
separate work on contracture development in animals and the impact on 
treatment regimens for patients as well as the use of systemic and localised 
medications. 
The current methods for treating spasticity have been promoted in scholarly 
articles, clinical guidelines and textbooks and involve a hierarchical stepped 
approach (Ward and KoKo 2001, Bogey et al 2004, Rekand 2010 and Australian 
Government – Department of Health 2015).  In an educational supplement for 
Archives of Physical Medicine and Rehabilitation, Bogey et al (2004) present five 
steps;  
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1. Remove nociceptive input. 
2. Begin therapeutic modalities. 
3. Introduce oral anti-spasticity medications. 
4. Give focal injections.  
a. Motor neuro-muscular transmission blocks such as botulinum toxin 
and/or  
b. Nerve blocks such as phenol. 
5. Surgical procedures.  
a. Intrathecal baclofen 
b. Tendon release or lengthening 
c. Tendon transfers.  
These have been described in further more recent reviews of spasticity 
management by Rekand (2010) and Kheder and Nair (2012).  Steps one and two 
are sometimes combined and termed physical modalities.  This stepped 
approach means that only when the previous step does not help should the next 
step be attempted.   
National guidelines are vague on any specific formalised approach beyond 
physical modalities.  The National Institute of Clinical Excellence in the UK 
guidelines for stroke rehabilitation do not mention spasticity management (NICE, 
2013).  The Canadian Guidelines and the UK RCP Guidelines suggest if 
spasticity is generalised then a systemically acting drug should be used 
(specifically Tizanidine in the Canadian guidelines) but if a specific area is 
involved then botulinum toxin should be used (Lindsay et al 2010 and ISWP 
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2016).  The US Guidelines merely list systemically and locally acting drugs that 
might be of benefit (Miller et al 2010). The Australian guidelines are the clearest 
regarding a formalised approach.  The clinical criteria for using Botulinum Toxin 
in Australia are stated as “The treatment must be used as second line therapy 
when standard management has failed (e.g. physiotherapy and/or oral spasticity 
agents) or as an adjunct to physical therapy.”  Further to these criteria is the 
additional criterion that “Treatment should not be initiated until 3 months post-
stroke in patients who do not have established severe contracture.” (Australian 
Government – Department of Health 2015). 
No investigations in to current practice of spasticity management have been 
made.  An international survey has gathered data about the use of botulinum 
toxin for arm spasticity (Bakheit et al 2010).  The treatment of 974 patients from 
122 centres in 31 countries was included in this cross-sectional survey of current 
medical practice with 72% having had a stroke.   
This survey identified that 75.4% of patients were being treated a year after the 
initial event and less than 15% of the group had been treated within six months 
of the event.  Furthermore, the timing of treatment was found to closely correlate 
with the specified main objective:  active function was the primary goal in those 
treated within three months; passive function was the main objective after the 
first three months  
This survey may not be entirely representative of current practice, as it was 
sponsored by one manufacturer of botulinum toxin, meaning that responses may 
relate to those who use this particular drug.  The survey results do not prove that 
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the hierarchical approach continues to be used, but it does show that treatment 
with focal injections appears to be delayed.   
 
1.3.1 Physical treatments and modalities to treat spasticity  
There are no well-investigated physical treatments that have decreased 
spasticity although attempts have included vibration (Murillo et al 2011), which 
appeared to decrease spasticity for a very short period, transcranial magnetic 
stimulation (Galvao et al 2014) and electrical stimulation (Dewald et al 1996).  
While national guidelines for spasticity in the UK (Royal College of Physicians 
Guidelines) state that a stretching programme should be in place for all patients 
with spasticity (Turner-Stokes et al 2009) there is limited evidence that the 
programme is effective.  Bovend’Eerdt et al (2008) systematically reviewed the 
research to identify whether stretching specifically affected spasticity.  From a 
potential 38 studies only ten were identified as adequately controlled trials.   The 
stretching interventions varied in these ten trials from clinical practice (holding at 
end of range) to mechanical interventions.  Another factor was the difficulty in 
distinguishing between treatments that purely held the joint at end of range and 
treatments that moved the joint through range passively and cyclically.  Perhaps 
unsurprisingly, given these problems, no conclusions were able to be made.  
Bovend’Eerdt et al (2008) did note that there was no evidence of an effect other 
than immediately after the stretch was stopped.  
Given the current understanding of pathophysiology of spasticity it is perhaps not 
surprising that no effect was noted from stretching. However, the hypothesis that 
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stretching might help prevent contractures is based on a stronger 
pathophysiological foundation and supported by animal models.  
 
1.3.1.1 Stretching to prevent contracture in the animal model 
A brace of important experiments by Williams investigating the effect of 
intermittent stretching on the ankle and soleus muscle of mice provide evidence 
to support stretching.  Williams (1988) maintained the ankle in full plantarflexion 
(with soleus in a shortened position) for ten days in two groups of mice, but 
provided an intermittent passive stretch to one of these groups.  These two 
groups were compared to a third control group which had forced shortening of 
soleus.  Using the intermittent stretch method (15 minutes every two days) 
prevented change in the proportion of connective tissue (collagen) to muscle 
tissue present (i.e. the constantly immobilised group had a significantly greater 
(p<0.01) proportion of connective tissue (4.9% standard error (SE)=0.4) but there 
was no difference between the control group (3.4% SE=0.1) and intermittent 
stretch group (3.5% SE=0.9)).  Despite no significant increase in connective 
tissue being identified there was still a significant loss of serial sarcomeres in 
number and passive range of movement at the joint between the intermittent 
stretch group and control group.  Additionally, the loss of sarcomeres in series 
between the constantly immobilised and intermittent stretch group was not 
significant despite the range of movement between the groups being significantly 
different.  
In a progression of this experiment (Williams 1990) the control and constantly 
immobilised groups were treated using the same methodology as the Williams 
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(1988) study (again using the soleus of the mouse).  The Williams (1990) 
experiment used four ‘treatment groups’ that received intermittent stretch on a 
daily basis for 15, 30, 60 or 120 minutes. 
This study identified that half hourly stretching prevented loss of range at the 
joint and prevented loss of sarcomeres in series compared to the immobilised or 
15 minutes per day stretching protocol.  There was however a significant 
(p<0.05) loss of muscle weight when compared to the control group (Williams 
1990) suggesting some change in the muscle morphology. 
The groups that received 60 or 120 minute daily stretches also showed no 
change in range of movement and maintained muscle weight.  These two groups 
showed significantly (p<0.01) greater numbers of sarcomeres in series (Williams 
1990).  
 
1.3.1.2 Stretching to prevent contracture in stroke survivors 
Based on the findings from these two animal models by Williams (1988 & 1990) 
many human studies have used a thirty-minute stretching protocol.  Horsley et al 
(2007) investigated whether daily stretching to the wrist lasting 30 minutes for 
four weeks was effective in preventing contractures in a group of stroke 
survivors.  The patients were recruited and began independent stretching a 
mean 30 days after stroke and there was no significant evidence of benefit at 
either end of treatment stage or follow up.  When the Horsley et al (2007) control 
group data is reviewed it was apparent that they did not develop contractures at 
the same rate as has been identified by Lannin et al (2007) or Malhotra et al 
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(2011).   Although no measures of function were taken in the Horsley et al (2007) 
study, their inclusion criterion that people could only participate if they did not 
have enough strength to actively bring their wrist to neutral suggests that those 
included were less likely to develop contractures in the first place.  This is based 
on the evidence that active movement appears to be preventative (Pandyan et al 
2003). 
Other studies such as de Jong et al (2006) and Ada et al (2005) have used 
prolonged stretches (two times 30 minutes/day, five days a week for five and four 
weeks respectively) to the shoulder with or without the elbow but not the wrist.  
These studies both identified statistically significant reductions of contractures in 
a single shoulder plane but not in all planes.  Contracture development of 
internal rotation was slowed but not shoulder flexion by Ada et al (2005).  This is 
different to de Jong et al (2006) where shoulder adduction contracture was 
slowed but not shoulder flexion, abduction, elbow extension or supination.  One 
argument that might be made for lack of efficacy could be that the stretch was 
too short a duration (de Jong et al 2006) although there was also no 
measurement of muscle activity. 
While the evidence does not support such interventions as being effective, there 
are further concerns.  Such activities are time consuming (one hour during a day) 
and take focus away from the main objective of physiotherapy which is to provide 
high intensity, repetitive, task specific treatments with the aim of achieving 
functionally meaningful objectives within the whole process of rehabilitation 
(Langhorne et al 2011). 
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1.3.1.3 Splinting and neuro-muscular electrical stimulation to 
prevent contractures 
The above studies employed a stretch and hold technique to provide a stretch 
and such methods are time-consuming.  Other strategies to achieve prolonged 
stretches include splinting and casting.  The Lannin et al (2007) paper that has 
already been introduced investigated whether splinting the wrist in end-range or 
mid-range extension for a mean nine hours could prevent contracture.  This 
study found no evidence for splinting the wrist in either position.  This is 
somewhat counterintuitive given the animal models but is in keeping with other 
studies of prolonged stretch in patients with varied acquired neurological injury 
(Lannin et al 2007).  Indeed, methods to treat contracture in the stroke 
population are the same as those used in other populations at risk of developing 
contracture.  A Cochrane Systematic Review of stretching to prevent 
contractures in all populations failed to identify any benefit (Katalinic et al 2010).  
Seven of the studies were stroke specific and meta-analysis of these trials 
showed the immediate effect of splinting provided a mean difference of 2.2 
degrees (95%CI=-1.6 to 6.0 degrees).  Three studies assessed the efficacy 
between one and seven days and the mean difference between the control and 
stretching group was 0.1 degree (95%CI=-3.6 to 3.4 degrees) in favour of the 
control (Katalinic et al 2011).  Heterogeneity of the studies was high in both the 
immediate and short-term effects analyses which are likely to be the result of 
varying protocols. 
Cyclical neuro-muscular (or transcutaneous) electrical stimulation to the 
antagonist muscle is another physical modality that can provide a cyclical 
stretch.  Dewald et al (1996) investigated how electrical intensities below motor 
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threshold over the upper arm affected torque in a group of nine patients post 
stroke.  This study identified that there was an immediate decrease in stiffness in 
seven patients but that this was not maintained (Dewald et al 1996).  An example 
of a more physiologically based protocol for using cyclical electrical stimulation is 
that of Malhotra et al (2012).  This study used cyclical transcutaneous electrical 
stimulation to the forearm extensors with the objective of passively moving the 
wrist from neutral to full extension and back with a three second hold at end of 
range.  The study found the control group had lost 0.8o (SD=-1.1 to -0.5) per 
week during the entire study but the treatment group lost 0.3o (SD=-0.6 to 0.06) 
per week in the same time (p=0.04).  While the low compliance rate (mean 28%) 
suggests other factors may have impacted these results other analyses tend to 
confirm that it was the electrical stimulation.  Secondary analysis showed that 
there was a statistically significant difference in both extensor and grip strength, 
presumably as a result of the electrical stimulation protocol (Rosewilliam et al 
2012). In a randomised controlled trial combining these two approaches (i.e. 
using electrical stimulation and splinting together) did not show a clear effect 
when assessed against splinting alone (Leung et al 2012). 
It can be concluded from this review of the literature that there is a lack of 
evidence on the best physical method to prevent contracture development.  This 
conclusion was also made in the NICE accredited UK Practice Guidelines on 
Splinting (Kilbride et al 2015).  
There are other factors in deciding which treatment option may be more useful. 
While the static stretches provided by splinting and holding at end of range are 
purely passive, neuro-muscular electrical stimulation has been shown to produce 
additional benefits other than slowing contracture development.  Electrical 
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stimulation to the arm results in muscle strengthening.  Nascimento et al (2014) 
pooled data from 11 trials (n=359) of electrical stimulation to the arm following 
stroke and identified a standardised mean difference of 0.47 (95%CI 0.26 to 
0.68) versus placebo.  When the trials were grouped according to time post 
stroke those treated within six months following stroke had a greater effect size 
than those treated later (Nascimento et al 2014).  This same systematic review 
identified data from four trials (n=198) that electrical stimulation provided 
improvements at an activity level beyond the intervention period effect size=0.39 
(95%CI 0.09 to 0.66) (Nascimento et al 2014).  A further positive effect of 
electrical stimulation is that it induces changes in the corticospinal pathways 
which might be important in motor re-learning (Golaszewski et al 2010). 
Given the lack of evidence pertaining to prevention of contractures the additional 
benefits that can be provided by electrical stimulation make this the best overall 
option.   
1.3.2 Systemically acting drugs 
As part of this thesis a Cochrane systematic review was carried out 
“Pharmacological interventions other than botulinum toxin for spasticity after 
stroke” (Lindsay et al 2016).  The objective was to assess if pharmacological 
interventions for spasticity are more effective than no intervention, normal 
practice, or control at improving function following stroke.   
The Cochrane Stroke Group Trials Register (May 2016), the Cochrane Central 
Register of Controlled Trials (CENTRAL, 2016, Issue 5), MEDLINE, Embase, 
CINAHL, AMED (all to May 2016), and eight further databases and trial registers 
were searched. In an effort to identify further studies, hand searches of reference 
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lists and study authors and commercial companies were undertaken by the PhD 
candidate. 
Randomised controlled trials (RCTs) that compared any systemically acting or 
locally acting drug versus placebo, control, or comparative drug with the aim of 
treating spasticity were included. 
Two review authors (one being the PhD candidate) independently assessed the 
studies for inclusion and extracted the data. They assessed the included studies 
for both quality and risk of bias. The PhD candidate contacted study authors to 
request further information when necessary. 
Seven RCTs with a total 403 participants were included.  A high risk of bias in all 
but one RCT was identified. Two of the seven RCTs assessed a systemic drug 
versus placebo. An indirect measure of spasticity (160 participants) from these 
two studies were pooled but found no significant effect (odds ratio (OR) 1.66, 
95% confidence interval (CI) 0.21 to 13.07; I2 = 85%) (Figure 1a). There was a 
significant risk of adverse events per participant occurring in the treatment group 
versus placebo group (risk ratio (RR) 1.65, 95% CI 1.12 to 2.42; 160 participants; 
I2 = 0%) (Figure 1b). Only one of these studies used a functional outcome 
measure, and there was no significant difference between groups. 
Of the other five studies, two assessed a systemic drug versus another systemic 
drug, one assessed a systemic drug versus local drug, and the final two 
assessed a local drug versus another local drug. 
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This Cochrane review has shown that there is very little evidence to continue 
using oral anti-spasmodics in the treatment of spasticity and that there is a high 
prevalence of side effects.   
Figure 1a: Meta-analysis of data from two studies that assessed a systemically 
acting drug against a placebo on spasticity 
 
 
Figure 1b: Meta-analysis of data from two studies that assessed a systemically 
acting drug against a placebo on risk of adverse events 
 
The side effect profiles of these drugs are reflected in a retrospective analysis of 
compliance with systemic drugs (Halpern et al. 2013).  This study reviewed data 
from a US health insurance company to identify adherence as a percentage of 
the expected prescribed drug dose.  Out of 285 stroke patients; 199 were on 
baclofen, 75 on tizanidine and eleven on dantrolene and adherence was 49% 
(SD35%), 44% (SD28%) and 52% (SD39%) respectively.  The numbers of 
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people taking the prescribed medication was dichotomised at the 80% 
compliance point and all three drugs showed only around 30% of people 
adhering at this level.  This study may have been negatively affected by the self-
selective cohort.  It should also be viewed in the knowledge that the study was 
funded by a botulinum toxin company that had potential benefit from negative 
results. 
The other important issue raised in the Cochrane Review is the potential 
deleterious effect of oral systemic anti-spasmodics on motor learning.  It is 
possible to relate all physiotherapy based treatments to neuroplasticity (whether 
peripherally or centrally). Neuroplastic changes must occur for any motor 
learning to occur (Langhorne et al 2011).  Following a stroke or any neurological 
lesion the main objective of physiotherapists is to optimise these neuroplastic 
changes to achieve appropriate functional activities with the patient.  For motor 
learning to occur in any human a downregulation of GABAnergic inhibition is 
necessary.  With this basic science knowledge, some therapeutic approaches 
have attempted to harness this in order to drive neuroplastic changes following 
stroke (e.g. Transcranial Magnetic Stimulation, transcranial direct-current 
stimulation). 
What appears to have been overlooked is that the mechanism by which the most 
commonly used anti-spasmodic (baclofen) decreases spasticity is by 
upregulation of GABAnergic inhibition. 
Willerslev-Olsen et al (2011) investigated how baclofen and another GABAnergic 
drug (diazepam) affected visual-motor learning in sixteen healthy young adults.  
Participants were randomly assigned to placebo, baclofen or diazepam for each 
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of three individual sessions separated by at least four weeks.   A training session 
consisted of ten three minute sessions where a visual-motor task was practiced.  
This task involved dorsiflexion movements that corresponded to a screen cursor.  
The study used a seemingly overly complicated methodology which measured 
training-induced changes in motor evoked potentials and reductions in 
intramuscular coherence as well as the primary visual-motor tracking task. 
The study is important as it is the only study that has investigated the impact of 
anti-spasticity medication on motor learning - which is the main basis for 
recovery of function post stroke (Langhorne et al 2011).  The results showed that 
only the placebo group achieved significant within session improvements in the 
task (p=0.05) (Willerslev-Olsen et al 2011).  These within session improvements 
were reflected in a significant difference (p<0.05) between placebo and 
participants who had received diazepam and baclofen at final session 
assessment.  Willerslev-Olsen et al (2011) highlighted that the changes could be 
down to increased drowsiness in the drug groups rather than the result of 
decreased plasticity.  The finding that motor evoked potentials threshold in the 
placebo group reduced in line with previous studies which did not occur in the 
drug groups suggests plastic changes had occurred.   
Although the numbers in each group were small in this study, these findings 
correlate with the current understanding of how neuroplasticity occurs 
(Willerslev-Olsen et al 2011).  The evidence suggests that this family of 
antispasticity drugs, that are based on up regulation of GABAnergic inhibition, 
are detrimental to neuroplasticity.  Neuroplasticity is the basis upon which neuro-
rehabilitation science is based (Langhorne et al 2011) and so it can be 
concluded that the use of these drugs would not be appropriate in this Trial. 
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1.3.3 Botulinum Toxin 
Botulinum toxin is an injectable drug that acts at the neuromuscular junction on 
the peripheral cholinergic nerve endings to inhibit the release of acetylcholine 
and so reduce muscle contraction (Barnes and Davis 2008).  Many large, 
international multi-centre and well organised randomised controlled trials 
investigating botulinum toxin have been conducted that clearly indicate that the 
stiffness measured by Ashworth scale can be decreased (Wissel et al 2009).  
Rosales and Chua-Yap (2008) carried out meta-analysis of the efficacy in post 
stroke spasticity in five out of nine identified studies that presented Modified 
Ashworth change as improving by one point.  This same study identified an odds 
ratio of 4.5 (2.79 to 7.25) in favour of botulinum toxin to reduce stiffness. 
There are two major problems with the majority of botulinum toxin studies, and 
indeed all the studies in the included meta-analysis above.  The first is the use of 
the Modified Ashworth Scale, while the second is that many trials exclude 
participants that had a stroke within the last six months. 
The Modified Ashworth Scale is an indirect measure of spasticity which is 
dependent on the perception of stiffness (Fleuren et al 20010).  This makes it 
impossible to state categorically that spasticity was treated as there is no 
evidence that the abnormal muscle activity was decreased.  It also means that 
the very impairment that is ideally trying to be prevented (i.e. contracture 
development) has already started by the time the drug is initiated.   
In regard to the second problem, the systematic review of botulinum toxin post 
stroke by Rosales and Chua-Yap (2008) identified nine randomised controlled 
trials that had presented Ashworth Scale data as mean and standard deviation.  
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These nine papers (Table 1.1) have been reviewed again to identify the specified 
time post stroke for inclusion to the trial and the mean time post stroke.  
None of the studies explained why they had specified a minimum time from 
stroke.  General comments that spasticity occurred late in the life time of stroke 
or that natural recovery should have completed by the time the patients were 
being investigated point to some of the rationale used. Moreover, in the seven 
studies that reported the actual mean time from stroke, it was greater than 24 
months (2 years) with the exception of Hesse et al (1998) who had a six-month 
inclusion window of six to twelve months from stroke.  
  Table 1.1 – Mean time from stroke to injection in the nine papers included in 
Rosales and Chua-Yap (2008) systematic review 
Author Date Inclusion criteria Mean time from stroke 
(Months) 
Bakheit et al 2000 > 3 months post stroke Not reported 
Bakheit et al 2001 > 3 months post stroke Not reported 
Brashear et al 2002 > 6 months post stroke 55.2 months * 
Burbaud et al 1996 Spasticity > 3 months Mean duration of spasticity 
23.5 months (SD - 33 8) 
(range 3.5 to 120) 
Childers et al 2004 >6 weeks post stroke 25.8 months (range 0.9 to 
226.9) 
Hesse et al 1998 6-12 months post stroke 7.45 months (range 6–11)  
Pittock et al 2003 >3 months post stroke 33.6 months (SD – 37.2) * 
Smith et al 2000 >1 year post stroke 24 months (SD – 19.2) * 
Simpson et al 2009 >9 months post stroke 37 months (range 9 to 133) 
*Data was only provided in groups (presented data was the group with smallest 
mean) 
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There are studies that have investigated botulinum toxin injection within the early 
stages post stroke (Cousins et al 2010, Rosales et al 2012, Hesse et al 2012, 
and Fietzek 2014).  The first three investigated only the arm whereas the Fietzek 
paper investigated equinovarus. 
An important point to make is that only Cousins et al (2010) measured the 
abnormal muscle activity indicative of spasticity.  The other three depended on 
the development of clinically perceived stiffness to initiate treatment (using the 
(Modified) Ashworth scale) and used this as the primary outcome measure.  A 
recent meta-analysis combined mean Ashworth scale data with the mean EMG 
data of these three studies and identified a standard mean difference (SMD) of 
−1.53 (95%CI: −2.47 to −0.58 p=0.002) (Rosales et al 2016).  This result is 
problematic since combining nominal data with continuous data in a meta-
analysis is not appropriate.  Only continuous data should be presented using 
SMD summary statistics as per the ‘Cochrane Review Handbook’ (Higgins et al 
2011).  Discussion with the stroke editorial team of the Cochrane review group 
confirmed that data from the Ashworth scale should only be presented as odds 
ratio. 
The Cousins et al (2010) study was able to prove that the abnormal muscle 
activity had been significantly decreased in the two treatment groups when 
compared to a placebo group.   Additionally, in those patients with no arm 
function at randomisation there appeared to be a benefit in functional outcome at 
final follow-up in the treatment groups compared to the placebo group.  The 
study was underpowered but these results are clearly worth investigating further.  
The method used by Cousins et al (2010) used measuring techniques similar to 
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those proposed for this study and provided a base reference that such an 
intervention was safe to use. 
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1.4  Conclusions  
Patients who are admitted to hospital following a stroke will present with a wide 
variety of impairments including weakness of the muscles.  If this muscle 
weakness is sufficiently severe, the patient will be unable to move the joint 
against gravity which will prevent recovery of function.  People who do not 
recover function are at very high risk of developing contractures.  Two catalysts 
to the development of contractures have been identified in animal experiments. 
• Muscles that are experimentally made over-active develop contractures 
faster than those that do not have abnormal muscle activity. 
•  Muscles held in shortened positions develop contractures faster than 
those held in a neutral or a stretched position. 
If these two known precipitators to the development of contractures in animals 
(and which are also present in some stroke survivors) could be removed then 
prevention or at least the slowing of contracture development may be achieved. 
The first catalyst, abnormal muscle activity, occurs as a result of the brain losing 
its inhibitory effect at the spinal cord level following stroke.  In stroke patients, the 
time at which this abnormal muscle activity develops following a stroke has not 
been identified.  A study using a neurophysiological measure to determine when 
the abnormal muscle activity occurs is likely to provide further insight.   This 
could also allow earlier treatment of spasticity to be initiated. 
The second catalyst, when the muscle is maintained in a shortened position for 
prolonged durations, also presents in humans. The normal posture for the arm 
while resting in bed or in a chair at rest is one of flexion at the elbow, wrist and 
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fingers.  In people who present with the most severe strokes, weakness will 
prevent them moving out of this position and so the person’s muscle will be 
immobilised in a shortened position for prolonged periods.     
Animal models suggest that prevention of contracture development might be 
achieved through stretching of the muscle for longer than 30 minutes, but 
previous studies using splinting have not shown this to be transferable to the 
population of stroke survivors.  There is some evidence that contracture 
formation is reduced in stroke survivors receiving therapeutic neuromuscular 
electrical stimulation to the wrist extensors which provides a cyclical extension to 
the wrist and fingers.   
It is possible that using botulinum toxin to the arm flexors (to reduce abnormal 
muscle activity) in conjunction with electrical stimulation to the wrist extensors (to 
passively move the wrist and fingers) might be effective in preventing or slowing 
down contracture development. 
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1.5 Research Questions 
1. When does spasticity in the arm develop following stroke in patients who 
initially have no arm function, and can the Tardieu scale identify this? 
2. Is it possible to prevent or delay contracture development by treating 
spasticity early with botulinum toxin? 
3. Do patients who have spasticity treated early have better recovery of function 
compared to those who are not treated? 
4. Does the sub-group of patients identified as least likely to recover function 
benefit from early treatment of spasticity more than others? 
1.6 Secondary objectives 
The secondary objectives of research question one were to:  
 identify the proportion of participants who recovered function in the first 6 
weeks (measured as scoring greater than 2 on the Grasp sub-section of 
the Action Research Arm Test (ARAT)). 
 identify if there were any variations in EMG pattern activity and if these 
are the same at the elbow and wrist. 
 identify any variations between the Tardieu scale (Held & Pierrot-
Deseilligny 1969) and the abnormal muscle activity identified on EMG. 
A secondary objective of research question two was to:  
 identify whether there was a significant difference in spasticity between 
the group treated with botulinum toxin and the placebo group and how 
long this lasted.  
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There were no secondary objectives for research question three. 
Secondary objectives of research question four were to: 
 identify whether the clinical measures used to predict recovery of arm 
function at baseline were able to detect two significantly different groups 
at six-month follow-up. 
 identify whether there was a significant difference in spasticity in treatment 
and placebo arms of the sub-group and how long this lasted.  
 identify whether those patients in the sub-group who have spasticity 
treated early have better recovery of function compared to those who are 
not treated? 
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2. Method  
2.1. Trial design 
Clinical studies can be divided in to two forms; observational (i.e. one where the 
researcher does not interfere) and interventional (i.e. one where the researcher 
alters a particular variable or variables) (Bland 2015).  To allow the investigation 
of all four research questions within the framework of a single study an initial 
screening phase (observational study) was followed by a single centre 
randomised controlled trial (interventional study). 
Using this combined methodology ‘time of onset’ was answered by analysing the 
screening phase data.  The other research questions were answered through 
analysis of between group variations in the placebo and treatment groups.  In 
order to answer a particular question, specific outcome measurements were 
analysed, or in the case of question four, a sub-group of the participating 
participants were analysed.  
In order to prevent duplicating the protocol methods four times, the protocol 
relating to the screening phase will be presented first (Section 2.7).  This will 
answer research question one in the form of a prospective longitudinal study. 
Subsequently the protocol relating to the randomised controlled trial is presented 
(Sections 2.8 to 2.10).  This will answer research questions two to four.  All 
participants who were involved in the randomised controlled trial phase had gone 
through the screening phase protocol prior to randomisation. 
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The outcome measures taken at each time point and the process involved in 
collecting the measurements are described.  Finally, the planned data analysis is 
described.   
2.2. Trial registration, funding and sponsorship 
The trial was funded by the National Institute of Health Research – Research for 
Patient Benefit programme (PB-PG-0808-16319).  An unrestricted grant from 
Allergan Ltd. provided funding to purchase equipment and they also provided the 
clinical trial drug. 
The study was approved by a local Research Ethics Committee (Greater 
Manchester South - 10/H1003/111) (Appendix 2).   No drug was requested until 
written research ethics committee authorisation had been received.  The 
Medicines and Healthcare Regulatory Authority (MHRA) acting as the national 
legal authority for the European Union provided legal authorisation for the clinical 
trial to commence (EudraCT number: 2010-021257-39) (Appendix 3).  The 
protocol has been published (Lindsay et al 2014) and also registered with 
clinicaltrials.gov (NCT01882556). 
Sandwell and West Birmingham NHS Trust and Keele University were co-
sponsors for this trial and as such an agreement between both sponsors was 
signed to ensure all Sponsor roles were covered.  Regulatory approvals were 
checked by both co-sponsors prior to the trial beginning.  Approval was received 
from the Research and Development department of SWBH NHS Trust on behalf 
of the sponsors to approve trial commencement (Appendix 4). 
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2.3. Sample Size Calculations 
Preliminary sample size calculations were identified using data from the study by 
Cousins et al (2010).  With an effect size of 0.5 (using the Action Research Arm 
Test (ARAT)) and at 80% power and a 0.05 significance level, 126 patients were 
calculated to be required. With an effect size of 0.6 and at 80% power (0.05) 
significance level, 88 patients were calculated to be required.  This study aimed 
to recruit 120 patients to a randomised controlled trial in 2 years. 
2.4. Study setting and eligibility 
All stroke patients admitted to Sandwell and West Birmingham National Health 
Service Trust (SWBH NHS Trust) were eligible to participate if they satisfied the 
study inclusion and exclusion criteria. The aim was to recruit 150 patients in total.  
Potential participants were recruited from the clinical case load of clinicians 
caring for them.  
 
2.4.1. Eligibility criteria  
Patients had to fulfil specific inclusion and exclusion criteria to be eligible to 
participate in the screening phase and further inclusion criteria to participate in 
the randomised controlled trial.  In order to prevent recruitment of people who 
would not be able progress to the randomisation phase the same exclusion 
criteria were used to identify eligibility for participation in the screening phase.  
The exclusion criteria therefore reflect contraindications to the trial drug. 
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2.4.1.1. Inclusion criteria (Screening Phase) 
 Over 18 years of age 
 Patients admitted to hospital with a diagnosis of stroke (between day 1 
and day 42 after onset) due to a primary cerebral 
haemorrhage/infarction, subarachnoid haemorrhage producing an 
upper motor syndrome affecting one body side which results in a 
hemiparesis 
 Capable of providing informed consent directly or indirectly, or, assent 
obtainable from next of kin 
 No useful arm function (i.e. less than or equal to 2 on the grasp 
subsection of the Action Research Arm Test) at the stroke onset (Lyle 
1981) 
 
2.4.1.2. Inclusion criteria for randomisation treatment phase  
 Evidence of upper limb spasticity demonstrated by surface EMG 
activity (Pandyan et al 2001) 
 
2.4.1.3. Exclusion criteria 
 Significant musculoskeletal conditions that affected upper limb function 
prior to the stroke 
 Unconscious or moribund during the screening period, or scheduled to 
have palliative care only 
 Recovery of useful arm function (a score of 3 or more in the grasp 
section of the Action Research Arm Test) prior to injections (Lyle 1981) 
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 Patients with contraindications to electrical stimulation including active 
implants (e.g. cardiac assist devices), metal implants at site of 
stimulation, scar tissue/cancerous tissue at site of stimulation, 
uncontrolled epilepsy, deep vein thrombosis in limb / muscle being 
stimulated  
 Previous spasticity due to multiple sclerosis, spinal cord injury or other 
neurological disorder 
 Patients with a known hypersensitivity to any botulinum toxin or to any 
of the excipients of Botox® (i.e. Human serum albumin) 
 Patients with myasthenia gravis or Eaton Lambert Syndrome or other 
neuromuscular junction or myopathic disorder 
 Patients with infection at the proposed injection site(s) 
 Patients who were pregnant or may become pregnant at the time of 
the proposed injections and for the duration of the study 
 Current treatment with any anti-spasticity agent or previous injection 
with botulinum toxin  
 
2.4.2. Withdrawal of patients 
Patients were able to withdraw from the study at any stage: in the screening 
phase prior to injection of Botox® or placebo: after injection either through 
personal choice (or at the request of their next of kin) or for a pre-determined list 
of clinical reasons.  Patients who withdrew from the study following injection 
were included in the intention to treat analysis unless they requested that all their 
data be removed from analysis. 
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2.5. Recruitment 
A screening log was used to track the number of patients who were approached 
to participate.  If the patient was ineligible or refused to participate, the reason 
was recorded in the log if they chose to provide this information.  Any patient 
who indicated willingness to consider study participation was provided with all 
the study details and a patient information sheet to review (See Appendix 5).  
Assessments were only performed after valid consent was obtained and a study 
code was allocated.  A demographic pro-forma was completed after consent to 
gain all the demographic data necessary for the clinical trial (See Appendix 6) 
and acted as a secondary verification of eligibility to recruitment.   
These included:  
 Past and presenting relevant medical history. 
 Pre-admission Barthel Index based on discussion with patient and carers 
(Collin et al (1988). 
 Features of the stroke (National Institute of Health Stroke Severity 
(NIHSS) scale (Brott et al 1989).  The NIHSS scale was completed by a 
consultant stroke physician or neurologist within 24 hours of a stroke and 
prior to any thrombolysis treatment – in cases where there was a 
significant deterioration in NIHSS post thrombolysis then the more severe 
NIHSS at 24 hours was used. 
 Classification of stroke using the Oxford community stroke project 
classification system (Bamford et al 1991). 
 Any relevant complications of stroke. 
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2.6. Consent  
For each trial patient, written valid consent was obtained prior to any protocol 
related activities. The research therapist explained verbally and provided the 
information in writing regarding the nature, duration, and purpose of the study, 
and the action of the drug in such a manner that the patient and/or carers were 
aware of the potential risks, inconveniences, or adverse events that might occur. 
The patient and/or carers were informed that the patient may withdraw from the 
study at any time. They received all information that is required by local 
regulations and ICH GCP guidelines (NIHR 2010).    See Appendix 7 which is an 
example of the consent sheet used that was accepted by the Research Ethics 
Committee. 
In cases where the patient was deemed to lack capacity the next of kin was able 
to provide consent for the patient to participate in the study. 
2.7. Screening Assessments 
From the date of consent, patients who were enrolled in the study were 
monitored for a period of up to six weeks from stroke onset by the research 
therapist (the candidate). Monitoring was normally carried out on a Monday, 
Wednesday and Friday. The frequency was increased to daily if clinically 
indicated (i.e. there was apparent developing spasticity or functional recovery on 
one day but confirmation to establish certainty was required the next day).  
 
For monitoring purposes, the study therapist conducted two simple bedside tests 
which took a maximum of ten minutes.   
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 Function - The grasp subsection of the Action Research Arm Test (ARAT) 
(Minimum score=0 and maximum score=3) (Lyle 1981) to assess for 
functional recovery, using the protocol by Yozbatiran et al (2008).   
 Spasticity - The surface EMG response of the wrist and elbow flexors to 
an externally imposed perturbation (Pandyan et al 2001). Presence of 
spasticity was a related increase in muscle activity observed on EMG 
during a passive movement.  
 
To measure the grasp subsection of the ARAT a 2.5cm cube was placed on a 
table in front of the patient and they were asked to pick it up and place it on a 
shelf 37cm above the table (Lyle 1981).  If they were unable to achieve this task 
they scored zero or only partly able to achieve this task then they scored one 
and so screening continued.  If they scored greater than two (i.e. they were able 
to place it on the cube on the shelf) on this task then they were deemed to have 
recovered function. 
 
To measure spasticity, non-invasive EMG electrodes (SX230 active surface 
electrodes for bipolar recording of muscle activity, Biometrics Ltd, UK) were 
placed on the elbow flexors and wrist flexors (See figure 2.1 for equipment). The 
joint was moved from full flexion to extension a maximum of six times from a 
position of rest. Patient positioning was documented as sitting or half lying and 
these tests took a maximum of ten minutes. (A more in-depth explanation of this 
assessment process is provided in Section 2.11.1).  Presence of spasticity was a 
movement related increase in muscle activity observed on EMG during a passive 
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movement (Pandyan et al 2001).  If no abnormal muscle activity was observed 
on EMG during the passive movement then screening continued.   
 
All patients who completed the screening phase could be classified in to one of 
four groups. They either developed: spasticity with functional recovery, no 
spasticity with functional recovery, no spasticity with no functional recovery or 
spasticity with no functional recovery. 
Figure 2.1 – Equipment used during screening assessment and trial  
1. MyoMeter 
M550, (Biometrics Ltd, 
UK) 
2. SX230 surface 
electrodes, (Biometrics 
Ltd, UK) 
3. SG 110 
electrogoniometer, 
(Biometrics Ltd, UK) 
4. DataLOG 
MWX8 (Biometrics Ltd, UK) 
 
If a participant scored greater than two on the grasp sub-section of the ARAT 
then they were deemed to have recovered function and, irrespective of their 
spasticity, the screening phase stopped.  They had baseline assessment 
measurements taken and were then followed up at three and six months. 
 
If a patient did not develop spasticity in the first 42 days following stroke then 
baseline measures were taken on day 42 and they were followed up at three 
months and six months following stroke.  
1 
2 
4 
3 
51 
 
Cameron Lindsay  
 
 
If a participant satisfied the inclusion criteria for the randomised control trial (i.e. 
developed spasticity with no functional recovery) they immediately progressed to 
have the baseline assessment measurements taken and were randomised to 
either active treatment or placebo. 
 
2.8. Randomisation 
Randomisation was carried out by a statistician at Keele University using 
computer generated random permuted blocks in a pseudorandom sequence.  
They were stored in a sealed envelope and held securely at SWBH NHS Trust in 
the Pharmacy Department.  The research therapist contacted pharmacy and the 
research pharmacist was asked to randomise the patient (by opening the next 
sealed opaque envelope in the randomisation pack). The pharmacist gave the 
research therapist the study identification number but did not disclose the 
allocated treatment to the injecting clinician or the research therapist. Please see 
Appendix 8 for the delegation log. 
 
2.9. Interventions 
2.9.1. Details of treatment groups  
There were two treatment groups: the treatment group received injections of the 
investigational medicinal product (BOTOX®/ onabotulinumtoxinA) and the 
placebo group received injections of 0.9% sodium chloride solution.  The 
investigational medicinal product was supplied to the site by Allergan Ltd.  All 
participants received standardised physiotherapy in addition to their normal 
routine physiotherapy and occupational therapy.  
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2.9.2. Investigational Medicinal Product  
There are three preparations of botulinum toxin type A available in the United 
Kingdom. Although the active substance in all three preparations is the same 
due to production processes there is variation in the dose/units.  Allergan 
manufacture Botox® (onabotulinumtoxinA), Ipsen manufacture Dysport® 
(abobotulinumtoxinA) and Merz manufacture Xeomin® (incobotulinumtoxinA).  
The active substance is a neurotoxin obtained from cultures of Clostridium 
botulinum (gram-positive anaerobic bacteria) and works by temporarily inhibiting 
the release of acetylcholine at the pre-synaptic nerve endings of the motor end 
plate, thus temporarily inhibiting muscle force production (Black and Dolly 1986). 
In this study Botox® was used as the injecting team had the most experience of 
using this product.  
2.9.3. Dispensing investigational medicinal product 
The research therapist identified which muscles required injection and completed 
the Study Medicines Request/Prescription Form (See Appendix 9). The form was 
then given to one of the medically qualified Clinical Investigators who would sign 
the form only after they were satisfied that there were no contra-indications or 
cautions why the patient could not receive the study medications and all 
exclusion and inclusion criteria had been checked.  This form was then sent to 
pharmacy. Copies of this were held in the patient’s medical notes and the 
patient’s Trial folder. 
 
The trial pharmacist dispensed either one or two vials of Botox®, and one 5ml 
ampoule of 0.9% Sodium Chloride solution (Treatment group) or only the one 
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5ml ampoule of 0.9% Sodium Chloride solution (Placebo group) depending on 
the randomisation. The agents dispensed were listed in a Dispensing Pro-forma. 
This form was held securely in the pharmacy with the randomisation envelopes 
in the Trial Folder. Had unblinding been necessary on clinical grounds then this 
form could be accessed 24 hours per day by the on-call pharmacist.  A standard 
operating procedure for emergency unblinding of a patient who has been 
randomised (e.g. in the event of a serious adverse event) was written (See 
Appendix 10). 
The dispensed medicines were passed to an independent clinician in a sealed 
opaque container. These clinicians (either a physiotherapist or nurse) had to 
have completed training in reconstitution of Botulinum Toxin and their 
competencies recorded in the trial folder. Because they were unblinded to the 
treatment group, they were not involved in the day to day rehabilitation therapy of 
the patient being injected. 
2.9.4. Reconstitution and masking 
The syringe was filled by the independent clinician with either the reconstituted 
botulinum toxin in 0.9% sodium chloride (NaCl) solution or NaCl solution alone if 
the patient is randomised to placebo treatment to the exact requirements as 
documented in the study medication request/prescription form filled out by the 
research therapist. In particular, care was taken to ensure when the toxin or 
saline was drawn up into the syringe, that the syringes always contained exactly 
2.0ml of solution. This was to avoid the risk of any difference in appearance of 
the syringe containing active toxin or saline alone which might have allowed 
unblinding to occur. 
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A second trained clinician unrelated to the trial was (a pharmacist or pharmacy 
assistant) in attendance throughout this activity and signed, in duplicate, the 
reconstitution pro-forma to confirm that the syringe was filled with the dispensed 
medicinal product.  
Once the syringe was ready it was placed in a mobile sharps tray with attached 
sharps bin and given to the injecting clinician outside the preparation room with 
the signed reconstitution pro-forma for review by the injecting clinician.  
The research pharmacist or pharmacy assistant then took the reconstitution pro-
forma and the used vials/ampoules back to pharmacy in the container. One copy 
of the reconstitution pro-forma was filed by pharmacy in the Trial folder. The 
second copy of the reconstitution pro-forma was filed in the patient’s notes with 
the drug chart which was signed by the injecting clinician once the medication 
has been administered. 
This procedure ensured that the independent reconstituting clinician and 
certifying pharmacy colleague were the only persons who knew whether a 
patient received a treatment or placebo injection. None were involved in any 
other part of the study.   
2.9.5. Injections 
The patient received the intra muscular injection of either BOTOX® or placebo 
within 48 hours of the baseline assessment. Because the injector was blinded 
even if the patient was allocated to receive placebo, the volume in the vial(s) and 
location of the injections was the same as if the patient were receiving BOTOX®. 
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2.9.5.1. Total dose and injection sites  
All eligible patients randomised to receive intra muscular injections of Botox® or 
0.9% Sodium Chloride solution were injected in six muscles of the affected arm 
in predetermined doses.    Muscles injected were flexor digitorum superficialis 
(FDS), flexor digitorum profundus (FDP), flexor carpi ulnaris (FCU), flexor carpi 
radialis (FCR), biceps and brachialis.  The volume to be injected was calculated 
on the number of units per ml that the injection solution would contain if it 
contained Botox®.  Table 2.1 shows the Botox® units administered to each 
muscle. In patients with a substantial lack or excess of muscle bulk or where 
there was excessive muscle activity leading to clonus, the research therapist 
adjusted the concentration of dosage.  
Table 2.1 – Muscles and dosage of Botox® Units to be injected 
Muscle Units (-25%) Main Dose units Units (+25%) 
Biceps 30 40 50 
Brachialis 30 40 50 
Flexor digitorum 
superficialis 
20 25 30 
Flexor digitorum 
profundus 
20 25 30 
Flexor carpi ulnaris 10 15 20 
Flexor carpi radialis 10 15 20 
 
Maximum dose / person: 200 Botox® Units 
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2.9.5.2. Method of administration 
Reconstituted Botox® and placebo was injected using a sterile 27- gauge 
electrical stimulation needle for muscles.  Localisation of the involved muscles 
were determined clinically by superficial anatomical landmarks and using 
electrical stimulation techniques using the techniques presented by Harding et al 
(2013) (Please see figure 2.2 which shows the electrical stimulation equipment 
being used to identify flexor digitorum superficialis from Harding et al (2013)).  
Where localisation of the muscles for injection proved to be difficult using surface 
anatomy and EMG then ultrasound was employed to guide the injection 
procedure and check accuracy of placement of the needle in the specified 
muscles. 
Figure 2.2 – Injection placement in to flexor digitorum superficialis using 
electrical stimulation (with permission from Harding et al (2013) 
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2.9.5.3. Standardised physiotherapy treatment  
The current Royal College of Physicians recommendation is that injections of 
botulinum toxin should be followed by a period of targeted rehabilitation therapy 
(Turner-Stokes 2009), although there is little guidance on what the content or 
duration of this therapy should be.  
This study standardised part of the patients’ overall physiotherapy by providing 
neuromuscular electrical stimulation to the forearm extensors.  On the day 
following the injections the research therapist reviewed the arm for any adverse 
events related to the injection and provided an electrical stimulator. 
The electrical stimulator (Nature’s Gate Ltd) provided the forearm extensors with 
an electrical stimulation to achieve wrist and finger extension.  The stimulation 
parameters were standardised to have a pulse-width of 400 microseconds and 
frequency of stimulation of 50Hz. The stimulation was provided for 30 seconds 
inclusive of a ramp up time of 5 seconds and ramp down time of 5 seconds.  A 
30 second rest was then provided (Pandyan et al 1997).  The machine was set 
to provide a stimulation intensity that produced a contraction and extended the 
wrist and fingers against gravity without evoking pain and the treatment lasted 30 
minutes.  The patient received the electrical stimulation three times a day for the 
first three months after the injection.  Whilst in hospital a physiotherapy assistant 
provided the electrical stimulation five days a week and the patient and carer 
were taught how to provide the stimulation independently.  On discharge the 
patient and or carer were asked to continue to provide the treatment three times 
a day until the three-month assessment.  A diary to tick when the treatment was 
carried out was completed to assess compliance of this treatment.  Because this 
treatment was primarily aimed at providing a passive movement to the wrist and 
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finger joints, patients who subsequently recovered a grade of three on the MRC 
scale discontinued the electrical stimulation in order to concentrate on more 
appropriate active functional task training as prescribed by the treating 
physiotherapist.  All other physiotherapy and occupational therapy was provided 
as appropriate by clinicians not directly involved in the study.  Content and 
quantity of therapy was monitored using a bespoke tick sheet documentation 
developed with the specific team. 
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2.10.  Outcome Measures 
The standard format to describe the outcomes is to state the primary outcome 
followed by any secondary outcomes. Because this study reports a number of 
research questions, the primary outcome measures vary depending on the 
question.  The research therapist carried out assessments at baseline (prior to 
randomisation), two, four and six weeks after the injections, three months after 
the injections and then at six months following stroke.  This section reports all the 
outcome measures taken at each time point from baseline through to final follow-
up assessment in a chronological format.  See table 2.2. 
2.10.1. Baseline assessments 
Once patients had either: developed spasticity without recovery of arm 
function (i.e. fulfilled the inclusion criteria for entry to the randomised 
controlled trial and prior to randomisation), recovered arm function, or 
reached the end of the six-week screening phase baseline measurements 
were taken.  Baseline assessments were: 
 Arm function (Action Research Arm Test - ARAT) (Lyle 1981) using the 
protocol by Yozabatiran et al (2008) – minimum score=0 and 
maximum score = 57.   
 Spasticity in the wrist and elbow flexor muscles measured using 
protocol by Pandyan et al (2001) and the Tardieu Scale (Held & 
Pierrot-Deseilligny 1969 and Morris 2002)  
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 Stiffness – the resistance encountered during a slow passive 
extension of the elbow and wrist measured using the protocol by 
Pandyan et al (2001) and Cousins et al (2010) 
 Passive range of movement – the maximum passive extension 
achieved during a slow passive extension of the elbow and wrist 
measured using the protocol by Pandyan et al (2001) and Cousins et 
al (2010) 
 Pain - measured using a visual analogue scale from 0-100 (Gallagher 
et al 2001).   
 Muscle function 
o Isometric strength at midrange of movement using a 
dynamometer for elbow flexion, elbow extension, wrist flexion 
and wrist extension. (MyoMeter M550, Biometrics Ltd, UK) 
(Cousins et al 2010). 
o Fatigue - Derived from the above measurement of isometric 
strength by estimating the time taken for the force generation to 
drop to 70% of the maximum isometric strength measurement).  
o Grip strength was measured using a grip dynamometer 
(Precision Dynamometer G200, Biometrics Ltd, UK).   
 A measure of activities of daily living was carried out - Barthel Index 
Score described by Collin et al (1988) (minimum score=0 and 
maximum score = 20). 
Please see Appendix 11 for the Baseline Assessment Pro-forma used. 
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2.10.2. Assessments at two, four and six weeks following 
injection 
 Grasp subsection of the ARAT 
 Spasticity in the wrist and elbow flexor muscles  
 Stiffness  
 Passive range of movement  
 
2.10.3. Midpoint assessment 
At the midpoint assessment - which was standardised as three months post 
injection ±7 days - all the baseline measurements were repeated and three 
additional measurements were taken.  These are: 
 Quality of life – measured using the EQ5D-5L (Herdman et al 2011) 
 Carer burden – measured using the Caregiver Strain Index (Robinson 
1983) 
 Patient satisfaction of how their arm was recovering was measured 
using a Likert scale (0 – 5) 
 
2.10.4. Endpoint assessment 
At the endpoint assessment - which was standardised as six months following 
stroke ±7 days - all measurements taken at the midpoint assessment were 
reassessed at this point with the addition of one further assessment: 
 Level of dependence -- As measured using the Modified Rankin Scale. 
Minimum score = 0 and maximum score = 6 (van Swieten et al 1988) 
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Table 2.2 (on page 62) indicate the occasions and approximate durations of 
contact between patient and research therapist. The time durations for the ARAT 
and isometric testing were dependent on the participant’s capability to attempt 
and/or complete these activities.  
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Table 2.2 – Activities involved in the study with approximate duration of activity at each time-point 
X – Indicates activities that all recruited patients participated in. 
● – Indicates activities that only those involved in the randomised controlled trial participated in. 
 
 
 
 
 
Person Approximate 
time 
Stroke 
diagnosis 
Pre-study 
- consent 
Screening phase 
(repeated Mon, 
Wed, Fri) for  up 
to 6 weeks 
Baseline Randomisation/ 
injection 
Week 2 
assessment 
Week 4 
assessment 
Week 6 
assessment 
Midpoint 
assessment 
Final 
assessment 
Screened CL 5 mins X          
Provision of trial 
information 
CL 10-20 
mins 
 X         
Consent CL 10 mins  X         
Grasp sub-section 
of ARAT 
CL 2 mins   X   ● ● ●   
EMG - Spasticity CL 10 mins   X X  ● ● ● X X 
ARAT CL 1 to 
20mins 
   X     X X 
Stiffness CL With EMG    X  ● ● ● X X 
PROM CL With EMG    X  ● ● ● X X 
Pain CL 2 mins    X     X X 
Isometric strength CL 1-30 mins    X     X X 
Barthel Index CL 5 mins    X     X X 
Randomisation CL      ●      
Injection CL 20 mins     ●      
EQ5D CL 10 mins         X X 
CGSI CL 10 mins         X X 
Patient satisf CL 2 mins         X X 
Modified Rankin CL 3 mins          X 
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2.11. Data collection 
The following section describes the process for collecting data for all the 
outcome measures in greater detail.  In order to allow the reader to understand 
the process that the patient went through this section is presented in the order 
that measurements were carried out at the six-month (final) assessment rather 
than in the order presented in section 2.10. 
2.11.1. Spasticity, stiffness and passive range of movement 
Data for spasticity, stiffness, and passive range of movement were all measured 
in the same procedure which has previously been used by Cousins et al (2010).  
The patient was positioned in either supported sitting or half lying.  A flexible 
electrogoniometer (SG 110 electrogoniometer, Biometrics Ltd, UK) was placed 
on the lateral border across the wrist or elbow depending on the joint being 
tested.  Surface EMG electrodes (SX230 active surface electrodes for bipolar 
recording of muscle activity, Biometrics Ltd, UK) were positioned in accordance 
with European recommended sites (SENIAM) for the biceps and long head of 
triceps (Hermens et al 1999).  There are no such recommendations for 
placement of electrodes on the forearm.  A standardised format to ensure 
uniform placement at the forearm was used.  To place the electrode on the 
forearm flexor muscles a line between the medial epicondyle of the humerus and 
medial border of the biceps tendon was visualised.  From the mid-point of this 
line the electrodes were attached approximately one-third of the length of the 
forearm in line with the radial styloid. To place the electrode on the forearm 
extensors the arm was placed in full pronation and the electrode is placed one-
third of the distance between the lateral epicondyle of the humerus and the radial 
styloid. 
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Using a hand-held force transducer, (MyoMeter M550, Biometrics Ltd, UK) the 
research therapist then moved the joint from full flexion to full extension, using 
two manually controlled velocities (i.e. high velocity and low velocity), a 
maximum of six times.  The assessor documented the passive range of 
movement during the low velocity movement as well as the angle at which any 
catch of the muscle was perceived during the high velocity movement to allow a 
spasticity angle to be calculated (described first by Tardieu et al 1954).  The 
assessor also graded the quality of muscle reaction during the high velocity 
movement using the Tardieu Scale (Held and Pierrot-Deseilligny 1969) and first 
described in English by Boyd and Graham (1999).  
1. No resistance throughout the course of the passive movement 
2. Slight resistance throughout the course of passive movement, no clear ‘catch’ 
at a precise angle 
3. Clear catch at a precise angle, interrupting the passive movement, followed 
by release 
4. Fatiguable clonus (c 10 s when maintaining the pressure) appearing at a 
precise angle 
5. Unfatiguable clonus (> 10 s when maintaining the pressure) at a precise 
angle  
The EMG electrodes, electrogoniometer and, myometer transducers were 
sampled at 1000Hz using a MWX8 DataLOG (Biometrics Ltd, UK.) and stored for 
post hoc analysis. The data was later extracted from the data files using a 
customised programme (Mathcad 15, PTC, USA.).  The current method is very 
similar to the method described by Burke et al (1970) and Ashby and 
Burke(1971) but has not been investigated for reliability.  
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(See figure 2.3 for a pictorial presentation of the elbow being moved from full 
flexion to full extension using the equipment) 
Figure 2.3 – Method employed to assess for spasticity at the elbow - (A) 
full flexion phase, (B) mid-position phase and (C) full extension phase. 
 A 
 B 
 C 
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2.11.2. Pain 
Pain was assessed according to how the patient was able to communicate.    
Patients who were able to communicate were asked whether they had any pain 
in the paretic arm at rest and any pain on movement of the arm.  They were then 
asked to indicate the severity on a visual analogue scale from 0 being no pain at 
all to 100 being the worst pain imaginable (Gallagher et al 2001).  This scale was 
recommended by an international consensus statement on the assessment of 
pain in older patients (Hadjistavropoulos et al 2007).  In patients who had 
communication impairments any evidence of pain during the passive movements 
described above such as grimacing or rubbing the arm afterwards were used to 
indicate that the patient had pain so that in these patients a dichotomous variable 
was identified. 
 
2.11.3. Barthel ADL Index 
The patient’s main carer (and in most cases the patient themselves) was asked 
how much assistance they required in ten specific tasks (feeding, bathing, 
grooming, dressing, bowels, bladder, toilet use, transfers, mobility and stairs) 
and a number assigned according to their response.  The original Barthel Index 
scored from 0-100 (Mahoney and Barthel 1965) however a change in the format 
to provide a score of 0-20 was tested for reliability by Collin et al (1988).  A score 
of 0 indicates that they are fully dependent on others and a score of 20 indicates 
that they are fully independent.   
With the exception of the variation in numbers, the original Barthel Index and 
Collin et al (1988) versions are identical in all other ways meaning that the 
psychometrics are equivalent (Quinn et al 2011).  Wade and Collin (1988) 
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recommended that the Barthel Index be adopted as the standard measure of 
physical disability and that future indices should be compared against this.  
Quinn et al (2011) reaffirm this statement for studies in stroke.   Wade and Collin 
(1988) advised “temptation to use variations on the standard Barthel Index 
should be resisted.”    Unfortunately, this advice was not taken.  Since then there 
have been a number of modifications to the original index which will have altered 
the psychometrics, Shah et al (1989) attempted to increase sensitivity by adding 
sub-units, Schönle (1995) extended the Barthel Index adding categories for 
tracheostomy and ventilation to reflect areas in early neuro-rehabilitation while 
others have truncated the original Barthel Index (Hobart and Thompson 2001).  
As a result of this proliferation in heterogenous Barthel Indices Quinn et al (2011) 
repeated the advice made by Wade and Collins (1988) and urged a consistent 
single version of the Barthel Index be adopted for stroke trials.  While Quinn et al 
(2011) suggest the original Mahoney and Barthel (1965) the fact that there are 
no psychometric differences between the original and Collin et al (1988) version 
make both acceptable.   
The 20-point version has been used at the recruiting hospital for many years and 
was therefore used in this trial.  This form of the Barthel Index has good test-
retest reliability and inter-observer reliability (Wade and Collin 1988).  Concurrent 
validity – assessed by associating the amount of nursing time required for 
patients – has been shown to be good (Novak et al 1996).  The one 
psychometric concern regarding the Barthel Index is how responsive it is.  A lack 
of sensitivity to changes at the extreme high and low ends of the scale have 
been identified (Cano et al 2006).  It was expected that the current trial would 
recruit severe stroke survivors who were likely to have very low Barthel scores.  
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This floor effect may be detrimental to identifying changes in this group.  To 
improve sensitivity to changes in stroke survivors at this severe level in stroke 
trials Quinn et al (2011) recommend using the Barthel Index in conjunction with 
the modified Rankin Scale.  Both of these outcome measures were used in the 
present study, 
2.11.4. Isomeric muscle strength testing 
Using the same surface EMG electrodes (SX230 active surface electrodes for 
bipolar recording of muscle activity, Biometrics Ltd, UK) placed as described in 
section 2.11.1 and the hand-held force transducer (MyoMeter M550, Biometrics 
Ltd, UK) also described in section 2.11.1 strength of the elbow flexors, elbow 
extensors, wrist flexors and wrist extensors was assessed. 
In order to assess elbow flexion strength, the shoulder was abducted to 90 
degrees and maintained in this position by the research therapist (or as much 
abduction as possible without evoking pain in cases where shoulder pain was 
reported) and the myometer was placed at the distal end of the ulnar and radius 
on the palmar side.  With the elbow in 90 degrees of flexion and the wrist 
supinated, the patient was then asked to bend their elbow as hard as possible 
and hold for as long as possible.  After a two-minute rest the trial was repeated 
again, and, following a further two-minute rest, the patient was assessed for a 
third time. 
In order to assess elbow extension strength, the same position was assumed by 
both the assessor and patient with the only change being the placement of the 
myometer being on the dorsal side of the wrist.  The patient was asked to 
straighten their elbow as hard as possible and hold for as long as possible.  They 
repeated this exercise three times with a two-minute rest in between each trial. 
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Wrist flexion and extension were assessed with the shoulder in neutral, the 
elbow in 90 degrees and the forearm resting on a table.  The patient’s forearm 
was held in position by the assessor and the myometer was placed across the 
metacarpal phalangeal joints (on either the dorsal or palmar side).  The patient 
was then asked to either bend or extend the wrist.  The assessor ensured that 
shoulder internal or external rotation did not become involved by maintaining the 
forearm position with their second hand.  They repeated this three times with a 
two-minute rest in between each trial. 
The final muscle function test used a grip dynamometer to assess the patient’s 
grip strength.  With the patient in the same position as for the wrist strength 
testing, the patient was asked to grip the dynamometer as tight and for as long 
as possible.  The assessor took the weight of the dynamometer so that even 
those patients unable to hold the weight of the dynamometer could be assessed.  
The wrist was maintained in neutral throughout by the assessor maintaining the 
position of the dynamometer.     
Bohannon (1986) identified that there was good test-retest reliability of this 
technique during a single session across various muscle groups of the arm in 
neurological patients.  Bertrand et al (2007) also found good reliability for use of 
the technique in strength ratio testing whereby the difference between the paretic 
and non-paretic arm are assessed.  Martins et al (2015) investigated the 
psychometrics of using hand held dynamometry in neurological patients.  Four 
studies had assessed reliability using intra-class correlation coefficients and 
identified excellent reliability. 
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2.11.5. Action Research Arm Test 
The Action Research Arm Test (ARAT) is a measure of arm function first 
described by Lyle (1981).  With the patient in a sitting position, a bespoke table 
with shelf was brought in front of them and they were asked to perform 19 
separate tasks.  The 19 tasks are divided into four sub-scales; grasp, grip, pinch 
and gross movement.  For each of these tasks an ordinal four-point scale from 
zero to three was given by the research therapist meaning the minimum score 
was 0 and the maximum score could be 57 (Lyle 1981).  
0 - no movement  
1 - the movement task is partially performed 
2 - the movement task is completed but takes abnormally long 
3 - the movement is performed normally 
The standardised protocol described by Yozbatiran et al (2008) was used to 
ensure that both scoring and placement of objects was consistent during all 
tests.  The grasp subscale involved six tasks with various items that had to be 
picked up from the table and placed on the shelf 37cm above the table.  If the 
person was able to pick up the largest wooden cube (10cm3) and place on the 
shelf in less than five seconds then they automatically scored 18 for the subscale 
and moved on to the next subscale Yozbatiran et al (2008).  If they scored less 
than three then they were asked to pick up the smallest cube.  In cases where 
the patient was unable to perform any part of picking up the smallest wooden 
cube (2cm3) they scored zero for the whole subscale (Yozbatiran et al 2008).    In 
patients who did not score zero for the smallest cube they were asked to pick up 
a 5cm3 wooden block, 7.5cm3 wooden block, cricket ball and sharpening stone 
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measuring 10cm×2.5cm×1cm.  They were then scored on each of these tasks 
and a score out of 18 identified.   
The grip subscale involves four tasks with the most difficult being pouring water 
from one glass to another and the easiest being to pick up a 2.25cm wide alloy 
tube from one side of the table and place it on a stand 30cm in front.   
The pinch subscale involved six tasks all of which required the patient to pick up 
and place various sized balls.  The easiest task involved picking a marble up 
between index finger and thumb and placing it on the shelf above while the 
hardest task involved picking up a 6mm ball bearing between ring finger and 
thumb and placing it on the shelf.   
A gross movement subscale involved three tasks with the hardest being to place 
the hand behind the head and the easiest being to place the hand on top of the 
head. 
 
The ARAT has repeatedly been found to be both valid and reliable to assess arm 
function in stroke survivors (Lyle 1981, Hsieh et al 1998, Hsueh and Hsieh 
2002).  Lin et al (2009) concluded the same and also identified that, based on 
inherent errors in assessment, the minimal detectable change (MDC) for the 
ARAT was four.  As a result of the improvement in the assessment protocol by 
Yozbatiran et al (2008) it is possible that this MDC might have become less.  
While the MDC indicates the change needed to be confident that a change in the 
score is real the minimal clinically important difference (MCID) indicates the 
change needed to for a patient to actually perceive a benefit.  Lang et al (2008) 
investigated what the MCID was for a number of different measures of arm 
function.  They estimated for the ARAT that a change of 12 for the dominant 
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hand and 17 for the non-dominant hand needed to occur for patients to perceive 
a benefit from any given treatment (Lang et al 2008). 
 
2.11.6. EQ-5D 
In order to assess the patient’s perceived health related quality of life a 
questionnaire called the EQ-5D-5L was completed (Herdman et al 2011).  This 
questionnaire is a descriptive classification system developed by the EuroQoL 
Group which initially had three levels but was further developed to have five 
levels (Janssen et al 2013).  The five dimensions are: Mobility, Self-Care, Usual 
Activities, Pain/Discomfort and, Anxiety/Depression, and patients were able to 
respond with; no problems, slight problems, moderate problems, severe 
problems and, unable to/extreme problems for each dimension.   Finally, the 
patient was asked to rate how good or bad they considered their health to be on 
a scale with 0 being the worst imaginable health and 100 being the best 
imaginable health. 
The EQ-5D-5L has been found to be superior to the original EQ-5D-3L as it had 
a reduced ceiling effect and improved discriminatory power in the general 
population (Janssen et al 2012). Golicki et al (2015) found that the 3L was more 
responsive in a stroke population when assessed longitudinally however they 
used a cross-walk technique to measure the difference between the two 
questionnaires.  Another study identified that EQ-5D-5L had good concurrent 
validity with the Functional Independence Measure and Stroke Impact Scale 
(Chen et al 2016).  This same study also estimated the MCID to be 0.1 (Chen et 
al 2016). 
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2.11.7. Caregiver strain index 
In order to assess the impact of the stroke and subsequent treatment on people 
who were providing care or support to the patient, the most appropriate person 
was asked to complete a questionnaire.  This was completed entirely separately 
to the other parts of the study and it was made clear to the care giver that it was 
entirely up to them whether they wished to complete it. 
The Caregiver Strain Index (CSI) was developed by Robinson (1983) and, 
although initially validated in carers of patients who had received treatment for 
hip surgery or heart problems, it is the most commonly used measure of 
caregiver burden in stroke (Rigby et al 2009).  Clinical validity and reliability of 
the CSI is good in the caregivers of stroke survivors (van Exel et al 2005) and it 
also has good reproducibility and moderate responsiveness (Post et al 2007). 
2.11.8. Patient satisfaction 
A simple five-point Likert scale to check patient’s satisfaction with trial 
participation was used.    Patients were asked how much they agreed with the 
statement “I am happy that I participated in this trial” with answers ranging from 
strongly disagree to strongly agree.  This was asked by the research therapist as 
a final question and the results of this question were not intended to be 
investigated or further analysed. 
2.11.9. Modified Rankin scale 
The modified Rankin scale was completed by the research therapist during the 
final review.  The original Rankin Scale (Rankin 1957) had a range from one to 
five with one identified as “no significant disability: able to carry out all usual 
activities” and five indicating “Severe Disability: bedridden, incontinent and 
requiring constant nursing care and attention”.  van Swieten et al (1988) altered 
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the scale from five grades to seven by adding zero and seven indicating no 
symptoms at all and death respectively.  The only other variation from the 
original was to clarify that a grade of one indicated continuing symptoms which 
did not impact on function. 
The modified Rankin Scale has been used extensively in stroke research and 
Banks and Marotta (2007) carried out a literature review and synthesis of the 
clinometric properties of the scale.  This study identified 224 articles and carried 
out detailed assessment of 50.  They identified that there was excellent 
consistency with test-re-test reliability, construct validity had been confirmed in 
relation to lesion volume, location and type of stroke and that convergent validity 
had been identified with various other disability scales (including the Barthel 
Index, Stroke Impact Scale and Functional Independence Measure) (Banks and 
Marotta 2007).  While reliability and validity are good, Dromerick et al (2003) 
identified that sensitivity was not as good as the Barthel Index in a group of 95 
consecutive stroke rehab patients.  A further limitation was the negative effect 
that co-morbidities may have had when scoring the modified Rankin scale 
(Banks and Marotta 2007).  Since many stroke patients have multiple co-
morbidities this may be an important factor. 
 
2.12. Data extraction 
Data from the myometer, electrogoniometer and surface EMG electrodes were 
sampled at 1000Hz and stored in a password protected personal computer.  
Data was then processed and analysed using a bespoke programme written in 
specialised software (Mathcad 15, PTC, USA).  The raw electromyography data 
was notch filtered at 50Hz and smoothed using a low-pass filter at 10Hz. 
76 
 
Cameron Lindsay  
 
Data from both the low velocity and high velocity passive movements were 
identified.  Passive range of movement was identified from the first low velocity 
movement (i.e. greatest angle at flexion and extension during this movement). 
 
The first and last 10% of the movement was removed from subsequent analysis.  
Mean velocity and EMG activity was then able to be calculated.  Stiffness was 
calculated as the slope of the force angle curve using standard linear regression 
techniques.  Spasticity was quantified as the mean muscle activity of the flexors 
throughout the movement.      
 
2.13. Data analysis 
In order to answer the four research questions in this thesis not all the outcome 
measures collected needed to be analysed.  Only descriptions of the analyses of 
the impairment measures of spasticity, stiffness, passive range of movement, 
and activity measure of arm function, are included in this section.  All other data 
has been analysed but is not pertinent to the research questions.   Statistical 
analysis of data was carried out using IBM SPSS Statistics for Windows Version 
19 (IBM, USA). 
 
2.13.1. Data analysis for research question one - When does 
abnormal muscle activity in the arm develop following stroke in patients 
who initially have no arm function and can the Tardieu scale identify this? 
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Spasticity was deemed to be present when there was evidence of abnormal 
muscle activity on EMG during a passive movement.  Presence or lack of 
spasticity was dichotomised and presence or lack of function was dichotomised 
as previously described using the grasp sub-scale of the ARAT. 
This meant patients were placed into one of four groups: those with spasticity 
and function, spasticity and no function, no spasticity and function, and no 
spasticity and no function.  Population proportion and 95%CI is presented for 
each group (Daniel and Cross 2013). 
The time at which spasticity occurs is presented as the median days with IQR. 
The Tardieu scale is presented as a scale – specificity and sensitivity were 
analysed against the abnormal muscle activity by dichotomising the Tardieu 
scale to be 0=no spasticity and 1=Tardieu scale greater or equal to one. 
Visual analysis of the electromyography after data extraction was used to identify 
any variations in the patterns of EMG activity. 
 
2.13.2. Data analysis for research question two - Is it possible 
to prevent or delay contracture development by treating spasticity early with 
botulinum toxin? 
Spasticity - Surface EMG activity - Raw data and the calculated mean difference 
from baseline data were calculated and presented with the mean difference and 
the 95%CI between the treatment and placebo groups reported. 
The presence of contracture was measured using both loss of range and 
development of stiffness. 
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Passive range of movement - Raw data and the calculated mean difference from 
baseline data were calculated and presented with the mean difference and the 
95%CI between the treatment and placebo groups reported. 
Stiffness - Raw data and the calculated mean difference from baseline data were 
calculated and presented with the mean difference and the 95%CI between the 
treatment and placebo groups reported. 
In order to study the rate of change in contractures the rate in the change of 
angle over time was estimated using least square estimate and the change in the 
control group was compared with that of the treatment group (Matthews et al 
1990). 
 
2.13.3. Data analysis for research question three - Do patients 
who have spasticity treated early have better recovery of function compared 
to those who are not treated? 
 
The Action Research Arm Test – Raw data is presented as mean and standard 
deviation and was used to calculate the mean difference and the 95%CI between 
the treatment and placebo groups. 
Using the pre-specified cut off point of greater than 2 on the grasp sub-scale of 
the ARAT, data was dichotomised to identify those who had recovered function 
against those who had not recovered function.  Odds Ratio with 95%CI was 
presented to identify differences between the treatment and placebo groups. 
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2.13.4. Data analysis for research question four - Does the 
sub-group of patients identified as least likely to recover function benefit 
from early treatment of spasticity more than others? 
 
Those stroke survivors least likely to recover function are likely to be at most risk 
of contracture development.  It is likely that these people are most likely to 
benefit from intervention.  A planned sub-group analysis of those patients who 
were least likely to recover function at any point over the first six months was 
carried out.  Current studies attempting to clearly differentiate patients who are 
least likely to recover post stroke function have been able to identify some 
predictors but are dependent on expensive scanning and remain incomplete 
(Winters et al 2014 and Stinear et al 2013).  The two clearest predictors remain 
severity of the stroke and recovery in the first two weeks of stroke Winters et al 
(2014). 
 
There is clear evidence that a more severe stroke will result in less likelihood of 
recovery (Winters et al 2014 and Byblow et al 2015).  Brott et al (1989) identified 
that those with an NIHSS score of greater than 15 had sustained severe strokes. 
 
The Barthel Index is a measure of function and indicates motor recovery that has 
translated in to functional improvements.  No change in this index, or 
deterioration, provides evidence that the person is not recovering function. 
 
Entry to this sub-group was restricted to patients who had an initial NIHSS score 
of 15 or greater and had no improvement in the Barthel index. 
80 
 
Cameron Lindsay  
Analyses of the baseline measures between those included in this sub-group 
and the rest of the patients were carried out and the mean difference and 95%CI 
is presented.  Between group analysis of this sub-group and the rest of the 
population at six months was also investigated with the mean difference and 
95%CI presented for each group and the mean difference and 95%CI between 
groups. 
 
For measurement of EMG, loss of range, and stiffness, the raw data and the 
calculated mean difference from baseline data were calculated and presented 
with the mean difference and the 95%CI between the treatment and placebo 
groups reported in the same way as question two.  Function between the two 
groups was also presented in the same way as question three. 
 
 
2.14. Adverse events 
All adverse events that occurred between the signing of the informed consent 
form and the last visit were reported in the case report forms. Adverse events 
were followed up routinely.  
 
For all adverse events, the research therapist obtained information to determine 
the outcome of the adverse event and to assess whether it met the criteria for 
classification as a serious adverse event, requiring immediate notification. The 
start date, duration, intensity, relationship to the study medication, actions taken 
and outcome were documented. 
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All serious events, reactions or unexpected reactions that occurred between the 
signing of the informed consent form and the last visit were reported immediately 
upon knowledge of the event occurring to both the Chief Investigator and 
sponsors. It was also reported in the case report form and outcomes were 
tracked and followed up. 
 
Causality and expectedness were assessed by the research therapist in the first 
instance and later by both the Chief investigator and the Sponsors. The research 
therapist kept detailed records of all serious adverse events relating to the trial.  
Had any suspected unexpected severe adverse reaction occurred, it would have 
been reported to the Medicines and Healthcare products Regulatory Agency 
(MHRA) in keeping with MHRA legal requirements and the local ethics 
committee. 
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3. Results 
3.1. When does spasticity in the arm develop following stroke in 
patients who initially have no arm function, and can the Tardieu 
scale identify this? 
Between January 2012 and December 2013, 1143 patients were admitted with a 
diagnosis of stroke to either City Hospital Birmingham or Sandwell Hospital (both 
part of Sandwell and West Birmingham NHS Trust) of whom 345 had no arm 
function at stroke onset (95% confidence interval for population proportion (95CI) 
between 28% and 33%).  The CONSORT diagram of recruitment for participants 
who were admitted with a stroke through the trial is presented on page 83.  One 
hundred and twenty patients consented to trial participation.  The median days 
from stroke to screening was eight (IQR=5-14) (mean=10.6 SD=8.2), median 
age was 71 years (IQR=56-80) (mean=68.2 SD=15.7), and median NIHSS score 
was 16 (IQR=10-20) (mean15.4 SD=6.0). 
Of the 120 participants who consented, one died during the screening phase.  At 
the end of the screening phase the remaining 119 participants could be classified 
in to one of four potential categories.  
• No function and developed spasticity – n=100 (84% 95CI between 76% 
and 89%). 
• No function and no spasticity – n=3 (2.5% 95CI between 0.8% and 7%). 
• Recovered function and developed spasticity – n=16 (13.5% 95CI 
between 8% and 21%). 
• Recovered function and no Spasticity – n=0 
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345 - No arm activity at 
stroke onset 
205 - Approached to provide 
information on study 
120 – Participants recruited 
to study screening 
140 – Not appropriate 
43 – Recovered arm function within 48 hours 
57 – Too unwell   12 – Previous  Stroke 
9 – Co-morbidities of arm  6 – Subsequent SAH or SOL 
5 – Aggressive (unable to assess)  5 – Transferred to Hospital but >42 
days post stroke.   3 – No next of Kin 
 
 
85 – Did not consent 
62 – Refused of which:  15 - Patient refused 
47 - Legal representatives refused 
23 – Became inappropriate for inclusion 14 – Became too unwell 
    9 – Recovered function 
100 – Developed 
spasticity with no 
arm function 
16 – Developed 
spasticity and arm 
recovery 
3 – Did not develop 
spasticity or recover 
function. 
1 – Died during 
screening 
97 
Randomised 
2 – Refused when protocol 
was explained again – did 
not want injections. 
1 – Became unwell 
 
48 – Placebo Group 
48 – Injected 
49 – Botulinum Group 
45 – Injected 
1 – Refused at point of injection 
2 – Became unwell prior to injection 
1- Identified as SOL at 3 month follow up 
43 – Assessed. 
1 – Died  1 – Ward closed 
(D&V) 
 
 
45 – Assessed. 
1 – SCP  2 - Refused 
41 – Assessed. 
3 – Died 1 – Data Lost 1 – D&V
  
2– UTC  1 – Transfer 
40 – Assessed. 
3 – Died  1 – Ward closed 
(D&V) 
1 – Transfer 
 
 
45 – Assessed. 
2 – Died  1 - Refused 
INJECT 
ION 
1143 people - Admitted 
with diagnosis of stroke 
CONSORT Diagram 
42 – Assessed 
3 –Died  
44 – Assessed 
4 – Died  
14 – Assessed 
2 – Died  
3 – Assessed 
 
40 – Assessed 
4 – Died 
1 – Migrated 
14 –Assessed 
2 – Died 
2 – Assessed 
1 – Died 
43 – Assessed 
5 – Died  
 
12 Week 
Assessment 
(End of treatment 
phase) 
6 Month 
Assessment 
(Follow-up Phase) 
 
Key – D&V = Diarrhoea and vomiting, SOL = Space occupying lesion, SCP=Supported care pathway 
(palliative care approach), UTC = Unable to contact 
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3.1.1. When does spasticity in the arm develop? 
Out of the 100 participants who did not recover function but developed 
spasticity, 54 were identified as having spasticity on the first day that screening 
was able to commence - a median 11 days post stroke (IQR=7.5-19) 
(mean=14.0 SD=9.5). The remaining 46 participants were screened for a 
number of days before spasticity was identified.  In this group, spasticity was 
identified a median 12 days post stroke (IQR=8-19) (mean=14.5 SD=7.2).  The 
group of 16 who recovered function but developed spasticity did so a median of 
7.5 days post stroke (IQR=6-10).  All of these subjects developed spasticity on 
the same day, or the day before, they recovered function. 
3.1.2. Can spasticity be identified using the Tardieu scale at 
this early stage? 
In order to investigate whether the Tardieu scale was able to identify the 
abnormal muscle activity indicative of spasticity, data from all 119 subjects was 
analysed.  By dichotomising all patients in to those who scored greater than or 
equal to one on the Tardieu scale and those who presented with or without 
abnormal activity on EMG (see table 3.1), it was possible to investigate the 
specificity and sensitivity of the Tardieu at this early point in spasticity.  
 
Three patients had no abnormal muscle activity and all scored zero on the 
Tardieu scale meaning that the specificity of the Tardieu scale is 1.0 at both 
elbow and wrist.  The sensitivity of the Tardieu scale was identified to be 0.53 
(61/ (61+55)) at the elbow and 0.49 (57/ (57+59)) at the wrist. 
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Table 3.1 – Variations between EMG and Tardieu in identifying spasticity at 
elbow and wrist at baseline 
Elbow   (Wrist) EMG Positive EMG Negative 
Tardieu Positive 61 (57) 0 (0) 
Tardieu Negative 55 (59) 3 (3) 
 
The number of participants who scored 0 on the Tardieu Scale (no 
resistance/spasticity) made up around 50% of all people identified with 
spasticity on EMG.  When a score of greater than one is used which appears to 
best represent clinical spasticity, those presenting with spasticity were 20% (23) 
and 13% (15) in the elbow and wrist respectively. 
3.1.3. Patterns of abnormal muscle activity observed on 
EMG 
The pattern of EMG activity was reviewed and two patterns identified.  Subjects 
either showed a combination of position and velocity dependent activity (figure 
3.1) or pure velocity dependent activity (figure 3.2).  These figures are 
representative of the two patterns as either an elbow or wrist is passively moved 
from full flexion (no stretch) to full extension (full stretch).    The EMG activity 
when the elbow is moved at high and low velocities are indicated by the brown 
and mauve coloured lines (respectively).  The blue and red lines indicate the 
speed at which the elbow was passively extended and is presented to clearly 
show the difference between the high and low velocity movements.  The mean 
velocity to passively move the joint at slow speed was 30.5 degrees/sec (deg/s) 
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SD=19.6deg/s and at high speed was 258deg/s SD=101.5deg/s.  These 
patterns were not uniform at the elbow and wrist joint within participants.   
Figure 3.1 – Representative diagram of position and velocity dependent 
spasticity 
 
 
 
  
 
 
 
 
 
 
 
 Flexor EMG at high velocity 
 Flexor EMG at low velocity 
 Low velocity 
 High velocity 
 
 
In this presentation of position and velocity dependent activity, the muscle 
becomes active during movement and continues to remain active on 
cessation of movement. The muscle became active at both slow and fast 
passive movements although the angle at which muscle becomes activated 
was usually earlier with high velocity movement. 
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Figure 3.2 –Representative diagram of velocity dependent spasticity 
 
 
 
 
 
 
The population proportion that developed velocity dependent spasticity at the 
elbow was 29 (25% 95CI between 18% and 34%) and the number who 
developed this pattern at the wrist was 41 (35% 95CI between 27% and 44%).  
While there was a significant association (p<0.01) between the spasticity 
presentation at the elbow and the wrist (tested using the Χ2 test) not all patients 
demonstrated the same pattern between wrist and elbow. (See table 3.1.1) 
 Flexor EMG at high velocity 
 Flexor EMG at low velocity 
 Low velocity 
 High velocity 
 
 
 
In this presentation the muscle becomes active during high velocity movement 
only and stops on cessation of movement.  There is no increase muscle 
activity during slow passive movement. 
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Table 3.1.1 – Variation in patterns of spasticity between elbow and wrist at 
baseline 
 Wrist joint patterns of spasticity Total 
elbow Velocity Dependent Position & Velocity Dependent 
Elbow joint 
patterns of 
spasticity 
Velocity Dependent 19 10 29 
Position & Velocity 
Dependent 
22 65 87 
Total wrist 41 75 116 
 
3.1.4 Patterns of abnormal muscle activity observed on EMG 
compared to the Tardieu scale  
When the score on the Tardieu Scale was analysed against the spasticity 
patterns there appeared to be some evidence that those presenting with a 
velocity dependent pattern of muscle activity were less likely to have resistance 
perceived during the passive movement.  This was more evident in the elbow 
(table 3.1.2) compared to the wrist (table 3.1.3). 
Table 3.1.2 – Spasticity identified at the elbow compared to the Tardieu score 
at baseline 
  Baseline Tardieu Score Elbow Total 
  No 
resistance 
Slight resistance 
no clear catch 
Clear catch at 
angle then release 
Baseline Elbow 
Flexor Activity 
Observed 
Velocity Dependent 19 (66%) 5 (17%) 5 (17%) 29 
Position & Velocity 
Dependent 
36 (41%) 33 (38%) 18 (21%) 87 
Total 55 (47%) 38 (33%) 23 (20%) 116 
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Table 3.1.3 – Spasticity identified at the wrist compared to the Tardieu score at 
baseline 
  Baseline Tardieu Score Wrist Total 
  No 
resistance 
Slight 
resistance 
no clear 
catch 
Clear catch 
at angle 
then 
release 
Fatigable 
Clonus  
 
Baseline 
Wrist Flexor 
Activity 
Observed 
Velocity 
Dependent 
24 (58%) 15 (37%) 2 (5%) 0 41 
Position & 
Velocity 
Dependent 
35 (47%) 27 (36%) 12 (16%) 1 (1%) 75 
Total  59 (51%) 42 (36%) 14 (12%) 1 (1%) 116 
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3.2. Is it possible to prevent or delay contracture development by 
treating spasticity early with botulinum toxin? 
From the 100 participants who developed spasticity with no arm function, 97 
were randomised to either the treatment group or placebo group.  Of the three 
who were not randomised, two refused injections when the protocol was 
explained to them again prior to randomisation, and one became unwell prior to 
randomisation occurring.   
Following randomisation, four subjects were deemed to be protocol deviations.  
One refused at point of injection, two developed illness that meant they could 
not be injected, and one was found not to be a stroke on three-month imaging.  
This meant that 93 participants were injected, (treatment group n=45 and 
placebo group n=48) and are included in the intention to treat analysis.  Of the 
93 participants, 65 had total anterior circulatory strokes, 19 partial anterior 
strokes, and 9 lacunar strokes. Forty-eight were male and 45 were female with 
a mean age of 67.5 (SD=15.8) and a mean NIHSS score of 16.2 (SD=6.2). 
Baseline demographics are presented as the mean with standard deviation in 
table 3.2.1.  Baseline measures were similar in both groups. 
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Table 3.2.1 – Baseline demographics for the intention to treat population. 
INTENTION TO TREAT Treatment 
Group 
Placebo 
Group 
P-
value 
(95%CI) 
Total 
 
 Numbers 45 48  93 
 Age in years 67 (17.1) 68.1 (14.8) 0.75 (-
7.6 to 
5.5) 
67.5 (15.8) 
 Sex female (%) 21 (47%) 24 (50%)  45 (48%) 
Type of Stroke Infarct 
(Thrombolysed) 
36 (7) 38 (10)  74 (17) 
Haemorrhage 9 10  19 
 NIHSS 16 (6.2) 16.4 (6.2) 0.76 (-
2.9 to 
2.1) 
16.2 (6.2) 
NIHSS Sub-
Group 
(Best score = 0) 
Arm (0-4) 3.6 (0.6) 3.6 (0.6) 0.9 (-
0.2 to 
0.3) 
3.6 (0.6) 
Leg (0-4) 2.8 (1.0) 2.9 (1.0) 0.58 (-
0.5 to 
0.3) 
2.9 (1.0) 
Sensation (0-2) 1.2 (0.7) 1.2 (0.7) 0.63 (-
0.4 to 
0.2) 
1.2 (0.7) 
Inattention (0-
2) 
1 (0.8) 1 (0.8) 1(-0.34 
to 0.34) 
1 (0.8) 
Barthel 
(Best score = 20) 
Pre stroke 19.4 (2.7) 19.5 (1.3) 0.58 19.4 (2.1) 
Admission 1.9 (2.9) 1.5 (3.1) 0.62 1.7 (3.0) 
 Stroke to 
Injection (days) 
16.8 (8.9) 19.1 (9.5) 0.66 16.0 (9.3) 
 
3.2.1. The effectiveness of botulinum toxin to decrease 
spasticity 
Before presenting the results of research question two it is important to identify 
that the botulinum toxin treatment was effective in treating spasticity. 
 
In the elbow, spasticity markedly decreased in the treatment group following 
injection and remained lower than that observed at baseline until six-month 
follow up.  Spasticity continued to increase in the placebo group over the same 
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period with a slight decrease at six months (Table 3.2.2).  There was a 
significant difference between the groups from week two to week twelve. 
Table 3.2.2 – Development of spasticity at the elbow for each time point in the 
placebo and treatment groups  
 Raw results Calculated mean difference from baseline 
Baseline 
(BL) 
Week 
2  
Week 
4 
Week 
6 
Month 
3 
Month 
6 
Week 2 
minus 
BL 
Week 4 
minus 
BL 
Week 6 
minus 
BL 
Month 
3minus 
BL 
Month 6 
minus 
BL  
Elbow 
EMG 
at 
slow 
stretch 
(µV) 
Placebo 6.9 (8.3) 10.5 
(16.4) 
10.8 
(12.7) 
13.1 
(14.4) 
14.2 
(27.9) 
11.6 
(16.5) 
3.4 
(13.4) 
5.7 
(16.0) 
7.3 
(29.5) 
3.5 
(13.2) 
4.7 
(19.1) 
Treatme
nt 
8.9 
(10.9) 
3.4 
(2.9) 
4.1 
(3.0) 
3.7 
(2.7) 
5.8 
(5.4) 
8.1 
(9.3) 
-4.5 
(10.4) 
-4.1 
(10.2) 
-2.8 
(9.4) 
-4.2 
(10.3) 
-0.6 
(9.5) 
Mean 
Diff. 
2.0 7.1 6.7 9.4 8.5 3.5 7.8 9.8 10.1 7.8 5.3 
P-Value 0.31 0.00
7 
0.00
2 
<0.0
01 
0.04
5 
0.21 0.003 0.001 0.03 0.002 0.09 
(95% 
CI) 
(-2 to 6) (-12 to 
-2) 
(-11 to 
-3) 
(-14 to 
-5) 
(-17 to 
0) 
(-9 to 
2) 
-12.9 to 
2.7 
-15.4 to 
- 4.3 
-18.9 to 
-1.3 
-12.6 to 
-2.9 
-11.3 to 
0.7 
  
Spasticity in the forearm flexors was slightly different to the elbow flexors.  
There was no decrease in spasticity following injections in the treatment group 
(as observed in the elbow flexors) but the rate of spasticity development was 
significantly slowed compared to the group who received placebo injections for 
the first six weeks as seen in table 3.2.3. 
Table 3.2.3 – Development of spasticity at the wrist for each time point in the 
placebo and treatment groups  
 Raw results Calculated mean difference from baseline 
 Baseline 
(BL) 
Week 
2 
Week 
4 
Week 
6 
Month 
3 
Month 
6 
Week 2 
minus 
BL 
Week 4 
minus 
BL 
Week 6 
minus 
BL 
Month 3 
minus 
BL 
Month 6 
minus 
BL  
Wrist 
EMG 
at 
slow 
stretch 
(µV) 
Placebo 4.6 (5.8) 8.5 
(7.5) 
8.1 
(6.0) 
10.9 
(10.6) 
7.8 
(6.2) 
10.1 
(7.3) 
3.9 (7.9) 3.4 (7.7) 6.1 
(10.5) 
2.9 (7.4) 5.0 (8.5) 
Treatme
nt 
4 (3.6) 4.1 
(3.8) 
4.9 
(4.7) 
5.2 
(5.9) 
7.5 
(7.9) 
9.3 
(9.2) 
0.2 
(4.7) 
1.2 
(5.3) 
1.4 
(6.3) 
3.3 (8) 4.9 
(8.8) 
Mean 
Diff. 
0.6 4.4 3.1 5.8 0.3 0.8 3.8 2.2 4.8 0.4 0.1 
P - 
Value 
0.57 0.00
1 
0.01 0.00
2 
0.85 0.58 0.007 0.12 0.009 0.78 0.95 
(95% 
CI) 
-2.5 to 
1.4 
-7 to - 
1.8 
-5.6 to 
- 0.7 
-9 to -
2 
-3.3 to 
2.7 
-4.4 to 
2.7 
-6.4 to -
1.1 
-5.1 to 
0.6 
-8.4 to -
1.2 
-2.6 to 
3.5 
-3.6 to 
3.4 
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Having identified that spasticity was significantly reduced in the treatment group 
the effect of this treatment on contracture development can be investigated.  
The raw data and calculated mean difference from baseline to each time point 
is presented for the elbow followed by the wrist. 
3.2.2. Contracture development at the elbow 
Quantitative measures of contracture are presented as stiffness (force required 
to move the joint through range) and loss of range of movement lost from the 
initial baseline measures (Table 3.2.4).  
3.2.2.1. Stiffness at the elbow 
Elbow stiffness significantly decreased in the treatment group immediately after 
injection before beginning to increase.  Stiffness continued to gradually increase 
in the initial stages in the placebo group.  A significant difference was observed 
at week two (Mean difference = 4.9mN/deg, p=0.042).  At three months after 
injection and six months post stroke there was no significant difference in 
stiffness identified between groups. 
 
3.2.2.2. Range of movement at the elbow 
Both groups gradually lost passive range of movement in the elbow over time.  
The placebo group lost range 2.9 times faster than the treatment group.  At 
three months, a significant difference between groups was identified (mean 
difference=6.3o p=0.03).  
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Table 3.2.4 –Development of contractures at the elbow each time point in the 
placebo and treatment groups 
ELBOW Raw results Calculated mean difference 
from baseline(BL) 
Basel
ine 
(BL) 
Wee
k 2  
Wee
k 4  
Wee
k 6  
Wee
k 12  
Mont
h 6  
Wee
k 2 
min
us 
BL 
Wee
k 4 
minu
s BL 
Wee
k 6 
minu
s BL 
Wee
k 12 
minu
s BL 
Mont
h 6 
minu
s BL  
Stiffne
ss at 
slow 
stretch 
(mN/d
eg) 
Placeb
o 
12.7 
(10.
2) 
13.
5 
(10.
1) 
13.
6 
(10.
0) 
14.
3 
(11.
6) 
16.
8 
(15.
0) 
19.
0 
(14.
7) 
0.8 
(12
) 
1.3 
(11.
9) 
1.5 
(13.
2) 
3.8 
(16.
4) 
6.4 
(16.
0) 
Treatm
ent 
14 
(11.
0) 
9.1 
(6.7
) 
10.
3 
(12.
6) 
11.
7 
(8.2
) 
14.
6 
(12.
6) 
15.
9 
(16.
2) 
-4 
(11
) 
-3.5 
(10.
9) 
-1.7 
(11.
3) 
0.9 
(13.
5) 
2.6 
(16.
6) 
Mean 
Diff. 
1.3 4.4 3.3 2.6 2.2 3.1 4.9 4.8 3.2 2.8 3.8 
P - 
Value 
0.55 0.0
2 
0.2
1 
0.2
3 
0.4
8 
0.3
4 
0.0
42 
0.0
56 
0.2
1 
0.3
6 
0.2
5 
95% 
CI 
-3.1 
to 
5.7 
-8 
to -
0.7 
-8 
to 2 
 -7 
to 2 
-7.5 
to 
3.6 
-9.7 
to 
3.4 
-9.5 
to -
0.2 
-9.6 
to 
0.1 
-8.3 
to 
1.9 
-8.9 
to 
3.3 
-
10.
5 to 
2.8 
Range 
of 
extens
ion at 
slow 
stretch 
(Degre
es) 
Placeb
o 
-0.4 
(3.3) 
1.7 
(10.
0) 
3.4 
(11.
9) 
4.4 
(11.
8) 
9.5 
(18.
9) 
9.7 
(17.
7) 
2.3 
(9.9
) 
3.9 
(11.
5) 
4.9 
(11.
8) 
9.9 
(18.
6) 
9.4 
(17.
7) 
Treatm
ent 
-0.6 
(4.5) 
0.6 
(5.2
) 
0.7 
(5.3
) 
1.4 
(7.5
) 
2.9 
(7.6
) 
5.0 
(11.
4) 
0.1 
(4.8
) 
1.5 
(5.5
) 
2.0 
(7.3
) 
3.4 
(7.8
) 
5.6 
(11.
0) 
Mean 
Diff. 
0.2 2.2 2.6 3 6.6 4.7 2.2 2.3 2.9 6.5 4.2 
P - 
Value 
0.82 0.1
9 
0.1
8 
0.1
5 
0.0
28 
0.1
3 
0.1
9 
0.2
4 
0.1
7 
0.0
3 
0.1
7 
95% 
CI 
1.43 
to -
1.8 
1.7 
to -
1.1 
1.4 
to -
6.7 
1.2 
to -
7.2 
-0.7 
to -
12.
6 
1.4 
to -
10.
8 
-1.1 
to 
5.5 
-1.6 
to 
6.2 
-1.3 
to 
7.1 
0.6 
to 
12.
3 
-1.8 
to 
10.
2 
 
 
 
 
 
95 
 
Cameron Lindsay  
3.2.3. Contracture development at the wrist 
In the wrist, both measures of contracture (the loss of range and development 
of stiffness) were significantly slowed in the treatment group when compared to 
the placebo group for the first six weeks following injections (Table 3.2.5). 
3.2.3.1. Stiffness at the wrist 
The change in stiffness in the wrist followed a similar pattern to the elbow.  
Stiffness reduced from baseline in the treatment group following injections but 
gradually increased in the placebo group.  At six weeks, there was still a 
significant difference (p=0.02) in stiffness between groups of 4.2mN/deg 
(95%CI=-7.7 to -0.7).  By three and six month measurements, there was no 
significant difference between the groups. 
3.2.3.2. Range of movement at the wrist 
The rate of loss of range of movement was identified to be 1.7 times faster in 
the placebo group compared to the treatment group over the first three months.  
By six weeks a mean difference in passive range of movement of 13.8o 
(95%CI= 6.1o to 21.6o) was noted between the two groups (p=0.001). 
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Table 3.2.5 – Development of contractures at the wrist at each time point in the 
placebo and treatment groups 
WRIST Raw results Calculated mean difference 
from baseline 
Base
line 
(BL) 
We
ek 
2  
We
ek 
4  
We
ek 
6  
We
ek 
12  
Mo
nth 
6  
We
ek 
2 
min
us 
BL 
We
ek 
4 
min
us 
BL 
We
ek 
6 
min
us 
BL 
We
ek 
12 
min
us 
BL 
Month 
6 
minus 
BL  
Stiffn
ess at 
slow 
stretch 
(mN/
deg) 
Place
bo 
11.8 
(5.5) 
13.
3 
(4.
8) 
13.
8 
(6.
3) 
14.
8 
(9.
1) 
15.
0 
(7.
6) 
20.
0 
(12.
8) 
1.4 
(4.8
) 
2.2 
(6.5
) 
2.5 
(9.4
) 
3.2 
(9.0
) 
7.8 
(13.5) 
Treat
ment 
13.1 
(6.3) 
11.
8 
(8.
5) 
11.
6 
(7.
1) 
11.
6 
(7) 
15.
4 
(10
.6) 
17.
2 
(11.
5) 
-1.6 
(8).
4 
-2.2 
(7.7
) 
-1.7 
(7.2
) 
2.3 
(10.
6) 
4.2 
(10.7) 
Mean 
Diff. 
1.3 1.6 2.2 3.1 -
0.4 
2.8 3 4.4 4.2 0.9 3.6 
P - 
Value 
0.29 0.2
8 
0.1
4 
0.0
7 
0.8
2 
0.2
7 
0.0
4 
0.0
06 
0.0
2 
0.6
8 
0.15 
95% 
CI 
-1.1 
to 
3.7 
-
4.6 
to 
1.3 
-
5.1 
to 
0.7 
-
6.8 
to 
0.3 
-
3.4 
to 
4.3 
-7.8 
to 
2.2 
-6 
to -
0.1 
-7.5 
to -
1.3 
-7.7 
to -
0.7 
-4.9 
to 
3.2 
-8.7 to 
1.4 
Rang
e of 
exten
sion 
at 
slow 
stretch 
(Degr
ees) 
Place
bo 
84.4 
(10.3
) 
74.
9 
(16
.3) 
72.
4 
(15
.8) 
63.
8 
(19
.5) 
58.
4 
(28
.5) 
56.
4 
(37) 
9.2 
(14.
8) 
12.
5 
(15.
9) 
20.
2 
(20.
2) 
24 
(32.
8) 
25.3(4
0.4) 
Treat
ment 
82.2 
(11.3
) 
78.
5 
(14
.1) 
78.
1 
(15
.9) 
75.
6 
(18
.7) 
65.
4 
(28
.6) 
65.
5 
(31.
4) 
3.6 
(11.
3) 
4.1 
(12.
5) 
6.5 
(16.
4) 
17.
2 
(23.
3) 
15.8 
(27.1) 
Mean 
Diff. 
2.2 3.6 5.7 11.
8 
7.1 9.1 5.6 8.4 13.
8 
6.8 9.5 
P - 
Value 
0.32 0.2
7 
0.1
1 
0.0
04 
0.2
4 
0.2 0.0
48 
0.0
09 
0.0
01 
0.2
5 
0.18 
95% 
CI 
-6.7 
to 
2.2 
-
2.8 
to 
10.
0 
-
1.2 
to 
12.
6 
3.8 
to 
19.
8 
-
4.7 
to 
18.
9 
-5.1 
to 
23.
3 
0 to 
11.
2 
2.3 
to 
14.
6 
6.1 
to 
21.
6 
-5.4 
to 
18.
1 
-4.6 to 
23.6 
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3.2.4. Serious adverse events 
There were no adverse reactions in either group.  There were 20 serious 
adverse events in the treatment group and 25 in the placebo group including 
four deaths occurring in the treatment and five deaths occurring in the placebo 
group over the six month period.   
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3.3. Do patients who have spasticity treated early have better 
recovery of function compared to those who are not treated? 
At baseline, the treatment group had a mean ARAT score of 1 (SD=2.6) which 
was slightly greater than the placebo group with a mean score of 0.44 (SD=1.7).  
There was no significant difference between groups (p=0.23, 95%CI=-0.36 to 
1.45).  Both groups showed evidence of recovery in function over the first six 
months.  There were no significant differences in function identified at any time 
points between groups.   
 
At the end of the treatment phase at 12 weeks the treatment group had a mean 
ARAT score of 11.9 (SD=19.23) while the placebo group had a mean score of 
9.5 (SD=17.95).  These were both significant improvements to the 
corresponding baseline measures but there was a mean difference between 
groups of 2.4 with no significant difference (p=0.53, 95%CI=-5.27 to 10.05).   
 
At six months post stroke, the treatment group had improved to 15.3 (SD=21.6) 
which was 2.9 points better than the placebo group who had a mean score of 
12.4 (SD=20.7).  There was no significant difference (p=0.51, 95%CI=-5.8 to 
11.6). 
 
The odds ratio for the number of people in each group who recovered function 
at three months (based on scoring greater than 2 on the grasp sub-section of 
the ARAT) was calculated.  17 out of 45 people injected in the treatment group 
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recovered this level of function while 12 out of the 48 people in the placebo 
group did.  The odds ratio was therefore calculated as 1.82 but this was not 
significant with a 95%CI of 0.75 to 4.43.  By six months 18 out of 45 injected in 
the treatment group recovered this level of function while 14 out of the 48 
people in the placebo group did.  The odds ratio was therefore calculated as 
1.62 but this was not significant (95%CI 0.68 to 3.83). 
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3.4. Does the sub-group of patients identified as least likely to 
recover function benefit from early treatment of spasticity more 
than others? 
Patients who had an NIHSS score of 15 or more on stroke admission and who 
had not recovered any function as measured by the Barthel Index between 
admission and randomisation were included in this sub group analysis. 
Out of the 93 patients included in the intention to treat analysis, 38 participants 
fulfilled the criteria for inclusion into this sub-group analysis. Seventeen were in 
the treatment group and 21 were in the placebo group. 
3.4.1. Differences between those included in the sub-group 
analysis and those excluded 
Analysis between the 38 participants deemed less likely to recover (and 
included in the sub-group) was made against the other 55 participants who 
were included in the intention to treat analysis.   These 55 participants were 
deemed to have a higher potential to recover function at baseline, while those in 
the sub-group had less potential.  These groups are respectively labelled as 
‘Good’ and ‘Poor’ in the column labelled ‘potential to recover’ in tables 3.4.1 and 
3.4.2.  
Those included in the sub-group analysis (i.e. had a poor potential to recover) 
were significantly older and had suffered significantly more severe strokes 
based on the NIHSS and had lower baseline Barthel Index and ARAT as 
indicated in Table 3.4.1. 
 
101 
 
Cameron Lindsay  
Table 3.4.1 – Mean differences between those identified least likely to recover 
and those with a high potential in a range of variables 
 Potential 
to 
recover 
N Mean Std. 
Dev 
Sig. (2-
tailed) 
Mean 
difference 
95%CI lower 
to upper 
Age 
(years) 
Good  55 62 16.4 <0.000
1 
-11.6 -17.4 to -5.8 
Poor  38 74 11.5 
NIHSS 
Good  55 13.0 5.4 <0.000
1 
-8.0 -9.9 to -6.0 
Poor  38 21.0 3.5 
NIHSS 
Arm 
Good  55 3.4 0.7 <0.000
1 
-0.5 -0.7 to -0.2 
Poor  38 3.9 0.3 
NIHSS 
Leg 
Good  55 2.5 1.0 <0.000
1 
-0.9 -1.3to -0.6 
Poor  38 3.4 0.6 
NIHSS 
Sensory 
Good  55 0.9 0.7 <0.000
1 
-0.6 -0.9 to -0.4 
Poor  38 1.6 0.55 
NIHSS 
Inattentio
n 
Good  55 0.7 0.7 <0.000
1 
-0.8 -1.2 to -0.6 
Poor  38 1.5 0.65 
Barth Pre-
Admission 
Good  55 19.8 0.9 
0.097 0.8 -0.2 to 1.8 
Poor  38 19.0 2.9 
Barthel 
Baseline 
Good  55 5.2 4.9 <0.000
1 
4.9 3.5 to6.3 
Poor  38 0.3 1.3 
ARAT 
Baseline 
Good  55 1.2 2.8 
0.002 1.2 0.5 to2.0 
Poor  38 0.0 0 
 
Having identified that there were significant differences at baseline between 
these groups, analyses of outcomes at the six month assessment were also 
made.  These analyses identified that the sub-group members had significantly 
worse measures in grip strength, ARAT, Barthel and Modified Rankin Scale at 
six months as presented in table 3.4.2.  
Despite there being significant differences in function between the groups there 
were no significant differences between the two groups in stiffness or spasticity 
at six months.  There were however, significant differences in the passive range 
of movement lost at both the wrist and elbow. 
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Table 3.4.2 – Measures of change from baseline to six months post stroke for 
those identified as least likely to recover versus the rest of the group 
 
Potential 
to 
recover 
N Mean 
Std. 
Dev 
Sig. 
Mean 
Diff. 
95%CI lower 
to upper 
Wrist Ext 
24minusBL 
Good 55 -13.3 19.8 
0.005 22.0 7.0 to37.0 
Poor 38 -35.3 42.9 
Elbow Ext 
24minusBL 
Good 55 -4.2 8.2 
0.009 9.3 2.5 to16.2 
Poor 38 -13.5 19.8 
Wrist Stiff 
24minusBL 
Good 55 4.7 10.7 
0.178 -3.6 -8.7 to1.7 
Poor 37 8.2 14.2 
Elbow Stiff 
24minusBL 
Good 55 2.1 15.0 
0.135 -5.2 -12.1 to1.7 
Poor 37 7.4 18.0 
Wrist EMG 
24minusBL 
Good 55 5.5 8.9 
0.66 0.8 -2.9 to4.5 
Poor 38 4.6 8.7 
Elbow EMG 
24minusBL 
Good 55 0.7 9.3 
0.404 -3.1 -10.6 to4.4 
Poor 38 3.8 21.6 
Maximum 
Grip 
Strength 
Good 55 6.2 6.7 
<0.001 4.91 
2.9 to 
6.9 Poor 38 1.3 2.9 
ARAT 
24minusBL 
Good 55 21.6 22.8 
<0.001 20.2 13.9 to26.6 
Poor 38 1.4 4.7 
Barthel 
24minusBL 
Good 55 8.7 5.2 
<0.001 4.2 
1.9 to 
6.5 Poor 38 4.4 5.6 
Length of 
Stay 
Good 55 52.6 30.4 
0.004 -18.4 
-30.9 to 
-5.9 Poor 38 71.1 28.7 
Modified 
Rankin 
Scale 
Good 55 3.1 1.1 
<0.001 -1.4 
-1.9 to 
-0.9 Poor 38 4.5 1.0 
Ext measured in degrees, Stiff measured in Nm/deg, EMG measured in µV 
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3.4.2. Sub-group analysis between the treatment and placebo 
groups 
Of the 38 participants included in the sub-group analysis, 17 were in the 
treatment group and 21 were in the placebo group.  There were no significant 
differences between groups at baseline (See table 3.4.3). 
 Table 3.4.3 – Demographics at baseline for the sub-group who were identified 
least likely to recover function 
INTENTION 
TO TREAT 
 Treatment 
Group 
Placebo 
Group 
P-value 
 Numbers 17 21  
 Age (years) 72.5 
(13.2) 
75.2 
(10.2) 
0.48 
 Sex female (%) 8 (47%) 8 (38%)  
Type of 
Stroke 
Infarct (Thrombolysed) 13 (1) 10 (5)  
Haemorrhage 3 6  
NIHSS 20.6 (3.6) 21.2 (3.5) 0.64 
NIHSS Sub-
Group 
Arm 3.9 (0.3) 3.9 (0.4) 0.82 
Leg 3.3 (0.7) 3.5 (0.6) 0.28 
Sensation 1.6 (0.5) 1.6 (0.6) 0.93 
Inattention 1.6 (0.5) 1.5 (0.7) 0.56 
Barthel Pre stroke 18.9 (4.1) 19.0 (1.6) 0.86 
Admission 0.9 (2.3) 0 (0) 0.14 
 Stroke to Injection 
(days) 
17.0 (9.2) 21.4 (9.8) 0.16 
 
3.4.2.1. Spasticity between the treatment and placebo groups in 
the sub-group analysis 
Spasticity in the elbow behaved the same way in the sub-group analysis as it 
had done so in the full ITT analysis described in section 3.2.1.  Spasticity 
significantly decreased in the treatment group following injection and remained 
lower than that observed at baseline until six-month follow up.  Over the same 
time period spasticity continued to increase from baseline in the placebo group, 
with a slight decrease at six months (Table 3.4.4).  There was a significant 
difference between the groups from week two to week six but this was lost by 
week 12. 
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Table 3.4.4 – Development of spasticity at the elbow for each time point in the 
placebo and treatment groups 
ELBOW  Raw results Calculated mean difference from 
baseline 
Base
line 
Week 
2 
Week 
4 
Week 
6  
Month 
3 
Month 
6  post 
stroke 
Week 
2 
minus 
BL 
Week 
4 
minus 
BL 
Week 
6 
minus 
BL 
Month 
3 minus 
BL 
Month 
6 minus 
BL post 
stroke 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
EMG 
at slow 
stretch 
(µV) 
Place
bo 
7 
(10) 
8.3 
(8.6) 
10.8 
(13.4) 
14.6 
(19.0) 
20.8 
(41.2) 
15.3 
(23.8) 
1.3 
(6.4) 
3.2 
(17.6
) 
7.3 
(22.6
) 
13.6 
(43.9) 
8.1 
(27.3) 
Treat
ment 
9 (7) 4.2 
(3.5) 
3.9 
(2.6) 
3.9 
(2.8) 
5.1 
(4.2) 
8.2 
(10.8) 
-5.5 
(6.4) 
-5.8 
(6.2) 
-5.8 
(6.6) 
-4.6 
(10) 
-1.5 
(9.6) 
Mean 
Diff. 
2 -4.1 -7 -10.7 -15.7 -7.1 -6.8 -9 -13.1 -18.2 -9.6 
P - 
Value 
0.4 0.07 0.044 0.02 0.09 0.26 0.00
3 
0.05
4 
0.02 0.074 0.14 
(95% 
CI) 
-3 to 
8 
-8.5 to 
0.4 
-13.7 
to -0.2 
-19.6 
to -1.7 
-34.6 
to 3.1 
-19.7 
to 5.5 
-11.1 
to -
2.4 
-18.2 
to 
0.2 
-24.1 
to -
2.1 
-38.3 
to 1.9 
-22.7 
to 3.6 
 
Spasticity at the forearm muscles was also similar to the full ITT analysis with 
much more variable presentations in EMG activity.  A significant difference 
between the two groups was only observed at week 6 (Table 3.4.5). 
Table 3.4.5 – Development of spasticity at the wrist for each time point in the 
placebo and treatment groups 
WRIST  Raw results Calculated mean difference from 
baseline 
Base
line 
Week 
2 
Week 
4 
Week 
6  
Month 
3 
Month 
6  post 
stroke 
Week 
2 
minus 
BL 
Week 
4 
minus 
BL 
Week 
6 
minus 
BL 
Month 
3 minus 
BL 
Month 
6 minus 
BL post 
stroke 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
EMG at 
slow 
stretch 
(µV) 
Placebo 6 (8) 9.7 
(7.1) 
7.0 
(5.5) 
13.6 
(13.6) 
8 (7) 12 (7) 3.5 
(7.2) 
0.6 
(8.9) 
7.6 
(13.5
) 
1.0 
(7.5) 
4.0 
(8.9) 
Treatme
nt 
4 (3) 4.4 
(4.8) 
4.3 
(4.1) 
3.7 
(2.5) 
6 (5) 10 (9) 0.1 
(5.6) 
0 
(9.0) 
-0.6 
(3.4) 
1.8 
(6.0) 
5.4 
(8.6) 
Mean 
Diff. 
2 -5.3 -2.7 -9.9 2 2 -3.4 -0.6 -8.2 0.8 1.4 
P-value 0.28 0.015 0.11 0.004 0.42 0.56 0.12 0.82 0.016 0.71 0.63 
(95% 
CI) 
-6 to 
8 
-9.4 to 
1.1 
-6.1 to 
0.6 
-16.4 
to -3.5 
-6 to 3 -8 to 4 -7.8 
to 
1.0 
-5.9 
to 
4.7  
-14.6 
to -
1.7 
-3.7 to 
5.4 
- 4.4 to 
7.2 
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3.4.2.2. Development of contracture at the elbow 
The development of stiffness at the elbow continued in the placebo group from 
baseline, whereas stiffness was reversed in the treatment group and remained 
less than baseline for the first 12 weeks following the injections (Table 3.4.6).  
Loss of range was 4.5 times faster in the placebo group than the treatment 
group.  This resulted in a 13 degree significant difference (p=0.04) between the 
two groups at week 12. 
Table 3.4.6 – Development of contractures at the elbow each time point in the 
placebo and treatment groups 
ELBOW Baseline Week 2 
minus BL 
Week 4 
minus BL 
Week 6 
minus BL 
Month 3 
minus 
BL 
Month 6 
minus 
BL post 
stroke 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Stiffness at 
slow 
stretch 
(mN/deg) 
Placebo 12.9 
(10.7) 
0.1 
(15.8) 
3 (15.4) 4.1 
(16.1) 
7.0 
(19.8) 
12.1 
(21.0) 
Treatment 15.3 
(8.0) 
-5.5 
(10.6) 
-6.9 (7.8) -3.2 (9.5) -0.3 
(8.9) 
1.7 
(12.1) 
Mean Diff. 2.3 -5.6 -9.9 -7.3 -7.3 -10.4 
P - Value 0.46 0.23 0.025 0.11 0.15 0.079 
95% CI -4.1 to 
8.8 
-14.9 to 
3.7 
-18.4 to -
1.3 
-16.4 to 
1.8 
-17.4 to 
2.9 
-22.1 to 
1.3 
Range of 
extension 
at slow 
stretch 
(Degrees) 
Placebo 0.9 (2.6) -4.3 
(14.0) 
-7.8 
(16.3) 
-9.0 
(16.3) 
-17.7 
(25.1) 
-17.6 
(23.1) 
Treatment 0.9 (2.7) 0.4 (3.0) -2.6 (7.0) -3.6 (8.4) -4.8 
(9.7) 
-8.4 
(13.9) 
Mean Diff. 0.1 3.9 5.2 5.4 12.9 9.2 
P - Value 0.99 0.25 0.23 0.22 0.04 0.14 
95% CI -1.7 to 
1.8 
-3.0 to 
10.7 
-3.5 to 
13.9 
-3.5 to 
14.3 
0.7 to 
25.2 
-3.1 to 
21.5 
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3.4.2.3. Development of contracture at the wrist 
The development of stiffness at the wrist continued in the placebo group from 
baseline, whereas stiffness was initially reversed in the treatment group.  
Stiffness in the treatment group gradually increased from week two but slower 
than in the placebo group, and a significant difference between groups was 
observed at all time points (with the exception of week six) (Table 3.4.7). 
Table 3.4.7 – Development of contractures at the elbow each time point in the 
placebo and treatment groups 
WRIST Baseline Week 2 
minus BL 
Week 4 
minus BL 
Week 6 
minus BL 
Month 3 
minus 
BL 
Month 6 
minus 
BL post 
stroke 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Stiffness at 
slow 
stretch 
(mN/deg) 
Placebo 11.5 
(6.2) 
2.4 (4.0) 3.8 (6.7) 2.5 (9.6) 5.6 
(10.2) 
12.9 
(16.8) 
Treatment 14.3 
(6.6) 
-3.0 
(12.2) 
-1.4 (5.4) -1.2 (5.7) 0.4 (7.1) 2.7 (7.5) 
Mean Diff. 2.8 -5.4 -5.2 -3.7 -5.2 -10.2 
P - Value 0.18 0.08 0.02 0.17 0.08 0.02 
95% CI -1.3 to 
6.9 
-11.6 to 
0.8 
-9.5 to -
0.9 
-9.1 to 
1.7 
-11.2 to 
0.7 
-18.8 to 
-1.7 
Range of 
extension 
at slow 
stretch 
(Degrees) 
Placebo 85.9 
(10.0) 
-10.7 
(11.9) 
-16.1 
(16.0) 
-25.9 
(23.2) 
-36.6 
(37.8) 
-48.0 
(46.8) 
Treatment 80.9 
(11.3) 
-7.2 
(11.7) 
-6.8 
(13.7) 
-11.8 
(17.1) 
-18.0 
(29.1) 
-19.6 
(32.2) 
Mean Diff. -5 3.5 9.3 14.2 18.6 28.4 
P - Value 0.39 0.38 0.08 0.04 0.1 0.03 
95% CI -16.5 to 
6.7 
-4.5 to 
11.5 
-1.2 to 
19.7 
0.4 to 
28.0 
-4 to 
41.3 
2.3 to 
54.5 
 
Both groups gradually lost range of movement at the wrist over time, with the 
loss of range in the placebo group being 2.1 times faster over the first three 
months.  The loss of range was significantly different (p=0.03) between groups 
by six months with a mean difference between the groups of 28.4o (2.3o to 
54.5o). 
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3.4.2.4. Function 
Table 3.4.8 indicates the six outcome measures that were used at six months, 
and which might indicate a functional benefit between groups.  The most likely 
measure to indicate benefit to arm function would be the ARAT.  Just two 
patients in the treatment group and one patient in the placebo group recovered 
function (based on scoring greater than 2 on the grasp sub-section of the 
ARAT).  Given this lack of change in function an odds ratio was not calculated.  
This lack of functional arm recovery was reflected in the mean ARAT scores at 
six months of 1.8 and 1.0 out of a possible 57 points. 
 
The only measure that did reach significance was the modified Rankin scale.  
The mean difference of 0.8 was statistically significant (p<0.01, 95%CI= 1.5 to 
0.2).  It is also clinically significant as it meant that the placebo group (mean 4.9, 
SD=0.8) scored five “Severe disability (bedridden, incontinent and requiring 
constant nursing care and attention)” compared to the treatment group (mean 
4.1, SD=1.0) scored four “Moderately severe disability (unable to walk without 
assistance and unable to attend to own bodily needs without assistance). 
 
The only other measure that tended towards significance was the Caregiver 
strain index (p=0.058).  A score of greater than seven indicates high stress and 
that further referral should be made.  The treatment group scored a mean 4.3 
(SD=3.6) compared to the placebo group who scored a mean 7.8 (SD=3.7). 
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Table 3.4.8 – Between group differences in functional outcomes at six months 
in the sub-group identified as least likely to recover     
 Group N Mean Std. Dev. Sig. Mean 
Diff. 
95%CI lower to 
upper 
ARAT 
24minusBL 
Treatment 17 1.8 4.9 0.595 0.8 -2.3 to3.9 
Placebo 21 1.0 4.6 
Barthel 
24minusBL 
Treatment 17 5.9 5.9 0.161 2.6 -1.1 to6.3 
Placebo 21 3.3 5.3 
EQ5D5L 
Index 
Treatment 14 -0.09127 0.27168 0.537 0.064
69 
-0.14767 to0.27706 
Placebo 14 -0.15597 0.27499 
Modified 
Rankin 
Scale 
Treatment 17 4.1 1.0 0.008 -0.8 -1.5 to-0.2 
Placebo 21 4.9 0.8 
Functional 
Ambulatory 
Scale 
Treatment 15 2.5 1.6 0.174 0.7 -0.3 to1.8 
Placebo 16 1.8 1.2 
Caregiver 
Strain 
Index 
Treatment 11 4.3 3.6 0.058 -3.5 -7.1 to0.1 
Placebo 8 7.8 3.7 
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4. Discussion 
This study showed that spasticity can be identified and measured much earlier 
than has previously been reported by using EMG assessment.  It also 
suggested that spasticity could be divided into two particular patterns of 
abnormal muscle activity.  The randomised control study showed that treatment 
with botulinum toxin and electrical stimulation could decrease spasticity and 
significantly slow contracture development in the short term when compared to 
electrical stimulation alone.  There was no significant difference in contracture 
formation at the six-month follow up between the treatment and placebo groups, 
and functional recovery was not affected.  In a sub-group analysis of patients 
who had been identified as the least likely to recover function (using pre-
randomisation clinical measures) the treatment effect and the clinical 
significance between the treatment and placebo groups was much greater than 
the whole group intention to treat analysis. 
The following chapter will review the results of the current study in the context of 
previous research.  Limitations of the current study will be recognised as each 
of three broad themes are discussed.  The first theme will focus on spasticity 
(onset, patterns, measurement and the treatment of spasticity).  The main 
theme of contracture development and whether it can be slowed will then be 
discussed.  The final theme will deliberate on current practice and future issues 
(focus on functional recovery, general limitations of the study clinical practice 
implications). 
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4.1. Spasticity onset and development 
In this study spasticity occurred within the first two weeks post stroke, and was 
identified as early as the second day after stroke.  Spasticity occurred before 
any stiffness was identified and any range of movement was lost (i.e. 
contracture formation).  The prevalence of patients who develop spasticity 
following severe strokes was much greater than has previously been reported. 
The finding that spasticity occurs early following stroke is not surprising given 
the current understanding of pathophysiology.  An increase in Ia afferent activity 
is the most likely cause of the majority of abnormal stretch reflex activity 
following stroke (Nielsen et al 2007).  There is no reason to assume that this 
increased activity would be delayed following a stroke.  This is in contrast to 
spinal cord injuries where the mechanism of spinal shock might cause a period 
of loss of reflexes. 
Previous prospective studies investigating the onset and prevalence of 
spasticity have not used EMG to identify spasticity, and this is the main reason 
why direct comparison between the present study and other prospective studies 
is not possible (a second difference is that the current study only recruited 
patients who had no arm function and were expected to have spasticity rather 
than all stroke survivors). Previous studies did not directly measure abnormal 
muscle activity, but instead assessed muscle stiffness (using the Modified 
Ashworth scale) to assess spasticity. The use of these scales, both clinically 
and in research, continues despite being repeatedly recognised as an invalid 
measure of spasticity (Nielsen and Sinkjaer 1996, Pandyan et al 1999, Patrick 
and Ada 2006, and Fleuren et al 2010).   Waiting for a secondary consequence 
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(muscle stiffness) will delay the identification of spasticity, and also prevents the 
identification of spasticity that does not go on to result in stiffness.   
Studies using the (modified) Ashworth scale have been used as evidence in 
spasticity consensus statements and clinical guidelines.  One example is a 
consensus statement by 26 European physicians, that suggested spasticity gets 
worse over time “some have suggested that 19% of patients after stroke have 
spasticity at 3 months and 38% at 12 months after the original trauma” Wissel et 
al (2009, p18).  Wissel et al (2009) used evidence from one prevalence study 
and one short longitudinal study to form this statement.  The prevalence study 
was carried out at twelve months but no longitudinal methodology was involved 
(Watkins et al 2002).  Sommerfeld et al (2004) carried out the longitudinal 
assessment of prevalence which slightly contradicts the consensus statement, 
as they reported a prevalence of 21% within a week post stroke which had 
decreased to 19% at three months. 
The findings by Sommerfeld et al (2004) are very different when compared to a 
more recent study by Urban et al (2010).  Urban et al (2010) identified no 
spasticity within five days post stroke (n=211) and 42.6% (n=90) at six-month 
follow-up in a prospective longitudinal study.  Opheim et al (2015) assessed 
spasticity at six time-points over the first year post stroke.  In a group of 117 
patients, this study reported that 25% of participants had a modified Ashworth 
Scale of at least one by day three, and that 46% of participants scored at least 
one on the MAS at one year post stroke. 
While prevalence is clearly highly variable in these studies - something 
described by Wissel et al (2013) when they attempted to investigate prevalence 
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in studies that only used the modified Ashworth Scale – there is uniformity that 
‘severity’ of spasticity appears to increase over time (Sommerfeld et al 2004, 
Urban et al 2010, Welmer et al 2006 and Opheim et al 2015), but this was not 
the case in the current study.   
The perceived increase in the severity of spasticity, when measured using the 
(modified Ashworth scale), is most probably due to an increase in contracture 
formation within the muscle and not related to spasticity.  This interpretation is 
strengthened by the observations from the present study, which showed that 
spasticity (abnormal muscle activity on EMG) decreased after twelve weeks 
while stiffness substantially increased between the twelve and six month 
assessment points. 
This finding of a decrease in spasticity by six months as observed in the 
placebo group (see tables 3.2.2 and 3.2.3 p92) was unexpected.  Having not 
predicted this outcome, the literature was reviewed and it became clear that this 
finding has been reported in previous studies. Thilmann (1991), in a cross-
sectional study found, that the magnitude of spasticity decreased after the first 
six months which is in line with Malhotra et al (2012).  Cousins et al (2010) also 
described a decrease in spasticity within the placebo group of a randomised 
controlled trial after 8 weeks.  Ada et al (2006) also present a graph which 
indicates the same finding but does not discuss the finding.  The commonality 
between the four papers listed in this paragraph and the current study is that all 
used EMG to measure spasticity. 
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4.1.1. Spasticity Measurement 
Using an objective neurophysiological measure to assess a neurophysiological 
impairment (i.e. spasticity) should be best practice, although in clinical practice 
this may be difficult to achieve.  Clinicians have depended on substitute 
measures of assessment, and it was felt important that the present study 
compare the best clinical measure of ‘clinical spasticity’ (the Tardieu scale) 
against the EMG identified spasticity.  The present study found that specificity of 
the Tardieu scale is 1.0 but that sensitivity was respectively 0.53 and 0.49 at the 
elbow and wrist.  The study used a score of ≥1 on the Tardieu scale.  A score of 
one on the Tardieu scale indicates “slight resistance throughout the course of 
the passive movement, with no clear catch at a precise angle” Boyd and 
Graham (1999) pS25 and this is not consistent with what might be considered 
“clinical spasticity” (i.e. a catch is perceived). When a more clinically relevant 
score is used (i.e.≥2 on the Tardieu), spasticity was only identified in 20% 
(elbow) and 13% (wrist) of patients at onset of abnormal muscle activity.  This 
data is consistent with the Sommerfeld et al (2004) study discussed previously 
that reported a spasticity prevalence of 21% one week post stroke. 
Two previous studies have assessed the Tardieu scale against a 
neurophysiological scale.  Patrick and Ada (2006) provided evidence that, 
relative to the Ashworth scale, the Tardieu scale was a more valid measure of 
spasticity when both were compared against a neurophysiological measure.  
This 2006 study measured elbow and ankle flexors/plantarflexors in patients a 
mean three years post stroke (SD=1.3), and considered spasticity on the 
Tardieu scale as ≥2.  Naghdi et al (2014) considered spasticity on the Tardieu 
scale as ≥1 and found that the Modified Tardieu scale was not a valid measure 
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of spasticity in a group of 20 patients with a diagnosis of stroke (mean 33 
months SD=31) when compared to neurophysiological measures in the wrist 
flexors. There are two differences between the Patrick and Ada (2006) and the 
Naghdi et al (2014) studies that may explain the divergent results – the 
neurophysiological measure used to assess spasticity and the joint being 
measured.  While Patrick and Ada (2006) used a similar method to assess 
spasticity as the present study methodology described in chapter 2 (correlation 
coefficient between Tardieu and the peak EMG activity was r=0.86, p=0.001), 
Naghdi et al (2014) used Hmax/Mmax ratio (correlation coefficient between 
Tardieu and Hmax/Mmax ratio was r=0.26, p=0.27).  Aymard et al (2000) 
identified variations in the Hmax/Mmax ratio between the soleus muscle of the 
leg and flexor carpi radialis muscle of the arm which may explain this variation 
to a point.  The more likely cause for the different results between Patrick and 
Ada (2006) and Naghdi et al (2014) is the variation in the muscle or joints being 
assessed.  Naghdi et al (2014) assessed the wrist flexors which are more prone 
to stiffness and are, anecdotally, less likely to develop clonus when compared 
to the ankle which was assessed by Patrick and Ada (2006).  The fact stiffness 
is more likely to be increased at the wrist is compounded by the decision to use 
a Tardieu scale of ≥1 rather than two and above as used by Patrick and Ada 
(2006). 
The clear difference between the current study and these two previous studies 
are the mean time post stroke.  Since these previous studies were assessing 
patients at least six months post stroke it is likely that stiffness would have been 
present.  While the Tardieu scale differs in many ways from the Ashworth Scale 
they are both dependent on the assessor identifying an increase in stiffness.  
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The catch associated with clinical spasticity is thought to be the muscle 
contracting - strongly enough to slow or halt the passive movement occurring - 
as a result of a high velocity stretch.  It is possible that this catch may only 
become strong enough to be perceived after a latent period from stroke onset 
during which time two possible changes may occur.  The first is that initial 
changes related to contracture formation may have developed increasing the 
opportunity of a catch being perceived and the second is that an increase in the 
output from the abnormal muscle activity has occurred.  While either of these 
hypotheses would explain the poor specificity of the Tardieu identified at this 
early stage further exploration is required to investigate. 
4.1.2. Spasticity Patterns 
This study detected two patterns of abnormal muscle activity which are 
described as velocity dependent and, position and velocity dependent.  A 
previous study described three patterns of EMG activity but the pure position 
dependent spasticity described by Malhotra et al (2008) was not seen in this 
study.  It is possible that this form of position dependent spasticity was an 
erroneous classification.  While a similar phenomenon was observed in the 
present study, it was not reproducible.  In patients presenting with position and 
velocity dependent spasticity in this study, the velocity dependent element 
occurred at varying time-points but always before the position dependent 
activity.  In some cases, the activity appeared to begin around the same time 
and might well have been classed as purely positional. It was possible to review 
a second set of measurement recordings, as the slow and fast passive 
movements were repeated immediately. They invariably showed a clearer 
variation between the onset of activity during high and low velocity movements. 
116 
 
Cameron Lindsay  
Ashby and Burke (1971), Powers et al (1989) and more recently Levin et al 
(2013), have reported similar findings of a static stretch response in the elbow 
which corresponds with the position dependent spasticity observed in the 
current study.   Indeed, such a position dependent response seems to have 
been described by Liddell and Sherrington (1924), and was more clearly 
described by Denny-Brown and Liddell (1927).  In the study by Ashby and 
Burke (1971), seven out of 15 participants had sustained prolonged muscle 
activity when the stretch was maintained at the end of range using a manual 
technique.  The other eight participants’ muscle activity ceased when movement 
stopped.  The participants in the Ashby and Burke (1971) study ranged from 
three weeks to two years post event, and chronicity may account for this 
variability in presentation.   In a cross-sectional study of time course of 
spasticity investigating one month, three months and twelve months post stroke, 
Thilmann (1991) did not identify any participants who had ongoing activity on 
cessation of movement.  This study used a mechanical device to move the arm 
but importantly did not go through the full range of motion to end range.  Many 
studies have used this methodology of moving a joint through a mid-range at 
varying velocities in order to measure the velocity-dependent nature of 
spasticity, as defined by Lance (1980).   
Those studies that have reported an ongoing stretch response at cessation of 
movement have always done so when the joint was at the end of range.  The 
muscle being assessed will therefore have been in a position of maximum 
length and therefore the muscle spindles will have been at a maximal stretch 
position.  This implies that there might be a length dependency element to 
spasticity in some participants.   
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The neurophysiological mechanism governing the dynamic component of the 
stretch reflex is well reported and is due to stretching of the primary muscle 
spindles which result in Ia afferent activity.  It is hypothesised that the static 
component results from the secondary muscle spindles, which activates group II 
afferents, which continue to fire for the duration that a muscle is stretched 
(Matthews et al 1984).  Stretch reflexes are known to be length dependent with 
the stretch reflex being more sensitive in the arm at longer lengths (Burke et al 
1971a). 
Once varying patterns of abnormal muscle activity are identified then the 
potential to distinguish any clinical variations is possible.  The abnormal muscle 
activity that only occurs when a joint is moved at more than 150 degrees per 
second (the Lance definition) is unlikely to interfere with function and may not 
require treatment at all. Conversely, a muscle that continues to fire even when 
the movement has ceased is at much greater risk of developing stiffness (as 
observed in the position and velocity dependent spasticity presentation).  This 
would mean that people presenting with the second pattern of activity are at 
more risk of developing contracture and are likely to benefit from botulinum 
toxin. This is because the muscles are in an almost continuously active state 
and as observed in animal studies such muscle will lose range much faster than 
less active muscle when held in a shortened position (De La Tour et al (1979), 
Tabary et al (1981) and Williams et al (1988). 
4.1.3. Spasticity treatment 
The present study showed that spasticity was treated by botulinum toxin in both 
the elbow flexors and wrist flexors but that the treatment effect was not 
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maintained beyond the 12-week assessment.  The pharmacokinetics of the 
drug indicates that the effects last between four to six weeks (de Paiva et al 
1999).  Many studies have suggested that efficacy may last up to twelve weeks, 
but these studies have generally used the Ashworth scale, which might explain 
the variation as decreased stiffness may be perceived for longer than the effect 
of the drug.  This was observed in the present study when the Tardieu Scale 
was used for assessment. 
There are two further possible explanations as to why the effect of the treatment 
did not last as long as expected.  The first is that the dose of botulinum toxin 
used was too low to sustain an effect for twelve weeks.  The doses provided in 
this study were half the dosage recommended in the Royal College of 
Physicians guidelines 2009 (Turner -Stokes et al 2009).  This half dose was felt 
appropriate as there was concern that injecting larger doses might negatively 
impact normal recovery. 
A second reason why the treatment effect on spasticity did not appear to last 
specifically in the wrist was that the surface EMG placement may not have been 
kept uniform.  This issue will be discussed in more depth in section 4.4.4.  
By identifying that spasticity had been effectively treated it was appropriate to 
then investigate whether decreasing spasticity could stop or slow the 
development of contractures. 
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4.2. Contractures 
The whole study ITT analysis found that the treatment group had lost less range 
of motion than the control group (mean difference=14o, 95%CI=6.1 to 21.6) in 
the wrist at six weeks.  While this is statistically significant it is perhaps more 
importantly clinically significant. Similarly, stiffness was found to be significantly 
less in the treatment group (mean difference=4.2mN/deg, 95%CI=-7.7 to -0.7) 
at the six week assessment.  No long-term benefit was observed at six-month 
follow up at the wrist.  
The results of the wrist contrasted to the elbow where spasticity was 
significantly improved until the twelve-week assessment but with less of a 
treatment effect in range or stiffness.  The one point when a significant benefit 
at the elbow, in the treatment group, occurred was at the twelve-week 
assessment in the elbow range of movement.  At this point a significant 
difference between the two groups was observed however it was of minimal 
clinical significance.   
One could argue from the results at the elbow that since spasticity was clearly 
treated at the elbow but no significant difference between groups in stiffness or 
range was observed, spasticity is not causative of joint stiffness or loss of 
range.  This view does not appear to be supported as treatment of spasticity 
using botulinum toxin decreased the stiffness in the elbow from baseline to six 
weeks whereas in the placebo group stiffness had continued to increase after 
baseline.  The fact there was no significance between groups may be because 
stiffness takes longer to occur at the elbow compared to the wrist.  While there 
is no evidence to support this hypothesis, the extra connective tissue that is 
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present in the forearm flexors compared to the elbow flexors makes this a 
theoretical possibility.  According to the work of Williams and Goldspink (1984) 
the fact that there is greater perimysium in the forearm relative to the upper arm 
means collagen deposition is likely to be greater with a resultant increase in 
stiffness.  Further investigation as to whether this could provide an explanation 
for the current results is warranted.  
One further difference between the development of stiffness at the elbow and 
wrist joint was that the wrist extensors were electrically stimulated ensuring a 
passive movement was provided to the joint.  Both groups received cyclical 
electrical stimulation to the forearm extensors.  This treatment has shown some 
benefit in slowing the loss of range at a joint without improving measures of 
spasticity or stiffness (Malhotra et al 2012).  The current study employed similar 
treatment parameters to the Malhotra study so that both groups benefitted from 
this treatment equally and the actual loss of range might have been greater had 
the electrical stimulation not been used.   
The combination of botulinum toxin to treat the flexors and electrical stimulation 
to treat the extensors might be greater than either of the two treatments acting 
independently.  It is likely that this is the case given what is known about 
contracture development and stiffness. Further academic discussion on how the 
treatment protocol could have been changed to investigate this issue will be 
presented in section 4.4.2. 
4.2.1. Contracture development in the sub-group analysis 
The a-priori sub-group analysis of those patients identified as being least likely 
to recover function from the presentation at clinical onset comprised of 38 
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participants, 17 in the treatment group, and 21 in the placebo group.   The 
results of this sub-group analysis are highly important, both to the 
understanding of contracture development, and in highlighting that further 
investigations of spasticity and contracture development must focus on this sub-
group.    Analysis revealed that the sub-group developed contractures more 
rapidly than the whole group.  Further, the placebo group of the sub-group lost 
range at the elbow 1.6 times faster and the wrist 1.5 times faster than the ITT 
placebo group over the first six months.  Despite the increased rate of 
contracture development in this sub-group the mean differences between 
treatment and placebo groups were similar to the six week time point of the 
mean differences between groups in the ITT analysis. (i.e. Sub group mean 
difference was 14.2o 95%CI=0.4 to 28.0 whereas the ITT mean difference 
between groups at the same time point was 14o, 95%CI=6.1 to 21.6).   
In the sub-group, there was a continued treatment effect that resulted in a 
significant difference between the treatment and placebo groups at the six-
month assessment.  At six months the treatment group had maintained much 
more range of movement than the placebo group (mean difference=28.4o 
95%CI=2.3 to 54.5) and developed less stiffness (mean 
difference=10.2mN/deg, 95%CI=18.8 to 1.7).  These differences were 
statistically significant and clinically meaningful for the wrist.  At the elbow the 
results of the sub-group analysis were similar to the ITT analysis.  The only 
statistically significant difference in the sub-group analysis between the placebo 
and treatment groups was found at the same time point of six weeks post stroke 
when a mean difference of 12.9o (95%CI=0.7 to 25.2) between the groups was 
identified. 
122 
 
Cameron Lindsay  
The scientific literature clearly suggested that this group, who were less likely to 
recover, would benefit greatest from early preventative treatment and this has 
been borne out.  Two previous randomised controlled trials investigating early 
treatment with botulinum toxin, albeit with the Ashworth scale as their primary 
outcome measure, appear to have used much less severely impaired 
participants.  Hesse et al (2012) used an inclusion criteria of “partly independent 
in the basic activities of daily living (>25/100 on the Barthel Index)”.  Similarly, 
Rosales et al (2012) had two groups with NIHSS scores at baseline [mean 
(SD)] of 4.9 (3.0) and 4.5 (2.7).  Despite these less severely affected 
participants, both studies reported similar benefits to the current study in 
reducing contracture formation. 
The results of the sub-group analysis will assist in developing the understanding 
of how contractures develop by identifying which stroke survivors are most at 
risk of developing them.  There were two other groups within the study who also 
contribute to this area of understanding and are now presented. 
4.2.2. Possible causation of contractures 
There are two groups of outliers - neither of which were included in the 
randomised controlled trial phase of the study - who are of great importance in 
trying to further clarify the causes of contracture progression. 
Both of these outlier groups consist of just three people each.  The first group 
were the group of three who did not develop any abnormal muscle activity in the 
first six weeks, and never recovered any function throughout the six months.  
One of these three subsequently died but at six-month follow up the other two 
were independently walking and wore an arm sling to ‘de-weight’ the arm while 
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walking.  This meant that their arm was kept in pro-longed flexion at the elbow. 
By six months neither of these participants had developed evidence of 
spasticity, stiffness or loss of range.  This group, who had no arm function, 
provides further evidence that spasticity appears to be required for contractures 
to develop within the first six months.   
The other important group of three people came from the group who had 
recovered function so that they were not included in the randomised controlled 
trial.  These three people were the only participants in the group of sixteen to 
recover function who did not achieve either 56 or 57 on the ARAT at six-month 
follow up.  These three patients all had a prior diagnosis of dementia.  The 
dementia was severe enough to limit activities of daily living and all three did not 
use the arm functionally during the day.  All three at six-month follow up had 
developed contractures.  
This suggests that it is the regular use of the arm functionally throughout the 
day that is important in prevention of contracture rather than just the presence 
of motor activity.  Previous studies have highlighted that strength is a predictor 
of contracture development (Kwah et al 2012) but these three people suggest 
function is even more important. 
This information is of importance in clinical treatment.  There are two specific 
impairments following stroke where a patient may recover motor activity and 
potentially even arm function but not use the arm functionally (without 
prompting) - those patients who have a hemi-neglect, and those with cognitive 
impairments.  These groups are therefore at risk of developing contractures 
even though they may appear to be unlikely to do so on testing of function.  This 
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data is only based on a very small group but could be vitally important to include 
if a treatment algorithm was being developed in the future to identify patients at 
risk of contracture development. 
4.2.3. Assessments of contractures 
One particular issue with the current study methodology was the measurements 
of contracture.  It can be argued that, to measure range of movement, a 
standardised torque should be employed during the stretch (Magnusson et al 
1996).  For instance, if an assessor only used a maximum of 10nM of pressure 
before deciding that the end point of a joint had been reached on one 
assessment but then used 50nM the next time, one could expect that the range 
would appear to have increased.   
 
If a standardised torque is not employed then other variables might theoretically 
be the cause of a change in range of motion such as tolerance of the patient to 
stretch (Magnusson et al 1996).  Folpp et al (2006) found that such an 
improvement in tolerance to stretch produced a mean 8o (95%CI 5o to 12o) 
treatment effect.  The current trial showed that range of movement decreased, 
so increased stretch tolerance is unlikely to have been an issue in the current 
study.  
 
Using a standardised torque in the current study would have necessitated the 
use of a large rigging system, such as that used described by Harvey et al 
(2006).  It was important that the present study used simple methods that could 
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be carried out in people’s homes or residential care homes.  It should also be 
acknowledged that maintaining a standardised torque throughout the whole 
range of movement of a joint (particularly the wrist that moves through almost 
180o) is very difficult to achieve.  It is unlikely that even the rigging system, 
designed to maintain a constant torque, actually achieves this aim throughout 
the whole muscle and joint range.  
 
It was always the aim of this study to allow the whole methodology to begin 
being used in practice if the evidence identified a useful outcome.  Range of 
movement is the easiest outcome measure for clinicians to use, and in this 
study the placebo group lost range 2.9 (4.5) times faster in the elbow and 1.7 
(2.1) times faster in the wrist over the first twelve weeks in the intention to treat 
(sub-group) analysis. 
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4.3. Functional recovery 
This study treated patients who had not recovered any arm function by the time 
that spasticity was identified.  Based on other studies, this lack of initial 
functional recovery over the early days post stroke suggested that full functional 
recovery was unlikely (Prabhakaran et al 2008 Nijland et al 2010).  Therefore, 
the expectation for this study was that there would be minimal recovery of 
function in either treatment or placebo group in the ITT cohort.   
In fact, seven individuals in each group (around 15% of the population) 
recovered almost full function (ARAT score between 53 and 57).  Analysis of 
these 14 patients did not detect any differences in demographic or initial stroke 
severity to the whole group.  Additionally, the results from the sub-group 
indicated that those with severe strokes (NIHSS>15) derived greater benefit 
from treatment than those with less severe strokes. When these results are 
considered together, it suggests that a better predictor of functional recovery is 
required than was used in this study. 
Since this study was initiated, better methods at attempting to prognosticate 
arm recovery post stroke have been described.  The use of shoulder abduction 
and finger extension muscle strength (SAFE assessment) described by Nijland 
et al (2010), and the SAFE assessment combined with motor evoked potential 
and magnetic resonance imaging (Stinear et al 2012), are two methods that 
appear to allow better identification of people who are unlikely to recover 
function.  Using a better method to establish who is least likely to recover 
function will allow stratification of patients into groups at greatest risk of 
developing contractures versus those at lower risk. 
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4.3.1. The influence of treatment on functional recovery  
The aim of spasticity treatment is to decrease an overactive muscle.  With this 
in mind, the treatment of spasticity on its own is unlikely to specifically improve 
function except in a small proportion of patients (with dystonic features on 
EMG).  While in this study there was no significant difference between groups, 
there was a tendency towards the treatment group improving more than the 
placebo group.  Any functional improvement observed in this study is possibly 
due to the treatment choices made by the physiotherapists.   The treating 
therapist only has a short period of time to provide treatment on a daily basis 
and, depending on the assessment, may focus this treatment on passive 
therapies with the aim of preventing contracture, or more active and functionally 
orientated therapeutic activities.  If the therapist perceived less stiffness in one 
patient then much more functional task specific treatments may have been 
provided.  This would have increased that patient’s likelihood of achieving 
function in the medium term. A second possibility is that if arm spasticity is not 
treated in a timely manner, then the resulting stiffness and pain will make any 
recovery of arm movement that does occur more difficult.  If arm movement 
becomes associated with pain then it is not as likely to be moved.  This will 
make the less affected arm become more active in order to compensate and 
lead to the development of learned non-use of the affected arm.  By maintaining 
the soft-tissue integrity of the arm for a longer period of time there may be an 
extended window for natural recovery to occur.  This hypothesis is more likely to 
be seen over a longer follow up period than was possible in this six-month 
study.   Any further study would ideally follow up participants for two years 
following stroke, and may include more than one cycle of injections.  
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4.3.2. Previous studies relating to functional improvement 
The phase II study by Cousins et al (2010), which acted as a point of reference 
for the present study, found a significant statistical and clinical difference in the 
group of patients who had no recovery of activity at injection.  In looking at the 
differences between the studies, the improvement in the placebo group in the 
present study appears to have been greater than in the Cousins et al (2010) 
study.  The current study used electrical stimulation as a standardised 
physiotherapy procedure.  It is also possible that the lack of significance in the 
present study was the result of variations in standard physiotherapy care 
between the two studies.   
Rosewilliam et al (2012) described a possible functional benefit in a randomised 
controlled trial involving a similar electrical stimulation protocol to the present 
study.  The difference between the two studies was that Rosewilliam et al 
(2012) used a six-week treatment period whereas the present study used a 
twelve-week treatment period.  The increased electrical stimulation treatment 
period provided in the present study may have resulted in the greater functional 
recovery of this placebo group compared to the Cousins et al (2010) botulinum 
toxin study.  This potential issue exemplifies the importance of expanding 
studies to multi-centre investigations in order to ensure the generalisability of 
the results and show external validity (Bellomo et al 2009).    This is one 
limitation of the current study and the next section will review other potential 
limitations to the study. 
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4.4. Limitations of the current study 
The current study was a single site study. Two meta-epidemiological studies 
have investigated the size of intervention effects between single centre and 
multi centre randomised trials when either a dichotomous outcome (Dechartres 
et al 2011) or continuous outcome (Bafeta et al 2012) is used.  Both studies 
found that single centre studies provided larger intervention effects (Dechartres 
et al 2011, Bafeta et al 2012).  Two issues could interfere with generalisability in 
a single centre study.  One is that the group being investigated are not diverse 
(Bellomo et al 2009).  In this current study, this did not appear to be the case.  
31% of the participants were not from the UK, and people from at least eleven 
different countries were included. Participants also showed large differences in 
terms of socio-economic and cultural backgrounds.   
 
The second factor is a potential confounding factor specific to the trial site such 
as “highly atypical expertise and commitment” (Bellomo et al, p3116, 2009).  
This factor is very relevant to the current study and might limit the 
generalisability of the results to the rest of the NHS and beyond.  The 
physiotherapists who work at the Trust involved in the study are almost unique 
in their keen commitment to advancing practice and experience in stroke 
recovery.  This is indicated by the fact that 89% of the injections in the trial were 
carried out by a physiotherapist and that electrical stimulation is normal practice 
in the hospital for patients who have no arm recovery. 
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4.4.1. Prevalence of spasticity 
This study identified a much higher prevalence of spasticity than previous 
studies.  Although the main reasons for this have already been discussed, a 
limitation of the present study is the sampling technique used.  In order to 
calculate prevalence, the whole population needs to be assessed.  This study 
only targeted patients who had suffered the most severe strokes so it is only 
possible to state that the prevalence is high in this specific group.  While other 
studies appear to have assessed the whole population, they have excluded 
patients who were not able to consent for themselves.  The current study was 
careful to include these stroke survivors as they were more likely to develop 
spasticity given their more severe stroke.  A further study needs to be 
completed to investigate the true prevalence of spasticity by recruiting 
sequential stroke admissions.  Using the same technique but including less 
severely affected patients may assist in the understanding of how patients 
motor recovery occurs, and whether they are indeed less likely to develop 
spasticity.  Some of the abnormal muscle activity observed in the acute stage 
could be a normal process of recovery that becomes inhibited as a person 
regains function.  
4.4.2. Trial methodology 
This study used a double blind randomised controlled trial methodology which 
has been credited as providing the strongest evidence for a clinical effect and is 
generally considered the gold standard for clinical trials (Bland 2015).  Through 
randomisation, patients will be placed in either the placebo or treatment group 
entirely through chance.  Within neurological rehabilitation the use of this 
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randomised controlled trial has been questioned (Ottenbacher 1995, DeJong et 
al 2005, Horn et al 2012) and in some cases even condemned (Kersten et al 
2010).  The common problem reported by all these papers is that there are so 
many variables to be considered in neurological rehabilitation that it is very 
difficult to account for all of them (DeJong et al 2005, Horn et al 2012).  Such a 
problem is not exclusive to neurological rehabilitation and, by ensuring a large 
enough sample size to carry out expected sub-group analyses, such a problem 
could be negated (Bland 2015).  Other concerns with the RCT as a 
methodology include difficulty in the stroke population to consent, ethical 
problems with randomisation, and difficulty with blinding patients (Horn et al 
2012).  These problems are not however confined to stroke rehabilitation and 
can be overcome with planning.  All such issues have been overcome in the 
present study. 
In some randomised controlled trials, there is a cross-over component to the 
intervention.  This means that everyone would receive the treatment followed by 
a wash-out period and placebo followed by a wash-out period (Harris et al 
2006).  The present study wanted to treat people in the acute stage where 
natural recovery will have an effect on outcomes.  The long treatment effect of 
Botulinum toxin was also a consideration and would have meant at least three 
months were required between each injection.  The result was that a simple two 
arm parallel study was employed in this case.   
The trial also ensured that both the patient and anyone involved in providing 
care and normal treatment were blinded to the study (in addition to the blinded 
assessor).  Through blinding of all interested parties the risk of intentional or 
unintentional bias was greatly reduced (Day and Altman 2000). 
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4.4.3. Treatment groups  
The basic objective of the current study was to try and prevent contracture by 
using both botulinum toxin and electrical stimulation.  This study employed two 
groups– a treatment group (where the participant received an injection of 
botulinum toxin), and a placebo group (where the participant received an 
injection of saline solution), and both groups received electrical stimulation.  
Because there were two treatments (botulinum toxin and electrical stimulation) 
aiming to achieve the same objective, other methodologies could potentially 
have been used (Craig et al 2008).  
One method would have been to use a four-armed trial, sometimes termed a 
2x2 factorial, design where the subject was randomised to treatment A or 
placebo and then to treatment B or placebo (Stampfer et al 1985).   
The current trial would thus have looked like this; 
BTX-A injections with E-stim BTX-A injections with placebo E-stim 
Placebo injections with E-stim Placebo injections with placebo E-stim 
 
A second possible study is a three-armed study which would have looked like 
this;  
BTX-A with E-stim Placebo with E-stim Placebo with placebo E-stim 
 
These designs would have provided information on the interaction between the 
two treatments (Stampfer et al 1985).  The main drawback to increasing the 
arms of a study is that a much larger sample size is needed to gain significance.  
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Given the difficulty with recruitment, and time limitations of the current study, it 
was providential that a larger sample size was not required. 
A further reason that the above two suggested methods were not employed was 
the use of placebo electrical stimulation.  As explained above, only in cases of 
clinical equipoise should a placebo be used (Hellman and Hellman 1991), and 
there is evidence for a clinical effect with electrical stimulation.  Pooled analysis 
of eleven trials indicates that the use of electrical stimulation in such a group of 
patients results in muscle strengthening, and leads to improvements at an 
activity level (Nascimento et al 2014).  It could be argued that there is less clear 
evidence of a treatment effect for electrical stimulation in slowing contracture 
development, though there is some (Pandyan et al 1997).   
Another factor was that the team at the recruiting hospital already routinely 
provided electrical stimulation to patients with no arm function. Withdrawing 
treatment for inclusion in a trial may be deemed unethical by some (and would 
have caused difficulty for therapists inviting patients to become involved) and so 
use of placebo electrical stimulation was not considered (National Institute for 
Health Research 2010). 
4.4.4. EMG placement 
In order to assess spasticity using surface EMG it is imperative that uniformity 
of electrode placement is ensured.  Placement to the forearm is notoriously 
difficult and this may have caused errors in measurement that could have 
confounded the statistical testing.  The European consensus (SENIAM) on 
electrode placement includes all leg and upper arm muscles with the exception 
of the forearm muscles, presumably as there are so many in close proximity 
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(Hermans et al 1999).  While the current study protocol used a standardised 
approach of palpation, it is conceivable that the surface EMG position varied 
slightly.  Despite ensuring precise placement through the use of skilled handling 
and palpation, evidence of which muscle the surface electrode was placed on 
was not possible (unless Ultrasound had been used).  This means that the 
surface electrode in some cases could have been placed over palmaris longus 
which is a muscle that was not injected.  This may have produced an increase 
in the measured EMG activity in the treatment group.   
Figure 5.9 - Muscles of the forearm 
This figure shows some of the muscle 
of the forearm with brachioradialis 
removed.  The muscles include – 
pronator teres, flexor carpi radialis 
(with needle), flexor digitorum 
superficialis and flexor carpi ulnaris. 
(with permission from Harding et al 
(2013)) 
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4.5. Implications of the research 
This study was instigated with the aim of providing information that would 
change clinical practice and rationale.  While the size of the study and results 
will not result in changes to clinical guidelines, there are several important 
implications for clinicians and researchers.  This section has been divided into 
clinical implications and research implications although some of the implications 
are equally relevant to both areas. 
 
4.5.1. Clinical implications 
Botulinum toxin is safe to use at this early stage following stroke.  Clinicians 
have tended to use a wait and see approach when spasticity is identified 
clinically and then been cautious with treatment.  Even within the research team 
involved in this study, there was concern that treatment with botulinum toxin at 
such an early stage would be detrimental to recovery.  This study has indicated 
that recovery is not impacted at a functional level (or at an impairment level 
(Lindsay et al 2015).  This evidence, combined with the Cochrane review 
‘Pharmacological interventions other than botulinum toxin for spasticity after 
stroke’ (carried out as part of this PhD), strengthens the argument against the 
traditional approach to spasticity management whereby anti-spasmodics are 
employed initially.  This study has shown by inference that delaying the 
treatment of spasticity will allow contractures to develop. 
Patients who develop contractures following stroke appear to have abnormal 
muscle activity and a lack of function.  Muscle strength may not be a good 
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indicator for contracture development, especially in patients who have 
dementia, and who are unlikely to use the arm for functional activities. Problems 
with validity of clinical scales of spasticity have been highlighted in this thesis.  
The use of EMG to assess spasticity in this study was simple to deliver in both 
the clinical and home environment.  The additional information gained from 
using EMG to assess spasticity makes its use in clinical practice worthwhile – 
particularly in an out-patient spasticity clinic setting.  Since the EMG machine 
would be set up already it would take an additional 3 minutes to carry out 
assessments using EMG measurement.  These types of clinics are spending 
over £8,000 to purchase an ultrasound machine whereas the cost of the EMG 
equipment used in this study was less than £3,000.  Using an EMG machine to 
assess spasticity in chronic stroke is likely to allow better identification of 
contractures, and thus decrease the amount of people having unnecessary 
treatment. 
4.5.2. Theoretical and research implications 
While the use of EMG within the clinical setting would be useful, the use of 
EMG to further investigate spasticity within the research context is extremely 
important.  While EMG has been used to assess spasticity, this study has 
highlighted that such investigations need to move a muscle through full range 
and hold at the end of range rather than move through a muscle’s mid-range at 
varying velocities.  The hypothesis that secondary muscle spindles, which 
activate group II afferents, may be the most important mechanism in causing 
contracture development (p117) needs further investigation, and could even 
identify novel therapeutic avenues to contracture prevention.    
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Another implication from the current study is the need to investigate dosage and 
frequency of injections of botulinum toxin.  While spasticity was treated in both 
the elbow flexors and wrist flexors the effect of the treatment did not continue 
for 12 weeks which has been observed in previous results.  The dose of 
botulinum toxin is recognised to contribute to the duration of efficacy, with 
higher doses leading to longer benefit.  The dosage used in this study was half 
the recommended dose described in the RCP guidelines (Turner-Stokes et al 
2009).  This dosage was felt appropriate as the concern that injecting larger 
doses might impact negatively on normal recovery was a strong influence on 
informing the whole process.  It is possible that these doses were too low to 
achieve the sustained 12-week effect.   
There are two options to improve the treatment effect which need further study.  
The first is to simply increase the dose, but this might overly weaken the 
muscles and thus prevent potential functional recovery occurring.  The 
alternative option would be to increase the frequency of injections.  If a patient 
had recovered function in the intervening time then re-injections would not be 
necessary.  In individuals where no recovery had been observed, re-injecting 
the muscles at an interval of between six and ten weeks at a similar dose may 
be beneficial.  It would be hoped that using a shortened interval between 
injections would help continue to prevent stiffness and loss of range, but this 
would need to be investigated in further studies. 
The summary of product characteristics state that re-injections should occur no 
sooner than 12 weeks following injection (Allergan SMPC (2015)). This 12 week 
delay is to prevent theoretical antibody formation, but this has not been reported 
as a problem in spasticity patients (Turner-Stokes et al  2009). Current clinical 
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practice has taken a pragmatic approach to this issue, and re-injections might 
be done more frequently when necessary.  Three recent studies using 
botulinum toxin at shorter intervals have been conducted, but these were in the 
treatment of blepharospasm and cervical dystonia, and used Xeomin 
(incobotulinumtoxinA) (Evidente et al 2013, Truong et al 2013 and Evidente et 
al 2014).  Patients were injected as necessary at as short as 6-week intervals, 
and Truong et al (2013) and Evidente et al (2014) carried out antibody assays 
on all participants periodically, and found that no participant developed 
neutralising antibodies over a one year period.  Further investigation of 
botulinum toxin dosing and treatment effect would be valuable to inform better 
clinical decision making and patient outcomes. 
The final implication from this study is that, given the positive results, it is 
important to carry out a further multi-centre randomised control trial.  This trial 
would differ from the current trial in that it would need to use a better prognostic 
method to identify patients who are considered to have no functional recovery 
potential at all.  The study will need to use contracture development as the 
primary outcome measure, but ideally would have a long follow-up period (of 
perhaps two years) to assess whether prevention of the contracture initially can 
lead to functional benefits later on.  Such a study would also require some form 
of cost-effectiveness analysis to be included to investigate whether the 
treatment’s clinical effectiveness is worth the cost to the Health Service.   
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5. Conclusion 
This study set out to answer four questions and has provided six potentially 
important findings.  The first finding came from a systematic review of the 
literature investigating the use of pharmacological methods to treat spasticity 
post stroke. This review found that there was insufficient evidence to determine 
if systemic antispasmodics were effective at reducing spasticity or improving 
function following stroke but did detect some very low-quality evidence that 
suggests there is an increased risk of adverse effects in people who take 
antispasmodics when compared with placebo.  
The initial screening phase of the study showed that use of electromyography is 
an effective method of identifying and categorising spasticity. Moreover, the 
study results established that spasticity occurred much sooner after stroke than 
had previously been predicated.  
Through the double blind randomised control trial, injections of botulinum toxin 
to the arm in the treatment group resulted in a significant slowing in the 
development of contracture formation including: stiffness being reversed; a 
slowing in the loss of range at both elbow and wrist joints.  
During the study, and against predictions, a significant number of patients 
recovered function in their arm. This suggests that a better predictor must be 
found and employed in order to assess who is likely to recover function after a 
stroke in further studies. 
In the sub-group – considered to have suffered the most severe strokes – there 
were significant differences, and much more clinically significant differences, 
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between treatment and placebo patients in the development of wrist 
contractures.  Further studies should concentrate on this sub-group.  
Finally, three people (in the group of sixteen assessed as having recovered 
function during the prospective stage) did not achieve either 56 or 57 on the 
ARAT at six-month follow up.  These three patients all had a prior diagnosis of 
dementia that was severe enough to limit activities of daily living.  None of the 
three used their arm functionally during the day and had all developed 
contractures at six-month follow-up. 
A further multi-centre study would be useful in proving the generalisability of 
these results in order that the early use of botulinum toxin to reduce contracture 
development could be included in to clinical guidelines. 
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Appendix 1 
Proposed mechanisms involved in spasticity and potential involvement in 
post stroke spasticity 
As described in the main text on page nine, Burke et al (2013) identified three 
major mechanisms by which spasticity may develop. 
 Changes in the properties of the spinal motorneuron 
 Changes in the afferent input to the spinal motorneuron 
 Changes in reflex circuits that affect the motorneuron 
This appendix will present the evidence for these mechanisms in further detail 
and describe reasons why some of the mechanisms do not fit into current 
understanding of post stroke spasticity. 
 Changes in the properties of the spinal motorneuron 
The changes in the properties of the spinal motorneuron primarily relate to 
calcium dependent ‘persistent inward currents’ (Gorassini et al 2004).  These 
currents amplify the input by between three and five times and cause sustained 
motorneuron firing through sustained excitatory drive following minimal synaptic 
excitation (Gorassini et al 2004).  While there is good evidence for this in spinal 
cord injury Mottram et al (2010), Mottram et al (2009) found that persistent 
inward currents played only a minor role in spasticity following stroke.  Dietz and 
Sinkjaer (2007) suggest this is the primary mechanism involved in spasms. 
Changes in the afferent input to the spinal motorneuron 
Burke et al (2013) reviewed three mechanisms by which afferent feedback from 
the muscle might change following an upper motor neuron lesion (enhanced 
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fusimotor drive via γ motor neuron activation, decreased pre-synaptic inhibition 
and homosynaptic depression).  Of the three mechanisms only the third has 
good evidence in the stroke population (Lamy et al 2009 and Burke et al 2013).  
Enhanced fusimotor drive has been disproven by Wilson et al (1999) and 
Nielsen et al (1993).  Faist et al (1994) identified that decreased pre-synaptic 
inhibition only occurred in spinal spasticity and not that arising from stroke.  A 
study by Lamy et al (2009) identified a small decrease in pre-synaptic inhibition 
in a group of stroke patients when compared to 42 healthy controls.  This study 
identified two concerns with their results.  The first was that the less affected 
stroke side produced the same results as the affected side.  They were also 
concerned at the lack of correlation Ashworth scale which is less of an issue. 
The one established and generally accepted mechanism is post activation 
depression (also termed homosynaptic depression) between the Ia afferent and 
the motorneuron.  This presentation is described in the main text of the thesis 
and was initially described in the cat by Curtis and Eccles (1960) who identified 
variations in the size of Ia excitatory postsynaptic potentials (EPSPs) varied with 
frequency of stimulation.  The depression of the Ia EPSPs with longer intervals 
occurred as a result of previous transmitter release (Grey et al 2008) however 
once again the aetiology of this is not understood (Grey et al 2008).  Aymard et 
al (2000) found that post activation depression correlated with the amount of 
spasticity in a population post stroke measured using the H-reflex.  
Changes in reflex circuits that affect the motorneuron 
A number of circuits have been identified as potentially playing a role in 
spasticity.  Many of the changes in reflex circuits that have been observed 
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during testing of stroke patients have identified the same two issues highlighted 
by Lamy et al (2009) study (discussed above).  Changes observed do not 
correlate with the degree of spasticity (when measured using a clinical 
assessment technique) and may also observed in the less affected stroke side 
(Burke et al 2013). 
Identified circuits include; recurrent inhibition (via Renshaw cells (Burke et al 
2013)) and motor axon collaterals (Nielsen et al 2007)); Reciprocal Ia inhibition 
(from the antagonist muscle) (Nielsen et al 2007); non-reciprocal group I 
inhibition (previously termed Ib inhibition) (Burke et al 2013) from the Golgi 
tendon organs; Ib facilitation (Burke et al 2013); and Group II facilitation (Burke 
et al 2013) and inhibition (Nielsen et al 2007). 
While the circuitry of these spinal reflexes is generally well studied, the 
importance of some mechanisms remains unclear (Lamy 2009).  It has been 
suggested that different individuals might have varying circuit involvement 
(Burke et al 2013). 
Discussion 
The main difficulties in investigating these mechanisms further are highlighted in 
the main thesis already.  It is possible that the importance of a single reflex 
circuit, or particular mechanism, may vary over time following a stroke.  Without 
longitudinal studies that begin within the first two to three days following stroke 
this will remain a hypothesis. 
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 Departments of Physiotherapy and Rehabilitation Medicine 
 
Information Sheet (V4) for:          (Name of patient)  
 
Is it clinically effective to treat arm flexor spasticity, with botulinum toxin – 
type A (BoNTA) and physiotherapy, as soon as signs of abnormal muscle 
activity are observed? – A phase II study 
 
You are invited to take part in the above study which is looking at the effects of 
early treatment with Botulinum Toxin on recovery of arm function following a 
stroke.  If you are interested in participating in this study, it is important that you 
understand why the research is being done and what it will involve before you 
make a decision.  Please take time to read the following information carefully, 
and discuss it with others if you wish, prior to confirming your willingness to 
participate in this study.  If any information is unclear or if you would just like 
more information please contact Mr Lindsay [Cameron], Dr Sturman, or Dr 
Pandyan (contact details can be found at the end of this form).   
 
If you do not want to take part in this study, we would like to assure you that your 
current medical care will not be compromised in anyway and we would like to 
thank you for giving us a bit of your time. 
 
The purpose for this study and the details of how the study will be carried 
out 
The results from this study will contribute to an educational training programme 
leading to a PhD being undertaken by Cameron Lindsay at Keele University 
under the supervision of Dr Anand Pandyan (Contact details for both are at the 
end of this form).  It is a study being funded by the NHS.  Many people do not 
recover arm function following a stroke. People who do not recover arm function 
are at a risk of developing spasticity, pain and limb deformities.  Botulinum toxin 
is already being used successfully for the treatment of established spasticity after 
stroke. In a previous pilot trial it was found that early use of Botulinum Toxin 
could lead to some improvement in function compared to those who were not 
injected with Botulinum toxin.  In this research project we would like to confirm 
whether this is the case. 
 
Who is eligible to participate in this study 
Adult patients admitted to Sandwell or the City Hospital Birmingham with a stroke 
who have not recovered arm function will be eligible to participate in this clinical 
trial.  Only patients who show evidence of spasticity will go in to the treatment 
phase of the study.  
 
Do I have to take part? 
It is up to you to decide to join the study. Participation in this clinical trial is 
entirely voluntary and you are not obliged to support this clinical trial. If you do 
decide to take part you will be given this information sheet to keep and be asked 
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to sign a consent form. If you decide to take part you are still free to withdraw 
at any time without giving a reason.  A decision to withdraw at any time, will not 
affect the standard of care you receive. Also, if you decide not to take part in this 
study the standard of care you receive will not be affected in any way. 
 
 
What will happen, if I decide to take part in this trial? 
If you are recruited to the trial we will initially need to check your health status 
and the extent of your disabilities. For this we will need access to your medical 
records and carry out an appropriate medical examination. In addition, we will 
need to measure the extent of your arm weakness, the range through which your 
arm can be moved, stiffness and the levels of spasticity. The time taken for these 
measurements will not exceed 40-minutes. If you show signs of spasticity you will 
automatically progress to the treatment phase of the study. 
 
Screening phase 
 If you do not show signs of spasticity on initial assessment, we will monitor 
your levels of spasticity either daily or every alternate day, as clinically 
indicated, for a period of up to six weeks. 
 If you were to develop spasticity at any point during the screening phase you 
will be automatically progressed to the treatment phase. 
 If you do not develop spasticity or if you were to have a full recovery of arm 
function a final measurement will be taken and you will have completed the 
study.  
 
Treatment phase 
 You will be randomly allocated to one of two groups. A computer does this 
allocation and we will not be able to influence this process.  
 If you are allocated to the treatment group you will receive an injection of 
Botulinum toxin Type A (Botox®) to the muscles that are at a risk of 
developing spasticity.  
 If you are allocated to the control group you will receive an injection of the 
“placebo” or “sham” or “dummy” treatment to the relevant muscles. As the 
drug is colourless and has no externally distinct characteristics, it will not be 
possible for you to identify which group you have been allocated to. 
 We plan to recruit 150 patients to this trial. This means that 75 patients will be 
randomly allocated to each group and people in the control group will not get 
the active treatment. It will not be possible to identify or influence the 
allocation process. 
NB: Treatment, even if you are in the control group, can cause discomfort at the 
time of injection and this discomfort could last for a day or two.  
 
Sometimes we don‘t know which way of treating patients is best. To find out, we 
need to compare different treatments. We put people into groups and give each 
group a different treatment. The results are compared to see if one is better. To 
try to make sure the groups are the same to start with, each patient is put into a 
group by chance.  In this study there is an equal chance that you are allocated to 
the treatment or control group. 
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Details of the drug being used in this trial 
Botulinum toxin is used to reduce the unwanted activity in your muscles. The 
drug is used extensively in the treatment of adults and children with established 
spasticity. Although no specific side effects have been associated with the drug 
used in this study, people have complained of mild flu like symptoms, pain and 
bruising following injections of botulinum toxin. Very rarely, transient swallowing 
difficulties lasting about two weeks have also been reported. All of the above 
symptoms are entirely reversible. This drug will need to be injected into the 
muscle by a doctor. Dr Sturman, the consultant on this project who has 
considerable experience on the use of Botulinum toxin in stroke, will be 
supervising treatment. 
 
 
Electrical stimulation 
You will be provided with an electrical stimulation device for the duration of the 
research.  This device attaches to your forearm and provides an electrical 
stimulation to the forearm muscles that makes them tighten and move the wrist.  
Initially a therapist will put this on for you however we will either teach you or a 
carer to apply treatment so that you can continue to benefit from this treatment. 
Treatment with electrical stimulation will be given to all patients. 
 
Measurements 
In order to assess the effect of the injections we will take measurements of 
muscle activity at 2, 4 and 6 weeks following injection.  We will also take 
measurements of arm weakness, range of movement, stiffness and muscle 
activity at 3 months and 6 months after the initial treatment. At these two points 
we will also request you fill in a questionnaire to measure quality of life.  We will 
also request that your main carer fills in a questionnaire at this point.  The time 
required for these measurements should not exceed 45-minutes. If you have 
already been discharged from hospital by the time of these assessments we will 
arrange transport for you to come to the clinic, if you wish. 
 
Diary and Weekly telephone calls 
On discharge from hospital we would like to phone you on a weekly basis to 
check how you are doing with the electrical stimulator.  A diary will also be 
provided to help remind you to carry out the electrical stimulation; we would also 
like you to write in this diary how frequently you require NHS appointments on 
discharge. 
 
Questionnaire 
You will be asked to fill in a questionnaire regarding your thoughts on your quality 
of life and how your health status has changed.  This questionnaire is a tick box 
sheet and takes less than 2 minutes to complete. 
 
What will I have to do? 
Once consent has been obtained you will need to do the following: 
1. Be available for a baseline measurement 
2. Be available for the injections 
 
In addition we will need to take follow-up measurements, and, ask you to fill in a 
questionnaire and a diary. If you have been discharged from the hospital we will 
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need to contact you once a week, to check that all is going well, for the first three 
months within the study.  The end of the Study is at 6 months following the 
Stroke. 
  
Are there any alternatives to the treatment that is being used? 
Physiotherapy is a recognised means of alleviating spasticity, but it does not 
work in all patients. You will be receiving physiotherapy as all the other patients 
after a stroke.  So far there are no drug treatments for the prevention of 
spasticity. Three different companies currently market Botulinum toxin. Of the 
three products currently available in the market we are using Botox®. The two 
other products act in a similar way and are called Dysport® and Neurobloc®.  
 
What are the possible disadvantages and advantages of taking part in the 
research? 
The disadvantage of taking part in the research is that patients who go in to the 
treatment phase of the study will be given by an injection into one or several 
muscles. This may cause mild flu like symptoms, pain and bruising following 
treatment. As pointed out earlier, allergic reactions and swallowing difficulties can 
theoretically develop after treatment with Botulinum toxin, but these are very rare. 
 
Injections of high doses of botulinum toxin into healthy muscles have been shown 
to cause temporary weakness in the muscles injected. However, research shows 
that using small doses of botulinum toxin in stroke patients (as used in this study) 
may improve strength instead of producing weakness. 
 
The advantage of taking part in the trial is that Botulinum Toxin may prevent the 
development of spasticity and pain in the arm, and as shown in an earlier study 
may result in a more functionally active hand. People in the control group are 
likely to have no additional benefit, however, without a control group it will not be 
possible to confirm if treatment with botulinum toxin can be given to all stroke 
patients who develop spasticity. 
 
What if new information becomes available? 
It is possible that new information becomes available about the treatment/drug 
that is being studied during the course of this research project.  If this happens 
we will tell you about it and discuss, with you, whether you want to continue in the 
study.  If you decide to withdraw, your medical treatment and therapy will not be 
affected in any way.  However, if you decide to continue in the study you will be 
asked to sign an updated consent form. 
 
What happens when the research study stops? 
At the end of the study we will analyse the data to check if additional treatment 
with botulinum toxin is clinically indicated. On completing the analysis if your 
doctors were of the view that you will benefit from treatment with Botulinum toxin 
the treatment will be provided to you via the normal NHS channels. 
 
What if something goes wrong during this study? 
Although the risks associated with treatment involving Botulinum toxin are low it 
is important to point out that if taking part in this research project harms you there 
are no special compensation arrangements.  However, if you are harmed due to 
someone’s negligence, then you may have grounds for a legal action but you 
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may have to pay for it.  Regardless of this, if you wish to complain, or have any 
concerns about any aspect of the way you have been approached or treated 
during the course of this study, the normal National Health Service complaints 
mechanisms will be available to you. 
 
Will my taking part in this study be kept confidential? 
If you consent to take part in the research we will need to inspect your medical 
records and notes.  However, your name and contact details will not be divulged 
to any third party outside the research team. Also, all information which is 
collected about you during the course of the research will be treated 
anonymously, i.e. it will not be possible to identify you from the data collected and 
any data collected will be stored on a secure computer. Any information, about 
you, which leaves the hospital, will have your name and address removed so that 
you cannot be recognised from it. We will, however, inform your GP about 
your participation in this study. 
 
What will happen to the results of the research study? 
The results from this study will contribute to an educational training programme 
being undertaken by the researcher at Keele University. On completing this trial 
we will need to analyse the data to identify whether early treatment with 
Botulinum toxin prevents the development of spasticity and helps the recovery of 
arm function. The results of this study will be published in Conferences and 
Medical Journals. Copies of any such publications can be obtained by contacting 
Dr AD Pandyan. Once again we would like to stress that you will not be 
specifically be identified from the published data. 
 
It is also possible that we will want to use the data collected in this study to 
support our other research projects. If you have no objections for us to use the 
data collected from you, during the course of this study, you will need to indicate 
this on the appropriate section in the consent form. If the data is used to support 
future research it will not be possible to specifically identify you from the data. 
 
We would now like to thank you for having taken the time to enquire about our 
study. If you have any further questions please contact us and we will be happy 
to answer all your questions. 
 
If we have answered all your questions and you want to support this study you 
will now need to sign the consent / assent form. If however, you have decided not 
to participate, we would like to thank you for taking the time to find out about this 
study. 
 
We cannot promise the study will help you but the information we get from this 
study will help improve the treatment of people who have a Stroke in the future. 
 
Thank you.  
 
Mr Cameron Lindsay  Dr. S Sturman  Prof. A D Pandyan 
 Advanced Physiotherapist  Consultant Neurologist  School of Health and Rehabilitation 
 City Hospital Birmingham  Queen Elizabeth Hospital  Keele University 
 Dudley Road   Mindelsohn Way   Keele Staffs – ST5 5BG 
 Birmingham B18 7QH  Edgbaston   
     Birmingham  B15 2W     
  
Early Use Of Botulinum Toxin in post Stroke Spasticity  EUBoSS 
 
173 
 
Case Report Form 
 
Demographic Data 
 
Site    Subject Initials    Subject I.D. 
 
Date 
 
Gender: Male ⁯  Female ⁯ 
 
Age: ………… 
 
Ethnic Group: 
 
First Language: 
 
Previous stroke: No  (If NO go to Current Stroke) Yes⁯  (If yes go to next 
question) 
 
Previous Stroke Type: TIA ⁯  POCI ⁯ LACI ⁯  
PACI ⁯ TACI ⁯ 
 
Current Stroke: 
 
Type of Stroke: Haemorrhage ⁯ Infarct ⁯ 
  
Thrombolysed: Yes ⁯  No ⁯ 
 
 Type:  POCI ⁯ LACI ⁯ PACI ⁯ TACI ⁯ 
 
 Area specified on CT ……………………………………………. 
 
 ……………………………………………………………………….. 
 
Hemiplegic Side: R L Normal dominant side:  R L  
 
National Institute of Health Stroke Scale on admission 
 
 
 Score 
Level of 
Consciousness 
0 = Alert 
1= Not alert but rousable to minor stimulation 
2=Not alert and requires repeated stimulation to attend 
3 = Responds on with reflex motor effects 
 
LOC Questions 0 = Answers both questions correctly 
1 = Answers one question correctly 
2 = Answers neither question correctly 
 
LOC Commands 0 = Performs both tasks correctly 
1 = Performs one task correctly 
2 = Performs neither task correctly 
 
Best Gaze 0 = Normal gaze 
1 = Partial gaze palsy 
2 = Forced deviation 
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 Vision 0 = No visual loss. 
1 = Partial hemianopia. 
2 = Complete hemianopia. 
3 = Bilateral hemianopia (blind including cortical blindness). 
 
Facial Palsy 0 = Normal symmetrical movements. 
1 = Minor paralysis (flattened nasolabial fold, asymmetry on smiling). 
2 = Partial paralysis (total or near-total paralysis of lower face). 
3 = Complete paralysis of one or both sides (absence of facial movement in the 
upper and lower face). 
 
Motor Arm 0 = No drift; limb holds 90 (or 45) degrees for full 10 seconds. 
1 = Drift; limb holds 90 (or 45) degrees, but drifts down before full 10 seconds; 
does not hit bed or other support. 
2 = Some effort against gravity; limb cannot get to or maintain (if cued) 90 (or 
45) degrees, drifts down to bed, but has some effort against gravity. 
3 = No effort against gravity; limb falls. 
4 = No movement. 
UN = Amputation or joint fusion, explain: _____________________ 
5a. Left Arm 
5b. Right Arm 
 
Motor Leg 0 = No drift; leg holds 30-degree position for full 5 seconds. 
1 = Drift; leg falls by the end of the 5-second period but does not hit bed. 
2 = Some effort against gravity; leg falls to bed by 5 seconds, but has some effort 
against gravity. 
3 = No effort against gravity; leg falls to bed immediately. 
4 = No movement. 
UN = Amputation or joint fusion, explain: ________________ 
6a. Left Leg 
6b. Right Leg 
 
Limb Ataxia 0 = Absent. 
1 = Present in one limb. 
2 = Present in two limbs. 
UN = Amputation or joint fusion, explain: ________________ 
 
Sensory 0 = Normal; no sensory loss. 
1 = Mild-to-moderate sensory loss; patient feels pinprick is less sharp or is dull 
on the affected side; or there is a loss of superficial pain with pinprick, but patient 
is aware of being touched. 
2 = Severe to total sensory loss; patient is not aware of being touched in the face, 
arm, and leg. 
 
Best Language 0 = No aphasia; normal. 
1 = Mild-to-moderate aphasia; some obvious loss of fluency or facility of 
comprehension, without significant limitation on ideas expressed or form of 
expression. Reduction of speech and/or comprehension, however, makes 
conversation about provided materials difficult or impossible. For example, in 
conversation about provided materials, examiner can identify picture or naming 
card content from patient’s response. 
2 = Severe aphasia; all communication is through fragmentary expression; great 
need for inference, questioning, and guessing by the listener. Range of 
information that can be exchanged is limited; listener carries burden of 
communication. Examiner cannot identify materials provided from patient 
response. 
3 = Mute, global aphasia; no usable speech or auditory comprehension. 
 
Dysarthria 0 = Normal. 
1 = Mild-to-moderate dysarthria; patient slurs at least some words and, at worst, 
can be understood with some difficulty. 
2 = Severe dysarthria; patient's speech is so slurred as to be unintelligible in the 
absence of or out of proportion to any dysphasia, or is mute/anarthric. 
UN = Intubated or other physical barrier, 
explain:_____________________________ 
 
Extinction and 
Inattention 
(formerly 
Neglect) 
0 = No abnormality. 
1 = Visual, tactile, auditory, spatial, or personal inattention or extinction to 
bilateral simultaneous stimulation in one of the sensory modalities. 
2 = Profound hemi-inattention or extinction to more than one modality; does not 
recognize 
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 Departments of Physiotherapy and Rehabilitation Medicine 
CONSENT FORM V4 
Study title: Is it clinically effective to treat arm flexor spasticity, with 
Botulinum toxin – type A (BoNTA) and physiotherapy, as soon as signs of 
abnormal muscle activity are observed? 
Please initial against each point below 
I confirm that I have read the information sheet (v3.0) about this study 
I confirm that I understand the above information sheet about this study 
I confirm that I have had the opportunity to ask questions about this study to Cameron 
Lindsay and that all my questions have been satisfactorily answered 
……….. 
……….. 
 
……….. 
  
I understand that staff involved in the study may examine those sections of my 
medical notes that are relevant to my taking part in research. 
I give permission for these individuals to have access to my records. 
 
………... 
……….. 
  
I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected or compromised in any way. I am under no obligation to partake in the study. 
 
………... 
 
I agree to take part in this study 
 
 
………... 
  
I permit the use of anonymous data from this trial to support other research projects  
………... 
  
I permit the study to advise my GP that I am participating in this research project  
………... 
 
 ......................................................  ...................................................... 
(Patient name)  (Patient signature)                            (Date) 
 
 
 ......................................................  ...................................................... 
(Witness name)  (Witness Signature)                          (Date) 
 
 
 ......................................................  ...................................................... 
(Researcher name)  (Researcher signature)                     (Date) 
1 copy for patient; 1 copy for researcher; 1 copy to be kept with hospital notes 
Researchers: Dr A D Pandyan, School of Health and Rehabilitation Keele University, Keele 01782734252. Fax: 
01782734255. Dr. S Sturman, Consultant Neurologist, City Hospital Birmingham, Dudley Road, B18 7QH. 
0121 554 3801 Cameron Lindsay, Advanced Physiotherapist, City Hospital Birmingham, Dudley Road, B18 
7QH. 07971 866 483 
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*These people require Certificates of GCP to participate in the Trial due to the 
Tasks delegated to them. 
Name Role in 
Study  
Start 
Date  
Tasks Performed  Signature 
C Lindsay* 
 
Research 
Physiotherapist 
May 2011 1,2,3,5,6,7,12,13,14,15,16,
17,19,20,21,22,23 
 
S Sturman* Principal 
Investigator 
May 2011 1,2,3,6,7,8,9,12,13,14,15  
A Pandyan Principal 
Investigator 
May 2011 12,13,14  
 
D Hicklin* Injector May 2011 6,18,  
 
S Clegg* Pharmacist May 2011 4,6,10,11  
 
J Simpson* Research 
Pharmacist 
May 2011 4,6,10,11  
F Siddiqui* Prescriber May 2011 6,9  
 
K Sharobeem* Prescriber May 2011 6,9  
 
J Khaira* Prescriber May 2011 6,9  
 
C Simcox Physiotherapist May 2011 3,6,22  
 
C Finnemore Physiotherapist May 2011 6,22  
 
J Bearsmore Physiotherapist May 2011 6,22  
 
P Harding* Consultant 
Physio 
May 2011 3,17 (Needs GCP)  
 
S Kurdowar 
 
Stroke 
research Nurse 
July 2011 3  
 Stroke 
research Nurse 
   
Sarah Pharmacy Tech May 2011 6  
     
1. Finally determine eligibility 13. Ethics/R&D Submissions 
2. Obtain informed consent 14. Bi-annual Ethics Report 
3. Screen patients/give patients information 
as part of consent process 
15. Maintain SOPS file 
4. Randomisation and allocation of patients 16. Pre randomisation assessment  
5. Complete CRF’s 17. Baseline Measures 
6. Sign CRF’s 18. Injector 
7. Report SAEs, AEs 19. Week 2,4,6 assessment 
8. Report SUSARS 20. Midpoint assessment 
9. Prescription of trial regimes 21.Endpoint assessment 
10. Order, receive, store and dispense trial 
drugs 
22. Teaching patient/carer to use 
E-Stim on D/C 
11. Maintain pharmacy file 23. Maintain Main Trial Folder 
12. Data Protection (Caldicott Guardian)  
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Date:______________ 
 
Please prepare a syringe containing: 
 
 
 
Units of Botulinum Toxin Type A / BOTOX or Placebo 
 ml of 0.9% Sodium Chloride 
   
and a further syringe containing: 
 
 
 
Units of Botulinum Toxin Type A / BOTOX or Placebo 
 
ml of 0.9% Sodium Chloride 
 
 
Signature of Prescriber:  ________________________ 
 
Date of Prescription:  ________________________ 
 
_____________________________________________________________________ 
 
For intra-muscular injection in to  
 
Muscle  Maximum 
dose allowed 
(Units) 
Dose to 
inject 
(Units) 
Injectors 
signature when 
administered 
Date 
Biceps:  50    
Brachialis:  50    
Flexor Digitorum Profundus: 30    
Flexor Digitorum Superficialis: 30    
Flexor Carpi Radialis:  20    
Flexor Carpi Ulnaris: 20    
Remainder (to be disposed of) --    
Maximum dose / person: 200 BOTOX® Units 
Early Use of Botulinum Toxin in Spasticity post Stroke (EUBoSS) 
Blinded Clinical Trial Prescription 
EUdraCT number: 2010-021257-39 Pharmacist (Sig)  
Version 1 Physiotherapist (Sig)  
SWBH NHS Trust P. Investigator (Sig)  
Patient Trial/Study No:  
Confirm patient name here 
 
 
 
 
 
Place Patient Label Here 
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Early Use of Boutinum Toxin in post Stroke Spasticity (EUBoSS) 
Unblinding Standard Operating Procedure 
EUdraCT number: 2010-021257-39 Pharmacist (Sig)  
Version 1 Physiotherapist (Sig)  
SWBH NHS Trust Investigator (Sig)  
 
Background 
This patient has agreed to be on the EUBoSS Trial.  The patient will have been given 
either a placebo injection of 0.9% NaCl solution or active injection of Botulinum Toxin 
reconstituted in 0.9% NaCl solution.  To ensure scientific rigour the patient and injector 
have been blinded to what type of injection they received. 
It is not expected that any adverse reactions to either injection will occur however this 
standard operating procedure should be followed in the case of a possible adverse 
reaction. 
 
Unblinding Criteria 
Blinding will only be broken where it is uncertain whether an adverse event is associated 
with the study drug AND knowledge of the drug allocation will have a direct bearing on the 
course of treatment.  
 
Unblinding Information 
The Principal Investigator should be contacted in the first instance (or delegated 
Consultant to cover leave). The Principal Investigator is Dr Sturman (Contact through 
IVOR).  Dr Sturman will then assess the situation and decide if it is necessary to unblind 
the patient from the Trial. 
 
Unblinding Procedure 
1. Dr Sturman will contact Pharmacy who hold the unblinding information.  If within 
hours this will be the Clinical Trial Pharmacy Team. If out of hours this will be the 
On-Call Pharmacist through switchboard. 
2. The pharmacist will ensure the correct identification of the patient by cross 
checking the details provided by Dr Sturman with the dispensing log: 
a. Name 
b. Date of Birth 
c. RXK (Hospital Number) 
3. The pharmacist will identify the correct number in the randomisation folder for the 
patient from the dispensing log.  
4. The sealed envelope containing the unblinded information shall then be retrieved 
from the pharmacy file.   
5. The envelope is then opened by the pharmacist who will inform Dr Sturman 
immediately of the group the patient was in. 
6. The Pharmacist shall then complete an unblinding notification form with the 
following information. 
a. Patients details: Treatment pack number, patient RXK number, Date of 
birth and Trial Number. 
b. Reason for unblinding 
c. Unblinding details: Name, Pharmacist Position, Signature of Pharmacist 
performing the unblinding and date and time of unblinding. 
7. The unblinding notification information should be sent to: Cameron Lindsay 
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EUBoSS Case Report Form 
 
Baseline Measures 
 
Site  Subject Initials    Subject I.D. 
 
Date 
 
Hemiplegic side:   R  L  
 
Subjective Discussion 
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Site  Subject Initials    Subject I.D. 
 
Date 
 
Range of movement 
 
Patient position:  High Lying in bed [] Sitting in Chair [] 
 
 PROM  AROM Power Additional information 
Sh Flex     
Sh Abd     
Sh L. Rot     
Does shoulder have: Pain  Tightness  Subluxation 
 
 
 
 
Spasticity 
Aims of these measures are to assess 
Velocity (for emg angle and force angle – both for fast and slow) 
EMG activity (EMG angle fast and slow) 
Pattern of EMG (EMG angle fast and slow) 
Stiffness (force angle fast and slow) 
ROM (EMG angle slow) 
Angle at which EMG occurs (EMG angle fast and slow) 
 
Patient Position  
With patients shoulder in 90o abduction and resting on table. 
 
Spasticity/Contracture Elbow Flexion Elbow Extension 
Slow angle EMG   
Fast angle EMG   
Slow Force angle   
Fast force angle   
Tardieu scale  R1           R3         (      ) 
 
Patient Position  
With patients shoulder in neutral and elbow in 90o flexion and in mid position 
(pronation/supination) resting on table. 
Spasticity/Contracture Wrist Flexion Wrist Extension 
Slow angle EMG   
Fast angle EMG   
Slow Force angle   
Fast force angle   
Tardieu Scale  R1           R3         (      ) 
 
 
ATTACH PRINT OUT AT BACK OF FORM 
 
Site  Subject Initials    Subject I.D. 
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Date 
 
Muscle function 
 
Aims of these measures are to assess 
Maximum strength 
Rate of force production 
Fatigue 
Duration 
 
Patient Position  
With shoulder in 45o flexion and resting on pillow. 
Apply load cell to palmar aspect / dorsal aspect of forearm 3 finger breadths from 
wrist crease.  With elbow in Supination. 
 
Isometric 
strength  
Elbow 
Flexion 
Elbow 
Extension 
Maximum strength   
Fatigue of strength   
 
Patient Position  
With elbow at 90o flexion and in mid position (pronation/supination) resting on table. 
Apply load cell to palmar aspect/dorsal aspect of hand in line with 5th MCP joint. 
 
Isometric 
strength  
Wrist 
Flexion 
Wrist 
Extension 
Isometric strength   
Fatigue of 
strength 
  
 
Patient Position  
With elbow at 90o flexion and in mid position (pronation/supination). Maintain wrist in 
neutral. 
 
Isometric 
strength  
JAMAR 
(Grip Strength) 
Isometric 
voluntary strength 
 
Fatigue of 
strength 
 
 
ATTACH PRINT OUT AT BACK OF FORM 
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Site  Subject Initials    Subject I.D. 
 
Date 
 
Action Research Arm Test Score  
 
Scoring:  3 = Performs test normally 
  2 = Completes test, but takes abnormally long time or has great difficulty 
  1 = Performs test partially 
  0 = Can perform no part of test  
 
a. Subtest grasp 
  Score Score 
  Left Right 
1. Block 10 cm 
(If score = 3, total = 18 and → GRIP) 
  
2. Block 2.5 cm 
(If score = 0, total = 0 and → GRIP) 
  
3. Block 5 cm   
4. Block 7.5cm   
5. Cricket ball   
6. Stone   
 
b. Subtest Grip 
  Score Score 
  Left Right 
1. Pour water from glass to glass (pronation) 
(If score = 3, total = 12 and → PINCH) 
  
2. Tube 2.25cm 
(If score = 0, total = 0 and → PINCH) 
  
3. Tube 1cm   
4.  Washer over Bolt   
 
c. Subtest Pinch 
  Score Score 
  Left Right 
1. Ball bearing, 6mm, 3rd finger and thumb 
(If score = 3, total = 18 and → GROSS MOVT) 
  
2. Marble, 1st finger and thumb 
(If score = 0, total = 0 and → GROSS MOVT) 
  
3. Ball bearing, 2nd finger and thumb   
4. Ball bearing, 1st finger and thumb   
5. Marble, 3rd finger and thumb   
6. Marble 2nd finger and thumb   
 
d. Subtest Gross Movement 
  Score Score 
  Left Right 
1. Place hand behind head 
(If score = 3, total = 9.  If score = 0, total = 0) 
  
2. Place hand on top of head   
3. Hand to mouth   
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Site  Subject Initials    Subject I.D. 
 
Date 
 
Pain  
 
Do you have pain anywhere during the ARAT? 
 
Do you have pain ALL THE TIME Yes [  ]   No [  ] 
  
Do you have pain at: REST   MOVEMENT  NIGHT 
 
The scale to the right is a measure of pain.  
The top red circle indicates pain as bad as it could be  
The bottom clear circle indicates no pain at all  
 
Which circle best describes the pain that you feel?     
 
Ability to use the SPIN screen  
Could the patient understand the scale:   Yes   No   Not sure  
  
Cross-section area of Bicep: 
Ultrasound Assessment of Biceps 
Muscle thickness 
With the patient in sitting resting forearm on pillow and elbow at 90 
degrees. Measure the distance between acromion process and the 
medial epicondyle of the humerus.  Divide this distance in to thirds 
and place the transducer at the distal third in a transverse plane.  
Ensure a good quantity of contact gel between the transducer and 
skin is used to minimise pressure required. Ensure the transducer is 
perpendicular to the skin before freezing image and saving. 
 
Measure the distance between the medial epicondyle of the 
humerus to the ulnar styloid process and divide this distance in to 
fifths.  Place the transducer at the proximal two fifths in a 
transverse plane on the anterior/flexor surface.  Ensure a good 
quantity of contact gel between the transducer and skin is used to 
minimise pressure required. Ensure the transducer is perpendicular 
to the skin before freezing image and saving. 
10 
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The most pain        
 you can imagine 
 
No pain at all 
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Site  Subject Initials    Subject I.D. 
 
Date 
 
Barthel Score:   
 
FEEDING 
0 = unable 
1 = needs help cutting, spreading butter, etc., or requires modified diet 
2 = independent ______ 
BATHING 
0 = dependent 
1 = independent (or in shower) ______ 
GROOMING 
0 = needs to help with personal care 
1 = independent face/hair/teeth/shaving (implements provided) ______ 
DRESSING 
0 = dependent 
1 = needs help but can do about half unaided 
2 = independent (including buttons, zips, laces, etc.) ______ 
BOWELS 
0 = incontinent (or needs to be given enemas) 
1 = occasional accident 
2 = continent ______ 
BLADDER 
0 = incontinent, or catheterized and unable to manage alone 
1 = occasional accident 
2 = continent ______ 
TOILET USE 
0 = dependent 
1 = needs some help, but can do something alone 
2 = independent (on and off, dressing, wiping) ______ 
TRANSFERS (BED TO CHAIR AND BACK) 
0 = unable, no sitting balance 
1 = major help (one or two people, physical), can sit 
2 = minor help (verbal or physical) 
3 = independent ______ 
MOBILITY (ON LEVEL SURFACES) 
0 = immobile or < 50 yards 
1 = wheelchair independent, including corners, > 50 yards 
2 = walks with help of one person (verbal or physical) > 50 yards 
3 = independent (but may use any aid; for example, stick) > 50 yards ______ 
STAIRS 
0 = unable 
1 = needs help (verbal, physical, carrying aid) 
2 = independent ______ 
TOTAL (0–20): ______ 
 
 
Specific rehabilitation of the arm should concentrate on  
 
Passive    [  ] 
Active Assisted   [  ]  
Muscle Strengthening/Active  [  ] 
Functional    [  ] 
 
 
